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Summary 
Huntington's disease (HD) is an autosomal dominant disease caused by an expansion of 
CAG repeats in the gene encoding for huntingtin (HTT) and characterized by motor, 
cognitive and psychiatric symptoms. Despite HD monogenic etiology, its pathogenesis 
is incredibly complex and several mechanisms of neuronal dysfunction have been 
proposed. Given the diversity of mutant HTT interactions and the fact that there is still 
no cure or neuroprotective treatment for HD, in this study we aimed to clarify the early 
pathological mechanisms involving deficits in energy metabolism linked to 
mitochondrial dysfunction, altered cell cycle and modified signaling pathways, as well 
as evaluate the influence of treatment approaches targeting distinct cellular mechanisms 
in vitro and in vivo. 
In the first part of this work we investigated the pathological mechanisms that have been 
proposed for neurodegeneration, including mitochondrial dysfunction and oxidative 
stress in HD patient-specific induced pluripotent stem cells (HD-iPSC) and derived HD-
NSC versus cells expressing normal HTT. We showed that HD-iPSCs possessed 
hyperpolarized mitochondria and reduced mitochondrial Ca
2+ 
storage capacity. HD-
iPSCs mitochondria exhibited round shape morphology, but no differences in 
fission/fusion proteins were found. HD-iPSCs also consumed less O2, exhibited 
decreased complex I+III activities and had lower ATP/ADP ratio, which was in 
accordance with the observation that HD cells relied more on glycolysis. Moreover, 
HD-iPSCs showed increased phosphorylation of pyruvate dehydrogenase (PDH) 
subunit E1α at Ser 232, 293 and 300, reflecting its inactivation. Concordantly, increased 
levels of pyruvate dehydrogenase kinase, isozyme 1 (PDK1) were found. In addition, 
increased levels of mitochondrial superoxide anion and hydrogen peroxide were 
observed in HD-iPSCs. These results were consistent with increased acetylation and 
decreased activity of superoxide dismutase 2 (SOD2) in HD cells. Our study suggests 
that human HD-iPSC can help to reveal the role of mitochondrial and metabolic 
dysfunction in early stages of HD.  
In the second part of the work we analysed the role of HTT in the control of mitosis, 
namely whether it has an important impact on asymmetric division and cell fate. Using 
human embryonic stem cells (hESC) characterized as adult-onset mutant gene carriers, 
we qualified the role of human HTT in mitotic spindle orientation in human neural stem 
cells (derived from the hESC) and the effect of the adult-onset HD mutation. RNAi-
 vi 
 
mediated silencing of HTT in neural stem cells derived from wild type hESC disrupted 
spindle orientation and mislocalized dynein, the P150
Glued
 subunit of dynactin and the 
large nuclear mitotic apparatus NUMA protein. We further addressed the effect of an 
adult-onset HD mutation on spindle orientation in neural cells derived from HD-specific 
hESC. After identifying single-nucleotide polymorphism (SNP) we combined SNP-
targeting allele-specific silencing and gain of function approaches, showing that 
expression of human HTT with 46 glutamines was sufficient to induce a dominant 
negative effect on spindle orientation and alteration of the localization of dynein, 
P150
Glued
 and NUMA in neural stem cells. These findings revealed that neural 
derivatives of disease-specific human pluripotent stem cells constitute a relevant 
biological resource for exploring the impacts of adult onset HTT mutations on neural 
progenitors division with potential application in HD drug discovery targeting HTT-
dynein- P150
Glued
 complex functions. 
Following the previous data from in vitro studies showing that Akt has a beneficial role 
on HD phenotype, in the third part of the work, we detailed the changes in an animal 
model of the disease and treatment response to IGF-1. Thus, we analysed brain 
metabolic dysfunction and altered Akt signaling and the protective role of insulin-like 
growth factor-1 (IGF-1)/Akt pathway in HD. We investigated motor phenotype, 
peripheral and central metabolic profile, and striatal and cortical signaling pathways in 
HD transgenic YAC128 mice subjected to intranasal administration of recombinant 
human IGF-1 (rhIGF-1), in order to promote IGF-1 delivery to the brain. IGF-1 
supplementation enhanced IGF-1 cortical levels and improved motor activity and both 
peripheral and central metabolic abnormalities in YAC128 mice. Moreover, decreased 
Akt activation in HD mice brain was ameliorated following IGF-1 administration. 
Upregulation of Akt following rhIGF-1 treatment occurred concomitantly with 
increased phosphorylation of mutant HTT at Ser421. These data suggested that 
intranasal administration of rhIGF-1 ameliorates HD-associated glucose metabolic brain 
abnormalities and mice phenotype. 
The present work enlightens the mechanisms underlying mitochondrial dysfunction and 
metabolic impairment as well as the role of HTT in cell cycle and cell fate occurring in 
early stages of HD. Moreover, we exploit therapeutic approaches targeting different 
molecular pathways, which were efficient per se in delaying disease phenotype, namely 
the selective inhibition of mutant HTT translation using shRNA in HD-patient’s derived 
neural stem cells and the activation of brain intracellular signaling pathways induced by 
 vii 
 
IGF-1 in an animal model of HD. These studies provide new insights into HD 
pathogenesis which, hopefully, may result in improved therapeutic approaches for the 
disease. 
 
 
 
Keywords: ESCs, iPS cells, cell proliferation, cell differentiation, Huntington‟s 
disease, huntingtin 
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Resumo 
A doença de Huntington (DH) é uma doença genética, autossomica dominante, causada 
por uma expansão de CAGs no gene que codifica a proteína huntingtina e caracterizada 
por distúrbios motores e psíquicos, e declínio cognitivo. Apesar da etiologia 
monogénica, a patogenia é extremamente complexa e vários mecanismos de disfunção 
neuronal têm sido propostos. Tendo em conta a complexidade das interações 
moleculares e celulares da HTT mutada e o facto de não existirem tratamentos eficazes 
para a DH, este trabalho teve como principal objetivo esclarecer os mecanismos 
patológicos envolvidos no défice metabólico associado à disfunção mitocondrial e ao 
ciclo celular, bem como a alteração das vias de sinalização nas fases iniciais da DH, e 
aplicar diferentes abordagens terapêuticas in vitro e in vivo. 
Na primeira parte deste trabalho investigámos os mecanismos fisiopatológicos 
associados à DH, incluindo a disfunção mitocondrial e o stresse oxidativo. A 
mitocondria tem sido sugerida como um factor patológico adicional em DH. Utilizando 
células pluripotentes induzidas provenientes de doentes de Huntington (HD-iPSC) 
mostrámos que as mitocôndrias se apresentavam hiperpolarizadas com menor 
capacidade de armazenamento de Ca
2+
. As HD-iPSCs registaram um menor consumo de 
oxigénio, diminuição na atividade dos complexos I+III e do rácio ATP/ADP, recorrendo 
menos à fosforilação oxidativa para produção de ATP. As mitocôndrias das HD-iPSCs 
apresentaram morfologia alterada, contudo não encontrámos diferenças nos níveis das 
proteínas de fissão ou fusão Mais ainda, as HD-iPSCs mostraram um aumento da 
fosforilação da subunidade E1α nas Ser232, 293 e 300 da piruvato desidrogenase 
(PDH), refletindo a sua inactivação. Concomitantemente, verificou-se um aumento dos 
níveis da piruvato desidrogenase cinase, isoenzima 1 (PDK1). Além disso, níveis 
mitocondriais aumentados do ião superóxido e de peróxido de hidrogénio foram 
observados em HD-iPSCs. Estes resultados foram consistentes com o aumento da 
acetilação e diminuição da atividade da enzima superóxido dismutase 2 (SOD2) em 
HD-iPSCs. Este estudo sugere que a disfunção mitocondrial é um evento precoce na 
etiopatogenia da DH. 
Na segunda parte do trabalho analisámos o papel fundamental da HTT no controlo da 
mitose, nomeadamente na divisão assimétrica e na definição da linhagem celular. 
Recorrendo a células estaminais embrionárias humanas (hESC) portadoras do gene 
mutante caracterizámos o papel de HTT humana na orientação do fuso mitótico em 
 ix 
 
células neurais humanas e o efeito da mutação da forma adulta da DH. O silenciamento 
mediado por shRNA dos alelos da huntingtina em células estaminais neurais derivadas 
de células estaminais embrionárias humanas wild type alterou a orientação do fuso 
mitótico e deslocalizou a dineína, a subunidade p150
glued
 da dinactina e a proteína 
NUMA. Após identificação de um polimorfismo de nucleotídeo único (SNP) no gene 
HTT, avaliámos o silenciamento de um alelo específico e estratégias de ganho de 
função, mostrando que uma expansão de 46 glutaminas na proteína humana HTT é 
suficiente para induzir um efeito negativo dominante na orientação do fuso e alteração 
da localização de dineína, p150
glued
 e NUMA em células estaminais neurais. Estes 
resultados revelaram que células estaminais neurais derivadas de células pluripotentes 
humanas constituem um recurso biológico relevante para explorar os impactos da forma 
adulta da mutação de HTT na mitose de progenitores neurais com potencial aplicação 
na descoberta de medicamentos visando as funções complexas da tríade HTT - dineina- 
p150
glued
. 
Estudos prévios in vitro mostraram que a cinase Akt desempenha um papel 
neuroprotector e passível de reverter o fenótipo da doença. Assim, na terceira parte do 
trabalho detalhámos a disfunção metabólica cerebral e as alterações nas vias de 
sinalização da Akt num modelo animal da DH (YAC128) e a resposta ao tratamento 
com fator de crescimento insulínico de tipo 1 (IGF-1). Especificamente investigámos as 
alterações motoras, o perfil metabólico central e periférico e as vias de sinalização 
corticais e estriatais no murganho YAC128 submetido à administração intranasal de 
IGF-1 recombinante humano (rhIGF-1), de modo a ceder IGF-1 ao cerebro. Mostrámos 
que a administração de rhIGF-1 aumenta os níveis corticais de IGF-1 e melhora a 
função motora e as alterações metabólicas periféricas e centrais no modelo YAC128. 
Consequentemente, a diminuição da ativação de Akt observada nos tecidos cerebrais de 
murganhos de DH foi revertida após administração de IGF-1. O aumento de expressão 
de Akt após o tratamento com rhIGF-1 ocorreu concomitantemente com o aumento da 
fosforilação de huntingtina mutante. Estes dados sugerem que a administração 
intranasal de rhIGF-1 melhora a alterações metabólicas cerebrais de DH e o fenótipo de 
murganhos YAC128. 
Os resultados obtidos neste trabalho permitem esclarecer os mecanismos subjacentes à 
disfunção mitocondrial e à deficiência metabólica bem como as alterações no ciclo 
celular encontrados nos estadios iniciais da DH. Mostra-se ainda que abordagens 
terapêuticas em alvos moleculares distintos podem ser eficazes em retardar o fenótipo 
 x 
 
da doença, nomeadamente a inibição da tradução seletiva da HTT mutante usando 
shRNA em células provenientes de doentes de Huntington e o efeito protetor do IGF-1 
num modelo animal da doença. Estes estudos fornecem novos dados sobre as fases 
iniciais da patogenia da DH, podendo ajudar a encontrar abordagens terapêuticas mais 
eficazes para esta doença neurodegenerativa e debilitante. 
 
  
Palavras –chave: Células estaminais embrionárias, Células estaminais pluripotentes 
induzidas, proliferação, diferenciação, Doença de Huntington, huntingtina  
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1.1. Huntington’s disease 
1.1.1. Historical background 
A first attempts to describe Huntington‘s disease (HD) as a “chronic hereditary disease” 
was made in the middle 19
th
 century but the most accurate description was done by 
George Huntington in 1872. He published his report in The Medical and Surgical Reporter 
(juulMargolis et al. 2003) about a hereditary form of chorea, describing “three marked 
peculiarities of this disease: 
1. Its hereditary nature. 
2. A tendency to insanity and suicide. 
3. Its manifesting itself as a grave disease only in adult life” 
 
 
 
Despite Mendel‘s Laws describing the principle of hereditary transmission were still 
recent and weakly disseminated, Huntington was able to note the autosomal dominant 
inheritance: 
“The hereditary chorea, as I shall call it, is confined to certain 
and fortunately a few families, and has been transmitted to 
them, an heirloom from generations away back in the dim 
past.……. When either or both the parents have shown 
manifestations of the disease, and more especially when these 
manifestations have been of a serious nature, one or more of the 
Figure 1.1. Original paper "On Chorea" published by George Huntington at The Medical and Surgical 
Reporter in April 1872 
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offspring almost invariably suffer from the disease, if they live 
to adult age. But if by any chance these children go through life 
without it, the thread is broken and the grandchildren and 
great-grandchildren of the original shakers may rest assured 
that they are free from the disease.” 
 
HD usually has a midlife onset, but juvenile (onset < 20 years) and older onset (> 70 
years) are also present (Nance et al. 2001) progressing inexorably to death 15-20 years 
after the onset (for review,(Rego et al. 2005). Only about 5-7% of patients exhibit 
symptoms before 21 years-old, in what was defined as the juvenile form of HD (Nance et 
al. 2001). 
In early stages of the disease mild symptoms such as subtle psychiatric or motor changes 
often are neglected by the patient. HD progression involves movement disorder in early 
stages (also named chorea) evolving to more disabling progressive bradykinesia, 
incoordination, and rigidity, but also involves emotional and cognitive disturbances, 
leading to dementia as described in the following section. 
 
1.1.2. Epidemiology  
HD is one of the most important genetic disorders of adulthood and is found worldwide 
but with asymmetric distribution. Europe has the largest number of prevalence studies and, 
as it can be seen in Figure 1.2., a uniform prevalence of HD. The high prevalence is 
related with specific HTT haplotypes, namely the haplogroup A where both HD 
chromosomes and intermediate alleles for HD were almost exclusively found on (Warby 
et al. 2011). Indeed, a prevalence of 4-7 per 100,000 people is found over a large part of 
the continent. Finland reveals an atypical low prevalence, of about 0.5 per 100,000 
individuals, which can be related to genetically distinct features from other populations, 
probably diverged from the common origin before such mutations occurred (Harper 1992). 
A previous study in South Wales found a prevalence of 8.85 HD cases per 100,000 people 
(Quarrell et al. 1988). A recent study in the UK reveal that the prevalence of diagnosed 
adult HD was 12.3 per 100 000 people and that the prevalence raised in the last decade 
probably due to patient longevity (Evans et al. 2013). Morrison, 2010 estimated that the 
current UK prevalence should be 14 to 16/100,000 or higher and that the prevalence in 
Caucasian populations is highly underestimates (Morrison 2010, Morrison 2012) 
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HD was originally described in North America, in families of British descent, as 
confirmed by the elevated rate of occurrence in descendants of Western European. In 
2000, there were 30,000 cases of HD in United States, indicating a prevalence of about 10 
cases per 100,000 people. The prevalence of HD in African Americans generates some 
controversy. Some studies described a much lower rate (Wright et al. 1981), but this 
number was refuted by the Maryland study, which found a prevalence of 5.15 per 100,000 
people, based on a population of 4,217,000, a similar number to the population of 
Western-European origin. In most of these affected families, the HD allele did not have a 
European origin (Folstein et al. 1987). 
 
 
In Portugal, the prevalence of HD is estimated to range from 2-5 per 100,000 people, 
overlapping the European values (Costa et al. 2003). 
The disorder is rare in Orientals and Africans, suggesting that HD gene is rare (Harper 
1992). Japan has a very low rate, of about 0.5 per 100,000 people (Walker 2007). In 
contrast, there are some regions where the prevalence is unusually high. Some studies 
were able to track the ancestor by genealogical analysis, mainly due to historical migration 
and geographic isolation of these areas. Tasmania has a prevalence of 17,4/100,000 people 
and the region of Lake Maracaibo, Venezuela, has more than 100 living HD patients, all 
descended from a single ancestor (Conneally 1984, Harper 1992). Importantly, HD affects 
equally males and females. The total heterozygote frequency in South Wales has been 
estimated at 20.2 per 100,000 people (Conneally 1984). 
 
Figure 1.2. Worldwide estimates of the prevalence of HD. Adapted from Warby et al., 2011 
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1.1.3. Genetics  
An expansion of cytosine-adenine-guanine (CAG) repeats was first described in the 
androgen gene, and since then a class of nine genetically distinct, gain-of-function 
disorders were described, constituting the polyglutamine-expansion diseases. These 
include HD, dentatorubralpallidoluysian atrophy, spinal bulbar muscular atrophy (SBMA) 
or Kennedy‘s disease and spinocerebellar ataxias 1, 2, 3, 6, 7 and 17 (Bates 2005). 
The gene affected in HD encodes the protein huntingtin (HTT) and the mutation results in 
a stretch of glutamine residues located at the N-terminal of mutant HTT (mHTT) (1993). 
This is believed to confer a deleterious gain-of-function to the mutant protein. The HD 
gene was mapped in 1983 with the eight polymorphic marker test (G8), which mapped the 
gene to chromosome 4 (4p) (Gusella et al. 1983). However, the HD gene was cloned only 
in 1993, which allowed the identification of a coding region occurring at the short arm of 
chromosome 4 (4p16.3), corresponding to an unstable DNA segment containing an 
expansion of a polymorphic trinucleotide repeat, near the 5‘ end in the exon 1 of the 
“Interesting Transcript 15” (IT15) gene, that spans over 200 kb and is composed of 67 
exons (Group 1993). 
Normal alleles are defined as alleles with < 26 CAG repeats; these are non-pathologic and 
segregated as a stable polymorphic repeat in > 99% of meiosis. In normal individuals, the 
most frequent allele length contains 17 and 19 CAG repeats (Kremer et al. 1994). 
Mutable normal alleles are defined as alleles with 27-35 CAG repeats. This repeat range is 
often referred to as the meiotic instability range or as "intermediate alleles". No case has 
been associated unequivocally with an HD phenotype (Rubinsztein et al. 1996) (Brinkman 
et al. 1997), but they can be meiotically unstable in sperm, and predispose to CAGs 
expansion from one generation to the next, particularly when the disease is transmitted by 
males (Myers et al. 1993, Rubinsztein et al. 1996). This susceptibility was only described 
during transmission through the male germline and is associated with advanced paternal 
age (Goldberg et al. 1993). 
HD alleles with reduced penetrance are defined as having 36-39 CAG repeats; these are 
meiotically unstable and associated with HD phenotype in both clinically and 
neuropathologically documented cases (Nance (Nance et al. 2001) et al., 2001). Few 
asymptomatic individuals over 75 years, with this allele size, have been documented 
(Rubinsztein et al. 1996). 
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Alleles with > 40 CAG repeats are defined as alleles with full penetrance. While there are 
several reports of elderly clinically asymptomatic HD gene carriers with 40 and 41 CAG 
repeats, no individuals with >41 CAG repeat length remained asymptomatic after middle 
life and the probability of an earlier onset is inversely related to number of CAG repeats 
(Brinkman et al. 1997). The presence of ≥ 60 CAGs is associated with juvenile onset that 
represents approximately 5-7% of all cases (Nance et al. 2001). A few cases of juvenile-
onset disease with more than 200 CAG repeats have been documented (Nance et al. 1999, 
Seneca et al. 2004). 
 
 
 
As an autosomic dominant disorder, the HD offspring have 50% chance of inheriting the 
disease in a Mendelian mode. 
The number of polyglutamines is inversely correlated with age of onset (Duyao et al. 
1993, Norremolle et al. 1993), but this only accounts for about 40% of the variation, with 
the remaining due to genetic polymorphisms adjacent to CAG repeat (for review,(Rego et 
al. 2005, Norremolle et al. 2009) and environment (Wexler et al. 2004). However, some 
studies did not find a relationship between the number of CAG repeats and the rate of 
clinical decline (Kieburtz et al. 1994), which suggested that CAG repeat length may have 
a small effect on the rate of progression that may be clinically important over time 
(Rosenblatt et al. 2006). 
A large population sample was analyzed in Portugal, showing that CAG ranged between 9 
and 40 repeats, with the 17 CAG allele occurring most frequently (37.9%). Intermediate 
alleles with 27–35 CAGs represented 3.0% and two expanded alleles (0.11%) were found, 
Figure 1.3. Representation of the HD gene and the impact of polyglutamine repeat size on HD onset 
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one of reduced penetrance (36 CAGs) and other with fully penetrant repeat (40 CAGs) 
(Costa et al. 2003).  
The number of CAG repeats is only highly predictive of the age of onset if CAG≥ 40. The 
genes encoding for NR2A/B receptor subunits of the N-methyl-D-aspartate (NMDAR) 
receptor may be responsible for the variance on the age of onset in individuals with CAG 
repeat lengths between 30-40 (ClinicalTrials.gov 2009). In a cohort of HD patients with a 
CAG repeat length between 41 and 45, 30.8% of the variance in age of onset could be 
attributed to CAG repeat number, while variations in the NR2A (N-methyl-D-aspartate 
receptor receptor subunit) and NR2B genes accounted for 4.5% and 12.3% of the variance, 
respectively (ClinicalTrials.gov 2009). 
 
 
1.1.4. Neuropathology 
Basal ganglia are a group of nuclei located subcortically that are involved in motor and 
cognitive processes. Cerebral cortex and substantia nigra pars compacta (SNpc) send 
glutamatergic and dopaminergic inputs, respectively, to caudate and putamen, and frontal 
cortex receives transiently excitatory input from the thalamus (Purves et al. 2004). 
Connections between basal ganglia output nuclei (GPi/SNr) (globus pallidus interna/ 
substancia nigra pars reticulata) and striatum are organized in two pathways: direct and 
indirect. 
The direct pathway is a monosynaptic transiently inhibitory projection between medium 
spiny neurons (MSN) of caudate and putamen to the tonically active inhibitory neurons in 
GPi/SNr, which in turn provides inhibitory innervation to thalamocortical projections 
(ventral anterior and ventral lateral thalamic nuclei - VA/VL complex). 
The indirect pathway is a polysynaptic connection that involves intercalated neurons in 
globus pallidus externa (GPe) and STN (subthalamic nucleus) and increases the level of 
tonic inhibition. Ninety-five per cent of all neurons in striatum are GABAergic and 
contain mainly the inhibitory neurotransmitter γ-aminobutyric acid (GABA) and 
enkephalin, dynorphin or substance P (SP) as co-transmitter. When the indirect pathway is 
activated by excitatory signals from the cortex, MSN discharge and inhibit tonically active 
GABAergic neurons of GPe. Enkephanin is a reliable marker of indirect pathway while 
substance P is of the direct pathway (Vonsattel et al. 2011). These neurons project to STN, 
which in turn sends excitatory inputs to GPi and SNpr that oppose the disinhibitory action 
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of the direct pathway. Thus, indirect pathway modulates the direct pathway. Most MSNs 
express D1 (subtype 1 dopamine receptor) and D2 (subtype 2 dopamine receptor) 
receptors, the majority of D1-expressing neurons being part of direct pathway and 
containing substance P, whereas D2- bearing neurons are part of indirect pathway, 
projecting to GPe and contain enkephalin (Purves et al. 2004). 
SNr also projects its axons to deep layers of superior colliculus, an area of the upper motor 
neurons that command the saccades (rapid orienting movements of the eyes). Immediately 
before saccade onset, discharge rate of reticulata neurons is greatly reduced through the 
input from tonic GABAergic MSNs of caudate, which have been activated by signals from 
cortex. As a consequence upper motor neurons of superior colliculus are activated, 
allowing them to generate bursts of action potentials that command the saccade (Purves et 
al. 2004). 
In patients with HD, MSN that project to the external segment of GP degenerate, 
especially those synthesizing enkephalin and GABA. In absence of their normal inhibitory 
input from spiny neurons, GPe cells become abnormally active; in turn, this activity 
reduces the excitatory output of STN to GPi, leading to the reduction of the inhibitory 
outflow of the basal ganglia (Figure 1.4.), (Purves et al. 2004). 
Without the restricting influence of basal ganglia, upper motor neurons can be activated by 
inappropriate signals, resulting in choreatic movements and slowing of saccadic 
movements (Purves et al. 2004). 
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As mentioned before, basal ganglia are also involved in other non-motor functions with 
significant clinical implications. Degeneration of specific subdivisions of prefrontal and 
limbic loop appears to be related with deterioration of cognitive and emotional function 
typical in HD (Purves et al. 2004). The prefrontal loop regulates the initiation and 
termination of cognitive processes (e.g. planning, working memory and attention) and the 
limbic loop regulates emotional behavior and motivation (Purves et al. 2004). 
Degeneration can be found at different degrees in MSNs. In early and middle stage HD, 
enkephalinergic striato-GPe projection and SP-containing projection to SNr (indirect 
pathway) are more severely affected than SP -containing projections to the GPi and SN 
(direct pathway), resulting in an imbalance between the direct and indirect pathways 
(Reiner et al. 2013). A possible explanation is that SP-containing striato-SNr neurons and 
enkephalin-containing striato-GPe neurons are lost at a greater rate than either SP-
containing striato-SNc or SP-containing striato-GPi neurons. In end-stage HD, all classes 
of striatal projection neurons are affected (including striate-GPi) which may explain the 
bradykinesia and rigidity (Reiner et al. 1988, Deng et al. 2004). In HD, glutamic acid 
decarboxylase (GAD), the enzyme that is involved in GABA synthesis, is significantly 
decreased in GPe but not in GPi in early stages, whilst in grade 4 patients the GAD fiber 
depletion from both structures was much larger. (Deng et al. 2004). 
Figure 1.4. - Direct and indirect pathways through basal ganglia in normal and HD.  
The balance of inhibitory signals in direct and indirect pathways is altered, leading to a decrease ability of basal 
ganglia to control the thalamic output to cortex. Projection from caudate and putamen to GPe is decrease (thinner 
arrow). This effect increases the tonic inhibition from GP to STN (larger arrow), making the excitatory STN less 
effective in opposing the action of direct pathway (thinner arrow). Thus, thalamic excitation of cortex is increased 
(larger arrow), leading to greater and often inappropriate motor activity. VA -ventral anterior thalamic nuclei; VL- 
ventral lateral thalamic nuclei (Purves et al. 2004). 
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Striatal projecting neurons and parvalbuminergic striatal interneurons degenerate during 
HD (Vonsattel et al. 1998, Reiner et al. 2013) whereas cholinergic striatal interneurons 
and striatal interneurons containing somatostatin, neuropeptide Y and/or NADPH 
diaphorase (or nitric oxide synthase) and medium-sized calretinergic striatal interneurons 
survive in the pathology (Ferrante et al. 1985, Ferrante et al. 1987, Ferrante et al. 1987, 
Fusco et al. 1999, Cicchetti et al. 2000)  The base for this vulnerability is uncertain but 
multiple factors seem to contribute for this selective vulnerability including: differential 
expression of HTT, changes in innervations, the extent of input from cortical or any other 
huntingtin-rich glutamatergic neurons implicating a prominent excitatory input, a high 
enrichment in Ca
2+
-permeable AMPA receptors and the BDNF dependence (Fusco et al. 
1999, Reiner et al. 2013). Reactive astrocytosis (gliosis) is also a common find together 
with neuronal loss (Verkhratsky et al. 2013). A 0-4 rating scale (the `Vonsattel scale') of 
gross and microscopic neurodegeneration, based primarily on changes in caudate and 
putamen (e.g. Figure 1.5.), has been used to semi-quantitatively describe the severity of 
HD. Grade 0 appears indistinguishable from normal brains after gross examination. 
However, 30–40% neuronal loss can be detected in the head of caudate nucleus upon 
histological examination. Grade 1 shows atrophy in the tail and in some cases the body of 
caudate nucleus. Neuronal loss and astrogliosis are evident in the head (50% loss), tail 
and, to a lesser extent, in the body of caudate nucleus. Grade 2 is associated with gross 
striatal atrophy that is more pronounced than that detected in grade 1 brain. Grade 3 
displays severe gross striatal atrophy. Grade 4 includes HD cases with severe atrophy of 
striatum and up to 95% neuronal loss (Vonsattel et al. 1985, Gil et al. 2008). 
More severe neurodegeneration in caudate and putamen were associated with longer 
expanded repeat nucleotide, which is associated with a faster deterioration and greater 
pathological severity and normal CAG repeat sizes can also influence the disease 
phenotype (Furtado et al. 1996, Aziz et al. 2009). However, the degree of tissue atrophy 
may not be solely determined. In advanced cases, total brain weight is reduced by 25-30% 
(Margolis et al. 2003). 
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Hypothalamus is a region of the brain involved in regulation of metabolism and sleep, and 
includes the pituitary gland that regulates hormonal levels in the body. A substantial 
trophy and cell death has been described in hypothalamus from HD patients (Kremer et al. 
1990). Cells more severely affected are located in the lateral tuberal nucleus (nucleus 
tuberalis lateralis, NTL) of hypothalamus. In NTL of HD patients, about 90% neuronal 
loss was found and the remaining neurons showed features of degeneration (Kremer et al. 
1990, Kremer et al. 1991). There was also astrocytosis and reduction of 40% in the 
number of oligodendrocytes  (Kremer et al. 1990).This NTL vulnerability appears to be 
related to the high density of NMDA receptors in this nucleus (Kremer et al. 1993, 
Timmers et al. 1996). There is also a significant loss of orexin-containing neurons in 
hypothalamus most probably responsible for the sleep disregulation and metabolic 
changes (Petersen et al. 2005, Gabery et al. 2010). 
 
 
Figure 1.5. Macroscopic image from a normal control (left) and of Huntington's brain (right).  
(A,D,G) coronal sections passing through the nucleus accumbes; (B,E,H) through the 
caudal edge of the anterior commissure; (C,F,I) through the lateral geniculate body. (A, B, 
C left) 43-years-old man control; (A, B, C right) 24- years-old man with CAG 70/20 (grade 
3/4) and onset at 13-years; (D, E, F) 53- years-old man with CAG 46/17 (grade 3/4) and 
onset at 36-years; (G, H, I) 56- years-old man with CAG 49/22 (grade 4/4) and 
symptomatic for over 40-years; Photo from (Vonsattel et al. 2011). 
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1.1.5. Symptoms 
HD symptoms typically manifest in midlife, between 35-50 years old and become fatal 15-
20 years after the onset and juvenile or late-onset forms have shorter disease (Foroud et al. 
1999) (Figure 1.6.).  
 
 
 
Psychiatric and behavioral problems have shown to be evident at least 15 years before 
motor hallmarks of the disease and are major constituents of the clinical spectrum of HD 
(Paulsen et al. 2001, Paulsen et al. 2006, Paulsen et al. 2008). The disease it‘s classically 
associated with progressive emotional, cognitive, and motor disturbances. In the 
prodromal phase (presymptomatic) relatively subtle symptoms (e.g. changes in 
personality, cognition, and motor control) may precede the disease onset by several years. 
Irritability or disinhibition, difficulty in developing multitasking, forgetfulness and anxiety 
are common, depression, impulsiveness, apathy and also motor changes including minor 
difficulties in coordination, balance, and slight adventitious movements of the trunk, 
limbs, and finger can be present (Foroud et al. 1999, Epping et al. 2011). Oculomotor 
abnormalities are primordial features and often the earliest motor sign; delayed initiation 
and slowing of saccadic movements, and inability to suppress glances at novel stimuli and 
an occasional nystagmus (Patel et al. 2012, Rupp et al. 2012). 
The most frequently used criteria for diagnosis of clinical HD is ‘Motor 4’- a rating within 
the Unified Huntington Disease Rating Scale ’99 (1996), made when there are signals of 
clear motor abnormalities. HD is a multi-system disease with a continuum of both 
Figure 1.6. Correlation between trinucleotide repeat length and age of onset of symptoms. Adapted 
from (Andrew et al. 1993). 
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involuntary and voluntary movement manifestations. Involuntary movements were first 
described by George Huntington as Chorea, derived from the Greek word χορεία (a kind 
of dance). Choreoathetotic movements are clonic spasm affecting voluntary muscles, with 
a random pattern. The severity varies from restlessness with mild, intermittent 
exaggeration of gesture and expression, through fidgety movements of hands and unstable 
dance-like gait, to a continuous flow of disabling and violent movements (Wild et al. 
2007). Motor symptoms commonly begin by slight twitchings in the muscles of the face, 
which gradually increase in violence and variety, which may interfere with vocalization, 
chewing and swallowing. Dysarthria and dysphagia are common in these patients (for 
review,(Walker 2007). 
Voluntary movements are also disturbed, leading to bradykinesia and rigidity with slow 
initiation and poor execution of coordinated movements, especially in later stages of the 
disease (Purdon et al. 1994). In children with the juvenile form, a dominant picture of 
bradykinesia, rigidity, dystonia, ataxia and epileptic seizures occurs (Seneca et al. 2004, 
Ruocco et al. 2006). Another finding in HD that contributes to patients overactivity is 
motor impersistence — the inability to maintain a voluntary muscle contraction at a 
constant level. Incapacity to apply steady pressure during handshake is characteristic of 
HD and is called milkmaid’s grip. Motor impersistence is a good marker of disease 
severity, since it is independent of chorea and linearly progressive. Fine motor skills, such 
as finger-tapping rhythm and rate, are useful for establishing an early diagnosis of HD 
(Walker 2007). Although chorea is the cardinal feature of HD, a significant percentage of 
patients do not refer it as the first symptom; rather, the patients refer other prominent 
symptoms, like cognitive or emotional changes (Foroud et al. 1999). 
Several studies showed a high frequency of psychiatric disturbances in HD. Depressive 
symptoms could be a direct result of brain degeneration or a psychological reaction to the 
disease. Affective component is a major concern given the high risk of suicide, estimated 
to be 5-10 times more frequent than in general population (Fiedorowicz et al. 2011).  
As disease progresses, memory deficits tend to appear. Reported impairments range from 
short-term memory deficits to long-term memory difficulties, including deficits in 
procedural and working memory. Cognitive problems tend to get worse over time and, in 
late-stage HD, leads to dementia (Montoya et al. 2006). 
Sleep disturbances are also common clinical problems in HD and include increased sleep 
onset latency, reduced sleep efficiency, disruption of sleep, more time spent awake and 
less slow wave sleep. These abnormalities appear to be related with duration and severity 
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Figure 1.7. - Major pathways of glucose 
metabolism. Adapted from (Mergenthaler et al. 
2013) 
of the disease, and degree of atrophy of the caudate nucleus. Patients also show an 
increased density of sleep spindles (Hansotia et al. 1985, Wiegand et al. 1991, Cuturic et 
al. 2009). Recently, it was shown that HD patients have a disrupted circadian rhythm 
(Morton et al. 2005) probably due to melatonin deficiency (Alders et al. 2009). 
Interestingly, the most frequent primary cause of death in HD is pneumonia and 
cardiovascular disease (Sorensen et al. 1992). 
 
1.1.6. Central and peripheral metabolic changes in HD 
The selective permeability of blood brain barrier makes the glucose as the mandatory fuel 
for cerebral energy metabolism. In particular conditions, such as starvation or extreme 
physical activity, the brain also consumes 
monocarboxylic acids, including lactate 
and ketone bodies, acetoacetate and β-
hydroxybutyrate (Mergenthaler et al. 
2013). Glucose-6-phosphate does not only 
generate ATP but it’s also used for 
pentose phosphate pathway (PPP) that 
generates NADPH to manage oxidative 
stress and to synthesize nucleic acid 
precursors. In glycolysis, glucose is 
degraded to pyruvate and then to lactate 
(Figure 1.7.). This process is not very 
energy-efficient, resulting only in the 
production of 2 mol of ATP/mol of 
glucose and in regeneration of reducing 
equivalents (the oxidized form of 
nicotinamide-adenine dinucleotide, NAD+). The use of lactate as a supplemental fuel 
varies with its availability and physiological state of the subject. The astrocyte–neuron 
lactate shuttle hypothesis supports the proposition that lactate (even from the bloodstream) 
is taken up and used by neurons under normal physiological conditions (Boumezbeur et al. 
2010). Alternatively, pyruvate enters the tricarboxylic acid cycle (or Krebs cycle) and 
produce ATP of glucose via mitochondrial oxidative phosphorylation (Mergenthaler et al. 
2013). 
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Bioenergetics defects are emerging as important pathophysiological mechanisms in 
neurodegenerative disorders. In a recent study, glucose metabolism was found to be 
significantly decreased in striatum and temporal and frontal cortical lobes, in both 
preclinical and affected HD patients, with marked striatal hypometabolism seen in later 
stages of disease reflecting neuronal atrophy (Ma et al. 2007). Thalamic hypermetabolism 
and cortical hypometabolism and hypoperfusion have also been detected in early stage of 
symptomatic HD patients with Positrons Emission Tomography or Single Photon 
Emission Computed Tomography (Ma et al. 2007). Also prodromal patients present 
unique pattern of brain metabolism and dopamine D2 receptor binding that appear to 
precede significant volumetric changes striatal which may be useful for following 
progression during different phases of the disease (Feigin et al. 2007).  
As it was described previously mHTT and its fragments can interfere with energy 
production, through interaction with a variety of key proteins involved in energy 
metabolism. HTT interacts with an important enzyme involved in glycolysis GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase) (Burke et al. 1996, Ratovitski et al. 2012) 
and when mutated partially inhibits its activity in a disease progression dependent manner 
causing a significant decrease in ATP production culminating in cell death but also 
oxidized GAPDH facilitates nuclear translocation of mHTT by translocating to the nucleus 
together with Siah (ubiquitin-E3-ligase) (Bae et al. 2006, Wu et al. 2007, Zala et al. 2013).  
The major cause for energetic deficit involves mitochondrial abnormalities triggered by 
mHTT which impairs oxidative phosphorylation, the final step in ATP production 
pathway. Defects in HD respiratory chain seems to be a secondary event involving 
specific mHTT-mitochondria interactions leading to increased production of reactive 
oxygen species therefore having a major role in both necrotic and apoptotic mechanisms 
of cell death. A dramatically decrease of the activity of complex II/III and mildly complex 
IV in the caudate or putamen, with normal levels in the frontal cortex or cerebellum was 
observed in postmortem studies of symptomatic patients or models of HD (Gu et al. 1996, 
Maksimovic et al. 2001, Benchoua et al. 2006, Browne 2008). Nevertheless the 
preferential decrease of respiratory chain enzymes, in particular complex II (SDH/II - 
succinate dehydrogenase) and to a lesser extend cytochrome c oxido-reductase (IV) seems 
to involve oxidative stress to which iron-sulfur cluster–containing proteins are more 
susceptive (for review,(Mochel et al. 2011).  
It has been widely described that HD patients have increased lactate levels in the basal 
ganglia and elevated lactate to pyruvate ratio in the CSF as well as reduced ATP synthesis 
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(Jenkins et al. 1993, Koroshetz et al. 1997). This findings suggests that damage to 
mitochondria and impaired energy metabolism occurs in the disease, leading to conversion 
of pyruvate in lactate to generate ATP (Koroshetz et al. 1997, Martin et al. 2007). 
Although glucose is the primary energy source for neurons and astrocytes, the first can 
utilize glial-produced lactate as an additional energy substrate under abnormal conditions 
(Pellerin et al. 1994). Increased lactate reflects metabolic and energy impairment, resulting 
in tissue acidosis which in turn induce glial and neuronal cell swelling (Koroshetz et al. 
1997). It has been described that pyruvate concentrations are significantly lower in HD 
patients group, which may also increase the L/P ratio (Koroshetz et al. 1997).  
In HD patients and in several transgenic mouse models, weight lost and muscle wasting is 
a hallmark of the disease, accompanying its evolution (Djousse et al. 2002, Gaba et al. 
2005, Aziz et al. 2008, van der Burg et al. 2008). The considerable weight loss, 
particularly on its final stages, seems directly associated with the number of CAG repeats 
(Aziz et al. 2008). Patients with higher body mass index were linked with slower 
progression of HD (Myers et al. 1991). HD patients are either underweight (Djousse et al. 
2002) or tend to lose weight during the course of their illness, eventually becoming 
cachectic in end-stage, despite adequate caloric intake (Aziz et al. 2008). Underlying 
mechanisms of weight loss remain to be clarified but some studies tried to elucidate this 
matter. Aziz and colleagues found an increased basal resting energy expenditure in early 
stage HD patients which was primarily due to an increased fat oxidation rate (Aziz et al. 
2010). One study reported that total energy expenditure was 11% higher in HD patients 
(Gaba et al. 2005). The majority of presymptomatic HD patients present an altered 
metabolic profile which may therefore represent an early step in HD pathogenesis and 
general metabolic derangement (Gaba et al. 2005). Moreover, some studies referred 
increased motor activity to be involved in weight loss (Pratley et al. 2000), whilst others 
referred a hypermetabolic state, leading to a negative energy balance (Aziz et al. 2008, 
Goodman et al. 2008).  
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Others proclaim that weight loss may be due to hypothalamic dysfunction (Petersen et al. 
2006, Gabery et al. 2010). Hypothalamus establishes the connection between peripheral 
endocrine system activity and central nervous system activity, as this organ facilitates 
hunger, thirst, reproductive function, and circadian rhythms. Loss of orexin-positive 
neurons in the lateral hypothalamic area, important for regulation of sleep and wakefulness 
and feeding behavior, was observed in R6/2 mice (Petersen et al. 2005). N171–82Q HD 
mice also present significant transcriptomic alterations in the hypothalamus (Martin et al. 
2012). Alterations in the hypothalamic–pituitary–adrenal axis of HD patients and mice 
Figure 1.8.- Hypothalamic and endocrine changes found in patients and in mouse models 
with HD. 1- atrophy, alterations in neuropeptide levels, and neuropathology in the hypothalamus 
of patients; 2 - Increased prevalence of diabetes; 3- increased levels of cortisol; 4- Reduced levels 
of leptin in HD patients and and adipocyte dysfunction occurs in R6 ⁄ 2 mice; 5- Alterations in 
gene expression and muscle pathology; 6-testis atrophy in HD mice and levels of testosterone are 
reduced; 7- Weight loss; 8- Neuroendocrine factors can be meaured in CSF, serum and ⁄ or urine 
such as ghrelin; leptin, orexin, testosterone, cortisol and insulin. Adapted from (Petersen et al. 
2006). 
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models point to increase evidences of important pathology of the hypothalamus and the 
endocrine system in HD (figure 1.8.) 
 
 
1.1.6.1.Diabetes mellitus in HD  
When glucose metabolism is impaired and glucose uptake by cells is reduced, blood 
glucose levels rise. If this occur chronically a metabolic disease, Diabetes Mellitus, can 
arise (WHO, 2006). The most common Diabetes mellitus (DM) forms are type I and type 
II. Type I diabetes is characterized by loss of insulin-producing β-cells in pancreatic islets 
of Langerhans leading to insulin deficiency. In type II diabetes insulin resistance is the 
main characteristic and, initially, there is no reduction in insulin secretion, but a deficient 
response to insulin (James et al. 1994). 
Neurodegenerative disorders are known to be associated with increased risk for DM. In 
HD the reports so far in human and mice have been controversy on the prevalence of DM. 
The leading causes for DM in several mouse models of HD are well known, nonetheless 
the mechanism for DM in HD patients not yet been elucidated. The first paper describing a 
higher prevalence of diabetes in HD was (Podolsky et al. 1977) in which 50% of the 
patients studied had impaired carbohydrate metabolism, probably due to decreased insulin 
secretion. In 1985, Ferrer studied 620 probands with HD and found that 65 of them 
(10.5%) had diabetes, suggesting that HD patients had 7 times more probability of have 
diabetes. A more recent study, focused on changes in insulin sensitivity and insulin 
resistance, major determinants of glucose homeostasis, in a group of consecutive 
normoglycemic patients with HD, showed impairment in insulin secretion capacity, 
accompanied by simultaneous decrease in insulin sensitivity and an increase in the insulin 
resistance (Lalic et al. 2008). Post mortem studies in 9 HD patients and controls revealed 
that islet cell area was unchanged in HD and mRNA insulin quantification by in situ 
hybridization were similar to levels in control individuals. Also, no cytoplasmic or nuclear 
inclusions in islet cells were found contrary to R6/2 mice models described previously 
(Bacos et al. 2008). Pancreatic β-cells inclusions are the most probable explanation for 
pancreatic dysfunction and subsequent DM 2 (Andreassen et al. 2002). The development 
of those inclusions may require a longer CAG repeat, not seen in late onset HD patients, 
and the slow disease progression may also spare the cells. Aziz et colleagues assessed 
lipid and glucose metabolism during both basal and insulin stimulated conditions in early 
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stage, medication free HD patients (44,4 CAGs) in comparison with matched controls and 
found no evidence for insulin resistance but verified an inverse association between 
mutant CAG repeat size and insulin sensitivity (Aziz et al. 2010). They suggest that 
peripheral polyQ length interference with insulin signalling therefore become clinically 
relevant in higher CAG carriers (Aziz et al. 2010). 
However, an increase risk among early and middle-stage HD patients was not found in 
another study perhaps because the patients studied had different anthropometric features 
(Boesgaard et al. 2009). Moreover, multiple HD mice models display metabolic 
dysregulation, developing glucose intolerance and glycosuria- R6/2 (Bjorkqvist et al. 
2005); R6/1 transgenic mouse (Josefsen et al. 2008) and HD-N171-82Q mice (Schilling et 
al. 1999). Recently, Hunt et al. (2005) found that from 9 weeks of age R6/2 glycosuria and 
glucose intolerance were detectable. It worsens with age, affecting more than 70 % R6/2 
mice at 14 weeks and its severity was associated with progressive formation of 
ubiquitinated inclusions in pancreatic β-cells. Pancreatic aggregates were identified at the 
same time as neuronal, around 3 weeks age, and its accumulation was associated with 
selective disruption in expression of transcription factors essential for glucose-responsive 
insulin gene expression leading to impairment of insulin release rather than insulin 
resistance (Hunt et al. 2005). Bjőrkqvist et al. (2005) identified two separate pathological 
processes that may be responsible for diabetes in R6/2 mice: impaired β-cell replication 
(resulting in deficient β-cell mass (~35%) most likely due to impaired regeneration of islet 
cells) and a reduction of insulin-containing secretory granules (abrogating stimulated 
hormone secretion). R6/1 mice, carrier of a shorter CAG repeat, although not diabetic, 
shows impaired glucose tolerance (Josefsen et al. 2008). 
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1.2.Normal function of huntingtin 
1.2.1. Development  
HTT is a protein with approximately 350 kDa, composed of more than 3100 aminoacids 
(aa). It is primarily a cytosolic protein, ubiquitously expressed in mammalian tissues, 
including brain (Trottier et al. 1995). Highest levels were found in the brain, particularly 
in cortical layers II and V and in the Cerebellar Purkinje cells (Trottier et al. 1995). 
Cellular functions of HTT remains unclear, however it has been associated with the 
nucleus, endoplasmic reticulum, Golgi complex, synaptic vesicles and mitochondria (Li et 
al. 2004). Some studies suggested that it has an important role during embryogenesis, 
being essential for gastrulation. Knockout of the gene in mouse during embryonic stage 
was lethal approximately at day 7.5, whilst the conditional knockout in mouse forebrain at 
postnatal or later embryonic stages causes a progressive neurodegenerative phenotype, 
suggesting a constitutive role important for neuron survival (for review,(Bhide et al. 
1996). HTT was also detected through human brain from 19th to 21st week of fetal 
gestation, suggesting that it may play an important constitutive role in neurons during 
brain development. This also suggests that the development controls heterogeneity in 
neuronal expression of HTT and that intraneuronal distribution of the protein may be 
directly correlated with neuronal maturation (for review,(Bhide et al. 1996). Transiently 
knockdown of endogenous HTT by morpholino oligonucleotides in zebrafish revealed that 
it may be essential to development and it may be involved in normal blood function and 
iron utilization (Lumsden et al. 2007). Furthermore, HTT appears to be important during 
adult life. In this regard, deletion of HTT gene in Drosophila showed that it may have an 
essential role in long-term mobility and survival of adult animals, accelerating the 
neurodegenerative phenotype (Zhang et al. 2009). Additionally, the conditional deletion of 
HTT in forebrain and testis of adult mice led to degeneration of these tissues (Li et al. 
2004). 
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1.2.2. Structure 
The human HTT protein has a polyglutamine stretch at the N-terminus, adjacent to a 
proline-rich region which is an important mediator of protein-protein interactions (Figure 
1.9). This region is followed by four clusters of HEAT repeats (Huntingtin, elongation 
factor 3 (EF3)) known for been a protein-protein interaction site (Warby et al. 2008). In 
the N-terminal domain relies a retention signal responsible for cytoplasmic targeting and 
at C-terminal a nuclear export signal was identified being both subject to posttranslational 
modifications (PTM) and thus the protein localization (Rockabrand et al. 2007).  
 
 
 
 
 
 
Figure 1.9. – Huntingtin and its post translacional modifications. Predicted HEAT repeats and PEST 
domains. Phosphorylation sites (yellow) occur at threonine (T) or serine (S) residues. Lysines (K) (green and 
purple) are modified by the addition of ubiquitin or sumo-1 and lysine (K) 444 by acetylation (red) and 
cysteine (C) 214 by palmitoylation (pink). HTT can be cleaved by several proteases: calpain (blue triangle) 
caspase −2 (green triangle), −3 (black triangle) and −6 (red triangle) and matrix metalloprotease-10 (ΔΨM-
10) site at 404 (orange triangle). Additional proteolytic cleavage sites lie at the N-terminus of HTT and 
cleavage between amino acid 104-114, 205-214, 81-129 and at R167 generate cp-A, cp-B , cp-1 and cp-2 
fragments. Adapted from (Ehrnhoefer et al. 2011).  
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1.2.3. Interactors 
HTT interacts with a wide range of cellular proteins through multiple interaction domains. 
Structural analysis of HTT identified up to 36 HEAT (huntingtin, elongation factor 3, the 
A subunit of protein phosphatase 2A and TOR1) repeats, with approximately 40-amino 
acid long, composed of two hydrophobic antiparallel helices that acts as a scaffold protein. 
 
 
Figure 1.10.- Quantitative analysis of normal and expanded HTT interactome. The graph shows the 
functional preferential interactors for HTT-20Q and HTT-50Q. Adapted from (Ratovitski et al. 2012) 
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1.2.4. Functions 
Proposed cellular functions of HTT include endocytosis, modulation of synapse structure 
and synaptic transmission; transcriptional regulation (especially of brain-derived 
neurotrophic factor (BDNF), essential for survival of striatal neurons in HD; axonal 
transport of BDNF and vesicles, and anti-apoptotic activity (Ho et al. 2001, Leavitt et al. 
2001, Leavitt et al. 2006, Caviston et al. 2009).  
HD pathogenesis has been suggested to be also related with a loss of function in wild-type 
HTT. This may be due to a 50% decrease in the expression of HTT and to its cleavage and 
sequestration into aggregates, thus impairing its neuroprotective function and culminating 
in neuronal dysfunction and death (Ho et al. 2001). The polyglutamine repeat (polyQ) 
expansion promotes association with several proteins, leading to their intracellular 
accumulation into 5-7 μm aggregates 
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1.2.5.Mitosis
1.2.5.1.Cell cycle 
Self-renewal and differentiation of cells is profoundly associated with cell-cycle 
progression. The main goal of cell cycle is to replicate and transmit genetic material to 
daughter cells. During S phase and M phase chromosome replication and chromosome 
transmission occurs, correspondingly, whereas G1 and G2 represent gap phases. In G1 and 
G2 cells increase in size and represent checkpoints where control mechanisms ensure that 
all the machinery is properly working for DNA synthesis and to enter M phase and divide. 
The hESCs maintains the four cell cycle canonical stages, G1, S, G2, and M, with a 
specific cell-cycle profile characterized, though. The fast proliferation rate is due to a very 
short overall cell cycle (15-16 h) and a lack of a functional restriction or check point at the 
G1/S transition (Becker et al. 2006, Wang et al. 2009). hESCs are characterized by a 
shortened G1 phase (∼ 2.5 h) and accelerated organization of subnuclear domains that 
mediate the assembly of regulatory machinery for histone-regulated gene expression 
(Becker et al. 2006). A recent study demonstrated that the duration of G1 in iPSCs is also 
considerably shorter, compared to somatic cells, only 2.5-3 h, but has a similar duration of 
S (~8 h), G2 (~4 h), and M phases (~ 1 h) (Ghule et al. 2011). Cell cycle progression is 
controlled by cyclin-dependent kinases (CDKs) that are activated by cyclin binding and 
inhibited by CDK inhibitors. CDKs regulate check-points and coordinate cell cycle 
transitions. The G1 →S phase transition is regulated by the activities of cyclin D1/CDK4, 
cyclin E/CDK2 and cyclin A/CDK2 complexes, whereas G2→M transition is mainly 
regulated by cyclin B/CDK1. CDK2 had the highest expression in the S phase, cyclin A 
and c-Myc in S and G2 phase, cyclin B1 in the G2 phase, cyclin E in the G1 and S phase, 
whilst Cdc25A in the G1 phase of the cell cycle of hESCs (Neganova et al. 2008). When 
hESC are cultured in suspension cyclin E expression is upregulated in Embryoid Bodies 
and CDK2 was considerably downregulated by day 10 of EB development. Some 
transcriptional factors could also regulate the cell cycle such as NANOG and Oct4 
(Neganova et al. 2008, Zhang et al. 2009). NANOG helps to maintain pluripotency and 
proliferation by enhancing transition from the G1→S phase in hESCs through the direct 
binding of the C terminal domain of NANOG to the regulatory regions of Cdk6 and 
Cdc25A. Another common feature of hESCs and iPSCs is the high expression levels of 
telomerase activity (Thomson et al. 1998). iPSCs also showed reduced levels of histone 
methylation at telomeres, compared to somatic cells, which facilitates the exchange of 
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DNA between telomeres showing a bias towards modulation of the pathways involved in 
senescence (Davy et al. 2009).  
 
 
 
 
1.2.5.2.The mitotic spindle  
Cell division is a serial of events aiming to transmit genetic content to daughter cells. 
During mitosis the duplicated chromosomes are divided equally through morphological 
changes occurring in five stages: prophase, prometaphase, metaphase, anaphase and 
telophase (Figure 1.11). In prophase chromosomes condense, the spindle starts to 
assemble and centrosomes move to opposite poles. At the end, nuclear envelope breaks 
down and prometaphase begins. Instantly, proteins attach to the centromeres creating the 
Figure 1.11.- Mitosis and cytokinesis. Prophase- chromosomes recruit condensin and begin to undergo a 
condensation process. Prometaphase- fragmentation of the nuclear envelope for spindle assembly. 
Metaphase – chromosomes assume their most compacted state. Anaphase - separation of sister 
chromatids. Telophase and cytokinesis - Mitosis ends and the nuclear membrane then reorganizations and 
the chromosomes begin to decondense into their interphase conformations. Telophase is followed by 
cytokinesis where the division of the cytoplasm into two daughter cells happens. Adapted from 
(http://ehumanbiofield.wikispaces.com). 
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kinetochores and chromosomes attach to the mitotic spindle through sister kinetochores 
beginning to move. During metaphase spindle fibres align the chromosomes along the 
middle of the cell nucleus known as metaphase plate allowing for a symmetric split. 
At anaphase sister chromatids separate and move towards the opposite sides. This is 
achieved by the shortening of kinetochore microtubules. Motion results from a 
combination of kinetochore movement involving grow and shrink of microtubules along 
the spindle and through the physical interaction of polar microtubules. During telophase 
chromatids arrive at opposite poles and a new nuclear envelop reassembles around them. 
The spindle fibers disperse and cytokinesis begins. A cleavage furrow, contractile ring of 
actin and myosin, forms at the equatorial cortex separating the two daughter cells. 
During metaphase a complex macromolecular structure designated the mitotic spindle, 
where the principal components are centrosomes and microtubules, is formed. Spindle 
poles consist of polarized array of microtubules, the minus end embedded at the spindle 
and the plus end pointing the cell cortex. This microtubules antiparallel array comprise 
kinetochore microtubules that attach to chromosomes, interpolar microtubules and astral 
microtubules connecting spindle to cell cortex. The spindle alignment is tuned by 
microtubules dynamical growth and shrinking through the addition and removal of tubulin 
dimers, referred as ‘dynamic instability’. The position and orientation is coordinated by 
pulling forces acting on astral microtubules, driven by dynein-mediated pulling forces 
generated at the cell cortex (Kotak et al. 2012, Laan et al. 2012). The spindle assembly 
and positioning is dependent on a protein complex comprising cytoplasmic dynein, 
dynactin, the nuclear mitotic apparatus (NUMA) protein, and the G protein regulator 
leucine-glycine-asparagine repeat (LGN) protein. During cell division, LGN is recruited to 
the cell cortex by glycosyl phosphatidylinositol-linked (Gαi/Gαo), which binds LGN 
carboxy-terminal GoLoco motifs (Zheng et al. 2010), which in turn recruits NUMA 
forming a conserved tripartite complex, NuMA/LGN/Gαi (Zhu et al. 2011). NUMA most 
probably recruits the dynein–dynactin complex to the cortex and this complex exerts 
pulling forces on astral microtubules that contact this cortical region (Peyre et al. 2011, 
Collins et al. 2012, Kotak et al. 2012, Laan et al. 2012, Elias et al. 2014). As referred, both 
dynein, a motor proteins involved in spindle orientation, and microtubule 
depolymerization are responsible for generate the pulling forces for poleward motion of 
chromosomes. In vitro evidences also showed that dynein can induce a catastrophe simply 
by holding the microtubule with its growing end against the barrier (Laan et al. 2012). The 
minus end–directed motor dynein often accumulates at the plus ends of microtubules, and 
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dynactin (dynein activator) has been shown to modulate this localization (for 
review,(Kardon et al. 2009). The mitotic spindle undergoes gentle rocking movements 
during metaphase allowing proper localization but never diverge far from the apical/basal 
polarity axis (for review,(Siller et al. 2009). Another partner required for appropriate 
spindle orientation is HTT (Godin et al. 2010, Elias et al. 2014, Molina-Calavita et al. 
2014). Has been widely described the interaction of HTT with proteins involved in vesicle 
trafficking and intracellular transport (Caviston et al. 2007, Caviston et al. 2009). 
Moreover, HTT-associated protein 1 (HAP1) is a huntingtin binding partner that interacts 
with p150
Glued
 subunit of dynactin (Engelender et al. 1997, Li et al. 1998). Furthermore 
was reported that huntingtin binds directly to dynein to enhance dynein-mediated vesicle 
motility along microtubules (Gauthier et al. 2004, Caviston et al. 2007, Zala et al. 2008). 
Elias et al (2014) proposed that HTT is a key regulator of kinesin 1-dependent trafficking 
of dynein, dynactin, NUMA, and LGN along astral microtubules to the cell cortex and in 
the cortex dynein/dynactin/NUMA/LGN complex are responsible for generating pulling 
forces on astral microtubules for mitotic spindle positioning (Figure 1.12) (Elias et al. 
2014). 
 
 
 
 
Figure 1.12. - Proteins involved in spindle assembly. HAP1- huntingtin associated-protein 1, HTT- huntingtin, 
LGN - Leu-Gly-Asn repeat-enriched protein, NuMa – nuclear mitotic apparatus 
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1.2.5.3.In development and cell fate specification 
Spindle orientation seems to be a decisive factor for regulating cell fate particularly in the 
cortex and retina. In many tissues when progenitors divide symmetrically two identical 
cell fates are generated (neuroepithelial progenitor/ neuroepithelial progenitor or 
neuron/neuron, depending neurogenesis timeline occurrence) and if apical/basal spindle 
orientation predominate two different cell types are formed (Figure 1.13.). Initial studies 
on ferret neocortex indicated that the apical-basal division were asymmetric and 
neurogenic, whereas planar divisions were symmetric and proliferative (Chenn et al. 
1995). Latter was observed that most neural progenitors divide with a near planar 
orientation even at stages where asymmetric divisions predominate and slight shifts in 
spindle orientation may regulate symmetric versus asymmetric division. The cleavage 
plans can bisect or bypass the apical domain determining the location of cell constituents 
responsible for cell fate (Kosodo et al. 2004, Noctor et al. 2008). This concept was 
reinforced by observation of asymmetric inheritance of regulatory proteins leading to 
differential gene regulation in daughter. Numb, a cell fate-determinant, display an 
asymmetrical and apical membrane pattern on dividing ventricular neural progenitors 
(Noctor et al. 2008, Couturier et al. 2012). Asymmetric cell divisions was proposed to 
comprise 3 steps: (1) a cell polarity axis is specified; (2) cell polarization is translated into 
the asymmetric localization of cell fate determinants; and (3) the mitotic spindle aligns 
with the cell polarity axis, leading to the segregation of fate determinants in only one 
daughter cell (Morin et al. 2011). Moreover, HTT was also found to be required in murine 
neuronal progenitors for appropriate spindle orientation and for cell fate determination 
(Godin et al. 2010). A recent study associated mHTT expression and increased 
asymmetric division and depletion of progenitors pool. Additionally the ventricular zone 
of mutant protein carriers embryos was considerable smaller as the thickness of layer VI 
was reduced (Molina-Calavita et al. 2014). In the same line, magnetic resonance imaging 
brain scan of prodromal Huntington's disease patients revealed smaller intracranial adult 
brain volume suggesting that mHTT can cause abnormal development, which may 
contribute to the pathogenesis of Huntington's disease (Nopoulos et al. 2011). 
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Figure 1.13 - Spindle orientation and positioning in the mammalian neuroepithelium. The mammalian 
cortex is a pseudostratified epithelium with morphologically distinct layers, including cortical plate (CP), 
intermediate zone (IZ), subventricular zone (SVZ) and ventricular zone (VZ). Neural epithelial cells or 
radial glia progenitors in the VZ (tan cells) can undergo planar and molecularly symmetric divisions (left); 
planar but molecularly asymmetric divisions (centre) or apical/basal molecularly asymmetric divisions 
(right). Molecularly, asymmetric divisions, generate a basal progenitor/neuron (green) and a neuroepithelial 
progenitor (tan). Adapted from (Siller et al. 2009)  
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1.3. Huntingtin and HD 
1.3.1. Loss of wild-type huntingtin 
Although HTT protein is crucial for embryonic development its constitutive role during 
lifespan is still controversial. Rigamonti et al (2000) proved that wild-type huntingtin acts 
by protecting CNS cells from a variety of apoptotic stimuli, including serum withdrawal, 
death receptors, and pro-apoptotic Bcl-2 homologs through the action of caspase-9. The 
full-length protein also modulates the toxicity of the poly-Q expansion and cells 
expressing full-length mutant protein are susceptible to fewer death stimuli than cells 
expressing truncated mutant huntingtin (Rigamonti et al. 2000). Another study, using a 
YAC transgenic mouse model, showed that wild type HTT can protect against the gain of 
function caused by the expanded polyglutamine tract in mutant huntingtin (Leavitt et al. 
2001). Wild type HTT seems to protect by reducing the cleavage of mutant full length 
HTT, as opposed to attenuating the apoptosis caused by the toxic fragment. In YAC 
transgenic mice was seen that the proapoptotic effect of mutant htt can be completely 
inhibited by increased levels of murine wild-type HTT (Leavitt et al. 2001).  
Wild type HTT was also found to reduce the cellular toxicity of mutant HTT exon 1 
fragments in both neuronal and non-neuronal cell lines (Ho et al. 2001). Strehlow et al 
(2006) found that cells lacking HTT exhibit a significant reduction in transcripts encoding 
proteins destined for the extracellular space, many of which are components of the 
extracellular matrix or involved in cellular adhesion, receptor binding and hormone 
activity (Strehlow et al. 2007). Moreover, in Hdh null cells lysosomal activity and 
apoptosis are increased suggestive of elevated cellular stress (Strehlow et al. 2007). In a 
full-length knock-in mouse model of HD cortical HTT was required for the correct 
establishment of cortical and striatal excitatory circuits, and this function of HTT is lost 
when the mutant HTT is present (McKinstry et al. 2014). An accumulative number of 
studies implicate HTT in early neural developmental processes. In ESC, loss of HTT, 
disrupted the specification for multiple stages of neural induction, whereas mHTT 
expressing clones displayed impaired proliferative potential, enhanced cell death and 
altered multi-lineage potential promoting precocious neurogenesis and oligodendrocyte 
progenitor cell elaboration (Nguyen et al. 2013). Recently, NSC lines generated from a 
series of heterozygous Hdh CAG knock-in ES with different CAGs expansion were 
successfully maintained and the lines showed no differences in terms of proliferation rate 
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and cell cycle distribution. Nevertheless wild-type HTT seems necessary to direct NSC 
towards a neuronal fate and its absence causes cells to undergo glial differentiation 
(Conforti et al. 2013). Taken together, all these evidences suggest a role for loss of wild 
type HTT function in the pathogenesis of the disease.  
 
 
1.3.2. Misfolding and aggregation of mutant huntingtin 
Formation of such aggregates could indicate either an inability to degrade the mHTT or an 
overall inhibition of cellular trafficking and degradation machinery (Gatchel et al. 2005). 
Two mechanisms have been hypothesized for aggregate formation of aggregates:  
- the Polar zippers model refers that aggregation results from multimerization by 
hydrogen-bonded polar zipper. This was confirmed by the reduction of monomeric 
fragments upon incubation in concentrated formic acid (Perutz et al. 1994). The 40 
residues threshold of polyQ has been explained by the fact that the protein sequence forms 
a helical fiber with 20 residues turn, and that two turns (40 residues) are required for 
stabilization of the helix and promotion of multimerization (for review,(Hoffner et al. 
2007);  
- Transglutaminase-catalyzed cross-linking. Transglutaminases are enzymes involved in 
cross-linking of glutamine residues and, thus, may also participate in the formation of 
aggregates. Several in vitro studies showed that depending on protein length HTT is a 
substrate of transglutaminase (Kahlem et al. 1998). Transglutaminase activity appears to 
be elevated in HD brain cortex and cerebellum, regions where HTT aggregates into 
nuclear inclusions (Karpuj et al. 1999). A possible function of brain transglutaminase is 
stabilization of neuronal aggregates. This is corroborated by its wide distribution and 
activation in brain and by the occurrence of ε- (γ-glutamyl) lysine cross-linking in normal 
brain (Karpuj et al. 1999, Hoffner et al. 2007, Gil et al. 2008), Inclusions were found in 
affected areas of brain (such as cortex and caudate/putamen) but not in unaffected areas 
(such as cerebellum) (Hoffner et al. 2005). Interestingly inclusions observed in affected 
areas are limited to neurons and are not detected in glial cells. In juvenile form of disease, 
with large polyQ expansion, inclusion tend to be located in nucleus whilst in patients with 
the adult onset HD patients (with shorten polyQ expansion) inclusions are mostly 
cytoplasmatic (DiFiglia et al. 1997).  
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A study using an antibody directed against the 17 most N-terminal amino acids of HTT, 
showed that the frequency of nuclear inclusions (but not that of cytoplasmic inclusions) is 
correlated with the severity of disease, suggesting that nuclear aggregation (but not 
cytoplasmic aggregation) might participate in neuronal death (Hoffner et al. 2005). 
Another study identified others aggregates located in neuropils, which are likely to 
correspond to dendrites, and that may contribute to neuronal death, by disturbing dendritic 
transport (Gutekunst et al. 1999).  
Several studies demonstrated that HTT fragments are more toxic to cells than full-length 
mHTT and that such toxicity is proportional to the size of polyQ tract, being also related to 
the progressive truncation of HTT (Thakur et al. 2009). A consequence of HTT cleavage 
is the release of N-terminal fragments (HTTNT) containing the polyQ tract, which 
interacts with at least 25 proteins that can be recruited into aggregates of mHTT. 
In affected areas of the brain (such as cortex) normal HTT exists as a soluble monomer, 
but the mHTT is found in fragmented, oligomerized and polymerized forms, which can be 
either soluble or insoluble in water. The water-soluble forms of cortical mHTT consist of 
oligomerized and fragmented HTT. Soluble oligomers appear to accumulate in cortex, 
where they are much more abundant than the normal protein. The water-insoluble mHTT, 
which is mostly associated with inclusions, consists of oligomeric, polymeric and 
fragmented protein, establishing bonds with each other via non-covalent bonds since they 
are released by formic acid. These structures are stabilized by covalent bonds since 
presents resistant to formic acid (Hoffner et al. 2007). Some evidences have shown that 
these inclusions could act as neuroprotective through sequestration of toxic N-terminal 
fragments and oligomers of mHTT and other misfolded proteins, which would be 
deleterious in the soluble form (for review,(Gil et al. 2008).  
Accumulation of unfolded or misfolded proteins in endoplasmic reticulum (ER) could 
induce stress and trigger neuronal death. The apoptosis signal-regulating kinase 1 (Ask1), 
a MAPK kinase kinase that activates JNK pathway (c-Jun N-terminal kinases), may play a 
role in this process, since Ask1 is activated by ER stress and that phosphorylated Ask1 
interacts with HTT fragments, allowing them to translocate into nucleus more efficiently. 
This interaction has a positive feedback loop, since it amplifies ER stress and may 
contribute to potentiate HTT toxicity (Cho et al. 2009).  
Activity of wild-type and mHTT can be modulated by post –translational modifications. 
MHTT can change post-tradutional modifications of proteins once they are formed. 
Several studies indicated that HTT phosphorylation at various sites is neuroprotective, by 
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preventing cleavage of mHTT and its consequent aggregation. Activation of insulin 
growth factor 1 (IGF-1)/protein kinase B (Akt) pathway is protective for neurons 
expressing mHTT, probably due to phosphorylation of HTT on Ser421 (serine 421) (Colin 
et al. 2008). 
 
 
 
1.3.3. Intracellular mechanisms of toxicity 
The gain of function of mHTT and the loss of function of wild-type HTT are potential 
contributors to neuronal dysfunction in HD (for review,(Landles et al. 2004). Several 
processes may be involved this deregulation, as described in Figure 1.14: 
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Figure 1.14.- Model for cellular pathogenesis in Huntington’s disease. 1) Wild-type HTT is cleaved and 
stays in the cytoplasm. 3) The mutation causes a conformational change and abnormal folding of the protein, 
which can be corrected by molecular chaperones. 4) Mutant HTT can undergo proteolytic cleavage, both in 
the cytoplasm (6) and in the nucleus. 5) HTT complexes also stimulate IP3 (Inositol 1,4,5-Trisphosphate) 
activation of the calcium release channel IP3R (IP3 Receptor), a key player in intracellular Ca2+ signaling. 7) 
HTT can also associate with transduction proteins and repress transcription. 8) HTT interacts with the 
NMDAR to increase intracellular Ca2+. 9) Mutant HTT increases the amount of IP3 produced by MGluR5 
(Metabotropic Glutamate Receptor-5) stimulation via G-Proteins and PLC (Phospolipase-C). PLC lead to the 
formation of IP3 and DAG (Diacylglycerol). DAG forms PKC (Protein Kinase-C) which activates NMDAR, 
whereas IP3 helps in calcium release by binding to IP3R. The combination of these effects increases the 
intracellular calcium concentration. 10) This leads to overactivation of Caspase3 11) Apoptotic stress 
induces mitochondrial depolarization and increases the release of Ca2+ enhancing the caspases activation and 
cleavage of HTT. 12) The number of CAG repeats in determines the degree of HTT interaction with HIP1 
and HAP1. As repeat numbers increase, HTT binds less to HIP1 and more to HAP1. 12) Huntingtin also 
enhances vesicular transport of BDNF (Brain-Derived Neurotrophic Factor) along microtubules. Huntingtin-
mediated transport involves HAP1 and the p150Glued subunit of Dynactin. The alteration of the 
HTT/HAP1/p150(Glued) complex due to the presence of mHTT, which cannot bind, correlates with reduced 
association of motor proteins with microtubules. 
 
 
 
1.3.3.1.Protein misfolded and inhibition of protein degradation 
Formation of aggregates in nucleus, cytoplasm and neurons all processes is one of the 
main features of HD, involving sequestration of several proteins by N-terminal fragments 
of mHTT (for review,(Landles et al. 2004) Several components involved in handling and 
degradation of misfolded proteins (e.g. chaperones, ubiquitin, proteasome subunits and 
autophagy proteins) were found on such aggregates (Mitra et al. 2009). Heat shock 
proteins (HSPs) may play an essential role in folding and assembly of newly synthesized 
proteins and in re-folding the misfolded ones and aggregation. HSP70, a molecular 
chaperone, is thought to bind in early stage of HD in order to maintain the protein in a 
soluble conformation. HSP 70 interacts with a co-chaperone protein that regulates its 
ATPase activity, the HSP 40 family. These chaperones also bind to misfolded proteins and 
are able to refold alone (Jana et al. 2000). Chaperones can also re-direct these proteins to 
the ubiquitin-proteasone pathway and increase the expression of HSPs, which has proven 
to be neuroprotective. These two chaperones were found in cytoplasmic and nuclear 
aggregates, probably as an attempt to refold the m protein (Jana et al. 2000). Chaperones 
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were also reported to inhibit caspase-3 and 9 activities and to improve cell viability 
independently of aggregate formation (Zhou et al. 2001). 
mHTT was shown to interact with numerous transcriptional factors, such as NF-Y, which 
has been reported to regulate HSP70 transcription, resulting in an overall reduction of HSP 
70 gene expression (Yamanaka et al. 2008).The ubiquitin-proteosome system (UPS) is 
another neuroprotective mechanism that prevents accumulation of misfolded proteins, by 
degrading them. In vivo studies have shown that UPS activity is impaired and some 
components of proteosome are sequestered into aggregates (Wang et al. 2008) . MHTT 
can be ubiquitinated, itself, which may represent an attempt to eliminate the aggregates 
(Finkbeiner et al. 2008). However, several hypotheses have been proposed to explain such 
impairment: 1) mHTT could be retained in proteolytic core and impair proteasome 
activity; 2) mHTT aggregation may impair proteasome or 3) for the proteasome regulatory 
complex to unfold mHTT and present it to the core catalytic subunits for proteolysis 
(Finkbeiner et al. 2008). In this regard, it has been suggested that HD could be a 
proteasomal storage disease (Goellner et al. 2003).  
A recent study used mass-spectrometry-based methods to quantify polyubiquitin chains 
from transgenic mouse and knock-in models demonstrating that the abundance of lysine 
48-linked polyubiquitin chains could be a faithful endogenous biomarker of UPS function 
(Bennett et al. 2007). These chains where shown to accumulate early in brains of mice and 
humans with HD showing that UPS dysfunction is a consistent feature of HD pathology 
(Bennett et al. 2007).  
While UPS mainly degrades short nuclear and cytosolic proteins, bulk degradation of 
cytoplasmic proteins or organelles is largely mediated by macroautophagy (also known as 
autophagy) (for review, (Chu 2006). Increased autophagy was previously found in HD, 
probably as a response to reduce the toxicity induced by the aggregates (Sapp et al. 1997) 
 
 
1.3.3.2.Caspase activation 
Proteases (including caspases, calpains and aspartyl endopeptidades) are involved in 
cleavage of HTT within the N-terminal domain (Graham et al. 2006). Several studies 
demonstrated that HTT is a caspase substrate with defined sites for caspase-3 at amino 
acids 513 and 552, for caspase-2 at amino acid 552, and for caspase-6 at amino acid 586 
(Wellington et al. 1998, Wellington et al. 2000). Two caspase-3 consensus sites at amino 
 36 
 
acids 530 and 589 that appear to be silent have been also decribed (Graham et al. 2006). 
HTT is cleaved by caspase 3 and 6 in vitro, and caspase-3-cleaved HTT fragments have 
been identified in HD brain, prior to the clinical onset. This suggests that N-terminal HTT 
fragments may play a role in HD pathogenesis (Graham et al. 2006). Both wild-type and 
mHTT can be cleaved by proteases, but fragments generated from wild-type HTT appear 
to be more efficiently cleared through the ubiquitin–proteasome pathway (Wellington et 
al. 2002). Such fragments were mainly detected in cytoplasm, which may indicate that this 
precedes nuclear uptake of N-terminal HTT fragments (Wellington et al. 2002).  
MHTT can also reduce the ability of HTT to bind and inhibit active caspase-3 and to bind 
HIP1 (HTT interaction –protein 1), which is then free to associate with HIPP1 (HIP1-
protein interactor) and activate caspase-8, an initiator caspase involved in the apoptotic 
cascade (for review,(Gil et al. 2008). In FVB-YAC128 mice expressing full-length mHTT, 
the inhibiting of caspase-6 (but not caspase-3) was shown to protect loss against striatal 
volume and neuronal loss, suggesting that caspase-6-mediated proteolysis of mHTT (586 
aa), generating a toxic fragment and mediates excitotoxic stress. Cleavage of HTT could 
be an ‗initiating‘ factor for neuronal dysfunction, by generating toxic fragments, altering 
cellular trafficking and gene expression patterns and activating cell death pathways via 
altered interaction with HTT-associated proteins. HTT proteolysis could also act as a feed-
forward loop, in which cleavage may occur prior to the onset of neurodegeneration in HD, 
and initiate or exacerbate progression towards activation of cell death proteases and 
subsequent cell death.  
Calpains are a family of Ca
2+
-dependent intracellular cysteine proteases, activated by 
elevated intracellular calcium levels, which cleave HTT between amino acids 437 and 540 
an area that overlaps with caspase cleavage sites in the protein (amino acids 518–586) 
(Wellington et al., 2003). 
 
1.3.3.3.Transcription deregulation 
It has been proposed that mHTT interacts with several transcriptional factors recruiting 
them into the aggregates and inhibiting their activity (for review,(Bithell et al. 2009). 
Important transcriptional factors (e.g. CREB [cyclic-adenosine monophosphate (cAMP) 
response element (CRE)] binding protein (CBP) (Steffan et al. 2000), Nucifora (Nucifora 
et al. 2001), specific protein-1 (SP1) (Li et al. 2002), TATA-binding protein (TBP), TBP-
associated factor TAFII130 (Dunah et al. 2002) and the pro-apoptotic transcription factor 
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p53) directly interact with mHTT (Steffan et al. 2000). CBP, with a polyQ stretch, is 
sequestrated into mHTT aggregates, suppressing CREB-mediated CRE transcription 
(Steffan et al. 2000). TBP, also containing a polyQ stretch, and was shown in an in vivo 
study to be incorporated into mHTT aggregates and to suppress its DNA binding by 
mHTT (Steffan et al. 2000). SP1, which binds to glutamine-rich region in certain 
promoters and activates transcription of the corresponding genes and TAFII130 interacts 
with a soluble form of mHTT, suppressing of SP1 transcriptional activity and finally 
downregulating dopamine D2 or nerve growth factor receptor (Steffan et al. 2000). p53 is 
incorporated into mHTT aggregates via its SH3 sequences, leading to repression of p53-
mediated transcription (Steffan et al. 2000).  
Interaction of mHTT fragments with transcriptional factors is sufficient for transcriptional 
deregulation in vivo suggesting a model whereby mHTT interacts directly with DNA, 
altering its conformation and transcription factor binding and ultimately leading to 
transcriptional deregulation (Benn et al. 2008). Benn et al. (2008) observed that both wild-
type and mHTT occupy gene promoters in vivo and proposed the enhanced genomic DNA 
binding by mHTT, (facilitated by its nuclear-localization) alters DNA conformation and 
subsequent binding of transcription factors, disrupting normal control of mRNA 
expression at an early time point in HD pathogenesis (Benn et al. 2008). Several 
transcription factors that interact with the mutant protein have acetyltransferase activity 
that may impair gene expression, by altering histone acetylation levels. Hypoacetylation 
has been linked to repression of gene activity (Sadri-Vakili et al. 2006).  
mHTT can also inhibit gene expression in the cytosol (Zuccato et al. 2003). Wild-type 
HTT was found to interact with the repressor element-1 transcription factor (REST) in 
cytoplasm. REST associates with neuron restrictive silencer factor (NRSF) to affect 
nuclear transcription of neuronal genes, including that of BDNF. This interaction REST– 
NRSF could prevent their entry to nucleus and thus reduce their suppression of gene 
expression. However, mHTT bind weakly with REST–NRSE, leading to increased 
accumulation of REST–NRSF in nucleus and subsequent inhibition of BDNF and other 
genes expression (Zuccato et al. 2003). 
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1.3.3.4.Disruption of axonal transport 
Several HTT-binding cytoplasmic proteins are involved in vesicle trafficking and 
intracellular transport. A particular protein, HAP 1, was proposed to facilitate the 
interaction with microtubule motor proteins, forming a complex with kinesin (plus-end 
directed microtubule motor protein) and with p150
Glued
 subunit of dynactin (Caviston et al. 
2007). A study demonstrated a co-precipitation of a complex that includes cytoplasmic 
dynein, dynactin, HTT, kinesin and HAP1 (Caviston et al. 2007). HAP1 is a multidomain 
protein with versatile functions that also interacts with HGS, which in turn participates in 
endocytosis of the epidermal growth factor (EGF) receptor (Gauthier et al. 2004). HAP1 
was recently found to interact with the type 1 inositol (1,4,5)-trisphosphate receptor 
(IP31), forming an IP31–HAP1A–HTT ternary complex in which the mHTT enhances the 
sensitivity of IP31 to inositol (1,4,5)-trisphosphate (for review,(Li et al. 2004). HAP1 
interacts with NeuroD (a transcription factor important for neuronal development and 
survival) and HTT interacts with NeuroD via HAP1 (for review,(Gil et al. 2008). HTT has 
also been linked to actin-based motors through optineurin, a protein that links myosin VI 
to Golgi membranes (Caviston et al. 2007). A neurotrophic factor essential for neuronal 
survival, BDNF, is decreased in striatal neurons. BDNF is secreted by cortical neurons, 
delivered by axonal transport and re-endocyted by striatal neurons (Gauthier et al. 2004). 
In several studies, it was shown that mHTT plays an important role such depletion, as a 
consequence of defective axonal trafficking (Gauthier et al. 2004). A study demonstrated 
an increased association of polyQ-HTT to HAP1 and p150
Glued
, leading to the depletion of 
HAP1, p150
Glued
, dynein IC (intermediate chain), and kinesin HC from microtubules 
(Gauthier et al. 2004). This occurs mainly in the early stage of disease, while in later 
stages neuritic aggregates accumulate and contribute to reduce axonal transport (Gauthier 
et al. 2004). 
 
 
1.3.3.5.Synaptic dysfunction 
Interactions of mHTT with cytoplasmic proteins have been involved in synaptic 
dysfunction, either by impairment of axonal transport or sequestration of synaptic vesicles 
or proteins necessary for endocytosis and recycling (e.g. membrane receptors) (Trushina et 
al. 2006). Inhibition of endocytosis occurs through a non-clathrin, caveolar related 
pathway (Trushina et al. 2006). A recent study revealed that mHTT leads to accumulation 
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of intracellular cholesterol, which is essential to promote synapse formation and 
maintenance membrane integrity in CNS (central nervous system) neurons (Trushina et al. 
2006)  
Another HTT-interacting protein is the neurospecific phosphoprotein PACSIN 1/syndapin, 
which is located along neurites and within synaptic boutons and has been implicated in 
synaptic vesicle recycling (Modregger et al. 2002). Interaction through C-terminal SH3 
domain with mHTT leads to re-localization of PACSIN 1 away from varicosities towards 
neuronal cell body (Modregger et al. 2002). SH3-containing proteins, binding partners for 
synaptojanin and dynamin I, play a major role in signal transduction from membrane 
receptors and in regulation of exo/endocytic cycle of synaptic vesicles (Sittler et al. 1998). 
MHTT was also found to bind to this domain and may contribute to neuronal cell death 
(Sittler et al. 1998). Another example of loss of function is HIP14 (a neuronal protein that 
is located mainly in Golgi apparatus and cytoplasmic vesicles) that interacts strongly with 
wild-type HTT but weakly with the mutant protein and may compromise intracellular 
traffic (Singaraja et al. 2002). Several proteins involved in exocytosis are decreased in 
HD, including complexin II (Smith et al. 2005). Complexin II interacts with the soluble N-
ethylmaleimide-sensitive fusion protein attachment protein receptor (SNARE) complex 
(involved in neurotransmitter release and regulation of membrane fusion between the 
synaptic vesicle and the presynaptic plasma membrane) (Smith et al., 2005). Another 
protein whose levels are decrease is rabphilin 3A that is involved in priming and docking 
of vesicles to the plasma membrane (Smith et al. 2005).  
Excitotoxicity induced by glutamate has been implicated as one of the main causes of 
neuropathology of HD (Fan and Raymond, 2007). R6 transgenic mice have an increased 
release and a decreased clearance of glutamate by the glial cell glutamate transporter 
GLT1 with subsequent sustained glutamate stimulation of striatal neurons (Smith et al. 
2005). Neurons from mice R6/2 were shown to have increased responses of NMDA and 
decreased Mg
2+
 sensitivity, suggesting that NMDA receptor alterations may occur very 
early in development and that constitutively abnormal NMDA receptors with enhanced 
response may be present (Starling et al. 2005). MHTT facilitates activity of NR2B subtype 
of NMDARs and InsP3R1, causing influx of Ca
2+
 (Tang et al. 2005). Activation of 
glutamatergic receptors alters Ca
2+
 homeostasis, which in turn affects downstream 
pathways and initiate second messenger cascades (Fan et al. 2007). When buffering 
capacity is compromised, activation of catabolic enzymes (such as nucleases, proteases 
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and phospholipases) as well as generation of free radicals and induction of mitochondrial 
damage can occur (Fan et al. 2007).   
Metabotropic glutamate receptors (mGluR) (e.g. mGluR1, mGluR2 and mGluR3) and 
ionotropic receptors (3-hydroxy-5-methyl-4-propionate (AMPA) and kainate receptors 
(KA)) as well as D1 and D2 dopamine (DA) receptors were also found to be decreased or 
with decreased binding activity in R6 ⁄ 2 mouse model (for review,(Gil et al. 2008).  
Interestingly, normal HTT associates with postsynaptic density 95 (PSD-95), a scaffold 
protein that causes clustering and activation of receptors in postsynaptic membrane. 
Decreased interaction of mHTT with PSD-95 may activate NMDARs (Li et al. 2004). 
 
 
1.3.3.6.Mitochondrial dysfunction and oxidative stress 
Defects in mitochondrial respiratory chain in caudate/putamen of HD patients have been 
reported include severe reduction in activity of complex II/III and milder decrease of 
complex IV activity (Sawa et al. 1999). Transcriptional impairments produced by mHTT 
could lead to disruption of Ca
2+
 homeostasis, which may further reduce CREB-dependent 
expression of mitochondrial oxidative phosphorylation proteins (Gopalakrishnan et al. 
1994). Mitochondrial respiration and ATP production were found to be significantly 
impaired in striatal cells expressing mHTT. Moreover, mHTT can also affect 
mitochondrial function by inhibiting expression of PGC-1α (peroxisome proliferator-
activated receptor gamma co-activator 1-alpha), a transcriptional factor required for 
expression of numerous genes that promote the detoxification of reactive oxygen species 
(ROS) and prevent oxidative stress (Quintanilla et al. 2009). Tang et al. (2004) propose 
that such vulnerability could arise from glutamate released by corticostriatal projection 
neurons, stimulating NR1/NR2B-composed NMDARs and mGluR5 receptors (Tang et al. 
2005). Activation of NR1/NR2B NMDARs leads to Ca2+ influx and activation of 
mGluR5 receptors through the production of InsP3 and Ca2+ release via InsP3R1. Indeed, 
mHTT sensitizes InsP3R1 to activation by InsP3, stimulating NR1/NR2B NMDAR 
activity, and directly destabilizing mitochondrial Ca
2+
 handling. As a result, an abnormal 
Ca
2+
 response in MSN occurs, leading to an overload in cytosolic Ca
2+
, which is then 
taken into mitochondria via Ca
2+
 uniporter/channel. If this occurs continuously, changes 
storage capacity limit of mitochondrial Ca
2+
 can lead to opening of mPTP (mitochondrial 
permeability transition pore), release of cytochrome c into cytosol, and activation of 
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caspase-mediated intrinsic apoptotic program (Oliveira et al. 2007). MHTT can also 
interact directly with outer mitochondrial membrane increasing the sensitivity of the 
mPTP to Ca
2+
 or other apoptotic stimuli and also the aggregates could impair 
mitochondrial movements along neuronal processes (for review,(Damiano et al. 2010). 
Weydt et al. (2006) found a decreased number of functional mitochondria, ATP/ADP and 
expression of PGC-1α target genes (involved in energy production) in brown adipose 
tissue from HD mice (N171-82Q mice) (Weydt et al. 2006). This suggests that inhibition 
of PGC-1α (usually involved in adaptive thermogenesis) may cause a global defect in 
mitochondrial function in HD mice. The authors also showed that these HD mice develop 
hypothermia associated with impaired activation of brown adipose tissue-mediated 
thermogenesis, supporting the hypothesis that impaired PGC-1α activity links 
neurodegeneration-associated mitochondrial dysfunction to thermoregulatory and 
metabolic defects in HD (Weydt et al. 2006).  
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1.4. Modeling HD 
The most reliable models reproduce neuropathological hallmarks such as degeneration of 
GABAergic medium spiny neurons at an early stage and cortical loss in advanced 
conditions and especially the phenotype of the disease (for review, Rubinsztein, 2002). 
Two categories of animal models were generated: the non-genetic and the genetic ones. 
Non genetics animal models were the only available before discovery of gene mutation 
and used excitotoxic mechanisms or mitochondrial dysfunction to induce 
neurodegeneration, primarily at striatum. Quinolinic acid (QA) and kainic acid (KA) are 
the most commonly used excitotoxic agents, acting as agonists of NMDA receptors, 
whereas 3-nitropropionic acid (3-NP) and malonic acid (MA) induce cell death in striatal 
neurons through inhibition of mitochondrial complex II (succinate dehydrogenase), 
disrupting mitochondrial electron transport chain with subsequent impairment in ATP 
synthesis (for review, Ferrante, 2009).  
Recently, genetic engineering led to the production of transgenic animals, inserting genetic 
material in the host genome or into the HTT gene locus, resulting in knock–in models. In 
HD cases, the material inserted comprised protein-coding region exon -1 (which expresses 
truncated protein) or the full length HTT gene, expressing the entire protein (for review, 
Ferrante, 2009). The most widely used animals are rodents and, recently, also non-human 
primates (Yang et al., 2008), but other non-mammalian animals exist (such as 
Caenorhabditis elegans, Drosophila melanogaster and Zebrafish) (Fecke et al., 2009). 
These models are simple and have a rapid development, allowing high-throughoutput 
testing of novel therapeutic compounds and strategies (Fecke et al., 2009).  
Currently, a wide range of models is available, differing in background, fragment/full-
length gene, CAG repeat length, promoter and endogenous expression of transgene. Those 
particular characteristics of each model influence the disease neuropathology and 
phenotype (for review, Ferrante, 2009). Frequently there is an inverse correlation between 
the severity of disease/symptoms, lifespan and mHTT expression and transgenes length 
(for review, Ferrante, 2009). The full-length models are genetically more accurate, but the 
fragment models have a rapidly disease progression with a robust phenotype, well-defined 
behavioural and neuropathological findings and premature death between 13 and 18 weeks 
of age (e.g. Carter et al., 2000). 
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1.4.1.  Animal models 
The early animal models of HD relied on neurotoxin-mediated striatal lesions. Latter on 
genetic approaches have prevailed to generate animal models of HD. Several approaches 
are currently been used to reproduce disease phenotype mostly by insertion of full-length 
or only a fragment of mutated HTT with a coding region containing only CAG repeats or 
one containing repeats that are interrupted with one or more CAA codons. The expression 
of the HD mutation can be from a transgene or knock-in of the mutation into the 
endogenous HTT locus and can resort to human HTT or the endogenous gene from the 
animal. 
 
1.4.1.1.N-terminal fragment mouse models 
The most common mice models using an insertion of truncated N-terminal fragment of 
mHTT exon 1 are the R6/1, R6/2 and N171-Q82. R6/1 and R6/2 express mHTT with 116 
and 144 CAG repeats, correspondingly, under the control of the human HTT promoter and 
N171 mice express a truncated HTT cDNA with 82 CAG repeats under the control of the 
mouse prion protein promoter (Mangiarini et al. 1996, Schilling et al. 1999). Common 
features of truncated forms are the widespread and generalized degenerative phenotype 
translated in a rapid onset of symptoms, including motor, cognitive and behavioural 
abnormalities, weight loss and a reduction in lifespan (Dragatsis et al. 2009, Cheng et al. 
2011). The exuberant phenotype exhibited by these mice models however culminates in a 
minimal neuronal death when compared to human HD patients. The premature death usually 
occurs into 12-14 weeks for R6/2, 4-5 months of age for R6/1 and 17-20 weeks for N171-Q82 
but with HD-like symptoms more similar in the last model (Yu et al. 2003, Reiner et al. 
2007). 
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CamkIIa, calcium/calmodulin-dependent protein kinase IIα; CMV, cyclomegalovirus; EGFP, enhanced 
green fluorescent protein; HD, Huntington’s disease; HTT, huntingtin; mHTT, mutant HTT; N, amino; Prp, 
prion protein. *Relative to endogenous levels except where noted otherwise. ‡Unstable, with expansions 
>250 CAG repeats reported. §These mice are no longer available. ||Relative to expression of a full-length 
human HTT transgene containing 18 CAG repeats. Adapted from (Pouladi et al. 2013). 
Table 1- Rodent models of Huntington’s disease 
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1.4.1.2.Full-length mouse model 
The full-length mHTT rodent models were created using yeast artificial chromosome 
(YAC) and bacterial artificial chromosome (BAC) technology. Those models targeted the 
human mHTT transgenes expression, including all the introns and exons as well as the 
regulatory sequences up to 24 kb upstream and 117 kb downstream of the gene, ensuring 
adequate symptoms timeline manifestation and tissue-specific expression of mHTT.  
In 1999 Hayden and colleagues developed a YAC transgenic mouse using a YAC vector 
system to express the entire human HTT gene under control of the human HTT promoter. 
YAC mouse strains contain either 72 or 128 CAG repeats. The mice with 72 expansions 
show a selective degeneration of medium spiny neurons in the lateral striatum with the 
translocation of N-terminal HTT generation specifically in the striatum (Hodgson et al., 
1999). The YAC128 has an increased size of CAG expansion of 128 CAG and in 2003 
Slow et al. characterize the natural history of disease in these mice. Motor abnormalities 
and age-dependent brain atrophy were found. In early stages of disease the mice develops 
a hyperkinetic phenotype manifest at 3 months of age, followed by a progressive motor 
deficit on the rotarod at 6 months with progression to hypokinesis by 12 months of age. 
There is a high correlation between motor abnormalities and striatal atrophy, which is 
evidently at 9 months of age, and develops into cortical atrophy at 12 months and 
significant decrease (~15%) in striatal neurons accompanied by a decrease in striatal cell 
surface area.  
The motor deficit at 6 months correlates well with evident neuronal loss at 12 months, 
suggesting that early motor dysfunction might be an indicator of the severity of the extent 
of dysfunction of striatal neurons YAC128 mice also develop mild cognitive deficits, 
which precedes the onset of motor abnormalities and progressively deteriorate with age 
(Van Raamsdonk et al., 2007). HTT inclusions appear latter to behavioral and 
neuropathological changes associated with neuronal death, at 18-month-old, presupposing 
that inclusions are not the main cause to neurons loss. Excitotoxicity was described has the 
most important mechanism responsible for cell death in which disturbed neuronal Ca2+ 
signaling is involved. An increased NMDAR-mediated current in the MSN cultured from 
the YAC128 model corroborates this idea (Shehadeh et al., 2006, Van Raamsdonk et al., 
2007; Zhang et al., 2008). This susceptibility to neuronal excitability is age-dependent in 
YAC128 which may be conditioned by background strain since FVB/N WT mice have an 
age-dependent decrease in susceptibility to excitotoxic stress probably resulting from 
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morphological changes including decreases in synaptic density, spine density and loss of 
distal dendritic segments (Graham et al., 2009). Body weight in YAC128 mouse line is 
increased at 2 month of age (Van Raamsdonk et al., 2007) represented by an increase in 
both fat mass and fat-free mass influenced by HTT which modulates the IGF-1 pathway 
(Pouladi et al., 2010). YAC128 mice were initially generated on the FVB/N background 
strain based on its advantages in generating transgenic mice and its known susceptibility to 
excitotoxicity (Taketo et al., 1991). This strain has a particular characteristic that makes it 
attractive to create HD transgenic mice, since it exhibits a high degree of neuronal loss 
when exposed to excitotoxic stress after injection of kainic acid or quinolinic acid, in an 
age dependent manner, not experienced in other HD transgenic strains (Schauwecker et 
al., 2002, Graham et al., 2009). YAC128 are useful to assess therapeutical interventions, 
since it reproduces well the phenotype of disease in humans. 
 
 
 
1.4.2.  Cellular models 
1.4.2.1.Characteristics of embryonic and induced pluripotent stem cells 
Human embryonic stem (hES) cells are pluripotent cells derived from the inner cell mass 
of a pre-implantatory blastocyst with the ability to self-renew and differentiate into any 
tissue of the three germ layers (Thomson et al. 1998).Isolation of mouse ES cells from 
blastocysts was first described in 1981 (Evans et al. 1981, Martin 1981). Based on this 
paradigm, James Thomson and co-workers (1998) derived human ES cells from 
blastocysts donated by couples undergoing infertility treatment (Thomson et al. 1998). The 
authors plated the inner cell mass onto mouse embryonic fibroblasts and after attachment 
and expansion they were able to replate onto another feeder cell layer with high success 
(Thomson et al. 1998). These cells had the capacity for self-renewal and grow for long 
periods without senescence and possessed high telomerase activity, all characteristics of 
immortalized cell lines. Moreover, structures from all three germ layers, namely 
mesodermal, ectodermal and endodermal lineages, were observed in the resulting 
teratomas. ES cells expanded in three-dimensional cultures tended to form aggregates 
grown in suspension called embryoid bodies (EBs); similarly, spontaneously formed EBs 
expressed markers representative of the three germ layers (Itskovitz-Eldor et al. 2000).  
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Undifferentiated hES cells exhibit a specific range of proteins involved in several signal 
pathways that affect their pluripotency and self-renewal. In recent years several cell 
surface and molecular markers have been shown to characterized ES cells, allowing the 
distinction with tumour stem cells. Membrane proteins are the most important markers in 
identifying ES cells; these include the carbohydrate epitopes associated with the lacto- and 
globo-series glycolipids Stage Specific Embryonic Antigens 1 (SSEA-1), SSEA-3, and 
SSEA-4 (Kannagi et al. 1983, Stewart et al. 2006) and the keratin sulfate-related antigens 
TRA-1-60 and TRA-1-81 (Andrews et al. 1984, Pruszak et al. 2007). These carbohydrate-
associated molecules are involved in controlling cell surface interactions during 
development. Another hallmark of ES cells is the expression of a specific range of genes 
that lead to the upregulation of some transcripts, such as Octamer-binding Protein 4 
(Oct4), Nanog, and Sox2 (Zhao et al. 2012). In humans, elevated levels of alkaline 
phosphatase are found in the cell membrane, concomitantly with elevated telomerase 
activity (Stojkovic et al. 2004).  
Although hES cells have a great potential for disease models and cell therapy application, 
several ethical questions are associated with the use of human embryos; furthermore, 
technical issues related with the limited source of ES cells, teratoma formation and graft 
immune rejection are also evident when using ES cells, thus limiting its potential 
application in treating human diseases.  
Generation of induced pluripotent stem (iPS) cells from somatic cells was one of the major 
discoveries of the last century. The work of Yamanaka and collaborators (2006, 2007) 
proved to be a milestone in the field of stem cells due to the possibility of obtaining 
pluripotent stem cells from almost any somatic cell, without raising ethical or legal 
objections (Takahashi et al. 2006, Takahashi et al. 2007). Thus, adult mammalian cells 
(usually fibroblasts or keratinocytes) can be reprogrammed into a pluripotent, self-renewal 
state maintaining a multi-lineage differentiation potential. iPS cell technology is based on 
inducing pluripotency in somatic cells through the retroviral-mediated introduction of four 
transcription factors, namely octamer-binding transcription factor-3/4 (Oct3/4), SRY-
related high-mobility-group (HMG)-box protein-2 (Sox2), c-Myc and Kruppel-like factor-
4 (Klf4) – known as the “Yamanaka factors” (Takahashi et al. 2006, Takahashi et al. 
2007). These authors selected 24 genes based on their pivotal role in the maintenance of 
pluripotency in ES cell and in early embryos. The authors differently combined these 
genes and introduced them into mouse embryonic fibroblasts in order to screen for proper 
reprogramming factors via the Fbx15-Neo reporter system. To determine which of the 24 
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candidates were critical, selective withdrawal of individual factors from the pool of 
transduced candidate genes was performed. The combination of the four transcription 
factor genes (Oct3/4, Sox2, c-Myc and Klf4) into mouse embryonic fibroblasts was 
enough to generate ES cell-like colonies. One year later the same transcription factors 
were transduced into adult human dermal fibroblasts, generating colonies morphologically 
similar to hES cells that formed teratomas when injected into immunodeficient mice 
(Takahashi et al. 2007). Resorting to tetraploid complementation, injection of iPS cells 
into the blastocyst generated live chimeras and germline transmitted mice (Okita et al. 
2007, Kang et al. 2009, Zhao et al. 2009).  
The protocol of iPS cell generation has been applied to numerous cell types, more 
commonly mouse and human, and refined to the combination of other factors and 
methodologies aiming to reduce the risk of insertional mutagenesis (Okita et al. 2008, 
Fusaki et al. 2009, Sommer et al. 2009, Woltjen et al. 2009, Yu et al. 2009, Zhou et al. 
2009, Okita et al. 2010, Anokye-Danso et al. 2011, Sommer et al. 2012).  
Several studies have proven that iPS cells are highly similar to ES cells in terms of growth, 
morphology, gene expression, epigenetic status and the potential for differentiation, but 
small differences were found at the molecular level (Chin et al. 2009, Marchetto et al. 
2009, Prigione et al. 2010, Razak et al. 2013). Marchetto and colleagues (2009) performed 
microarray analysis and concluded that 1,952 Refseq-annotated genes were significantly 
enriched in iPS versus hES cells and that 1,072 genes were enriched in hES versus iPS 
cells. They identified three groups of biologically interesting genes that changed by at 
least 4-fold compared to hES cells. The first group of iPS cells-expressed genes were 
proteins important in early embryonic fate, such as Stella, ZFP42 (the same as REX1), 
CLDN10, LEFTY1 and LEFTY2, which were not sufficiently induced when compared to 
hES cells. The second group contained iPS cells-expressed genes that were not sufficiently 
repressed, such as ZIC1, OLIG2, EN2 and PTX3, but were associated with the neuronal 
lineage. The third group consisted of genes that were upregulated in iPS cells, but silenced 
in hES cells; these included downstream factors involved in reprogramming to induce 
pluripotent cells (Marchetto et al. 2009). Chin (2009) showed that late-passaged hiPS cells 
clustered similarly as hES cells than early-passaged iPS cells, suggesting that some gene 
expression patterns have not yet been efficiently silenced from the original somatic cell; 
however, upon passage extension the different gene expression profile of hPS cells 
appeared to decrease (Chin et al. 2009). Moreover, the expression profiles of miRNAs 
were also found to be different between ES and iPS cells. For instance, several miRNAs 
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from the chromosome 19 miRNA cluster were more strongly expressed in iPS cells than in 
ES cells (Razak et al. 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.15. – A) Induced Pluripotent Stem Cell (iPS) Pathway. iPS cells are capable of 
differentiating into cells of the 3 germ layers From http://www.sigmaaldrich.com/life-science/stem-cell-
biology/ipsc.html. B) Multiple applications for iPS cells. Adapted from (Power et al. 2011)  
A) B) 
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1.4.3. Mitochondrial function and metabolism in stem cells 
1.4.3.1.Altered metabolic profile and mitochondrial function following 
reprogramming to pluripotency 
Mitochondria are double-membrane organelles, usually referred as the powerhouse of the 
cell due to its fundamental role in energy production in the form of ATP. Mitochondria are 
also involved in multiple processes including calcium homeostasis, cell signaling, reactive 
oxygen species (ROS) formation and apoptosis (Dyall et al. 2004). Interestingly, 
reprogramming somatic cells to a pluripotent state resets genetic and epigenetic 
landscapes, originating distinct metabolic signatures. Specific metabolic cellular pathways, 
such as glycolysis, the pentose phosphate pathway (PPP) and mitochondrial function have 
been reported to be involved in the regulation of stem cell physiology (Varum et al. 2009, 
Chen et al. 2010, Liu et al. 2013, Son et al. 2013).  
Highly proliferative cells such as stem cells recur to glycolysis as the main ATP source 
under aerobic conditions. A high glycolytic flux provides not only  ATP, but also anabolic 
precursors for rapid proliferation, with the associated PPP generating ribose-5-phosphate 
for nucleotide synthesis and NADPH-reducing power for biosynthetic pathways (e.g. 
nucleotide and lipid synthesis); furthermore, activation of the PPP decreases intracellular 
levels of ROS by producing NADPH through the activity of glucose-6-phosphate 
dehydrogenase, which is essential for the regeneration of reduced glutathione (GSH) by 
glutathione reductase (Prigione et al. 2010). Recent studies revealed that human ES cells 
obtain most of their ribose from added glucose, with genes in the PPP and lipid 
biosynthesis pathways highly expressed before their differentiation (Varum et al. 2009, 
Zhang et al. 2011).  
During differentiation of pluripotent stem cells (PSC) a significant shift occurs in energy 
production resulting in a shunt of most of the cytosolic pyruvate into mitochondria, where 
it is oxidized via the Krebs cycle into acetyl-coenzyme A by pyruvate dehydrogenase, 
along with stimulation of the electron transport chain to synthesize ATP through oxidative 
phosphorylation (OXPHOS).  
Thus, during reprogramming to pluripotency a few dramatic metabolic changes succeed 
such as glycolysis being the referential ATP production mechanism over OXPHOS. Rapid 
proliferative pluripotent stem cells, such as hESC, require a high glycolytic flux to support 
anabolic metabolism; glycolysis provides intermediate metabolites and, as referred, 
protects against oxidative stress avoiding the production of high levels of ROS.  
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Nuclear reprogramming also induces profound morphological and structural changes at 
mitochondria. This remodelling results in globular or spherical structures with similar 
minimal and maximal axes lengths and small and undeveloped cristae reflecting a more 
condensed configuration (dark condensed matrix and expanded translucent cristae), as 
compared to their differentiated progeny; indeed, more differentiated cells show 
mitochondria with tightly packed thin cristae within an expanded translucent matrix 
(Prigione et al. 2010, Suhr et al. 2010, Zeuschner et al. 2010, Folmes et al. 2011). Stem 
Figure 1.16 - Metabolic pathways Pathways: green – glycolysis; red – tricarboxylic acid (TCA) 
cycle; blue – oxidative phosphorylation; brown – non-essential amino-acid synthesis; pink – pentose 
phosphate pathway and nucleotide synthesis; purple – fatty acid synthesis. The SDH complex is 
involved in both the TCA cycle and oxidative phosphorylation Different complexes of the electron 
transport chain are represented in this diagram. Solid arrows indicate direct conversion whereas dotted 
arrows indicate a general pathway (King et al. 2006). 
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cells mitochondria usually assume a punctate or fragmented pattern compared with the 
well-developed filamentous network of somatic cells (Zhang et al. 2011). Mitochondrial 
localization also suffers significant changes, by transiting from a wide cytosol network to 
a dominant perinuclear and bipolar localization, most likely to support the vast genetic and 
epigenetic alterations or probably due to the lack of cytoplasmatic space. Reprogramming 
induces mitochondria to recede into an immature state observed in ES cells, characterized 
by low copy number of mitochondrial DNA (mtDNA) and spherical mitochondria with 
poorly developed cristae (Facucho-Oliveira et al. 2007, Kelly et al. 2013).  
An important parameter of mitochondrial function, membrane integrity, and energy 
coupling is mitochondrial membrane potential (ΔΨm). Recently it was found that iPS and 
hES cells have an elevated ΔΨm, which decreases upon differentiation; indeed, increased 
ΔΨM is observed in mouse embryonic fibroblasts (MEFs) undergoing the reprogramming 
process. This hyperpolarized-associated mitochondrial state of pluripotent stem cells is 
most likely related to the reduced ATP consumption, and the preferential glycolysis-based 
energy metabolism, as described before. Prigione et al (2011) observed that ΔΨm was low 
in all fibroblast cells, but increased in iPS cells independently of the age of the donor and 
in a similar manner as in an hES cell line (Prigione et al. 2011). Despite all immature 
features, mitochondrion is still able to produce ATP from OXPHOS and consume oxygen. 
Some controversial papers have been published about mitochondria content. Prior studies 
refer a low content in hES cells (St John et al. 2005, Facucho-Oliveira et al. 2007), 
whereas recent data demonstrated that when mitochondrial mass (measured by 
mitochondrial proteins, mitochondrial labeling with MitoTracker Red and calcein-AM, 
and mtDNA copy number) is normalized to total cellular mass, the ratio between these 
cellular parameters is similar in iPS cells and differentiated cells (Birket et al. 2011, Zhang 
et al. 2011). To maintain the mitochondria hyperpolarized, cells rely on the hydrolysis of 
glycolytic ATP (described before in this section). Due to a reduced function of the electron 
transport chain, the F1F0 ATP synthase (complex V) is reversed, hydrolyzing glycolytic 
ATP to maintain the ΔΨM (Zhang et al. 2011). Studies comparing hES cells and 
fibroblasts demonstrated higher ATP levels in the last ones and when ATP production by 
glycolysis was blocked with sodium oxamate, a lactate dehydrogenase inhibitor, the ATP 
levels dropped dramatically, whereas inhibition of OXPHOS only caused a slight 
reduction in ATP levels in both hES and IPS cells (Varum et al. 2011, Zhang et al. 2011).  
A few studies successfully stimulated glycolysis to promote pluripotency. Some submitted 
hES and iPS lines to hypoxia conditions and verified that activation of transcription factor 
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hypoxia-inducible factor one alpha (HIF1α) enhanced reprogramming through the 
upregulation of pyruvate dehydrogenase kinase 3 (PDK3) and pyruvate kinase isoform M2 
(PKM2), while the ablation of HIF1α resulted in a dramatic loss of colony formation 
(Mathieu et al. 2013, Mathieu et al. 2014, Prigione et al. 2014). In early stages of iPS cells 
generation HIF1α and HIF2α overexpression enhanced the metabolic switch by promoting 
the kinetics of PDKs. Varum and colleagues (2009) inhibited the mitochondrial respiration 
chain specifically using antimycin A, a complex III disruptor that blocks the flow of 
electrons from semiquinone to ubiquinone in the quinone cycle of complex III and disrupts 
the proton gradient across the inner membrane, prevents O2 consumption at complex IV, 
as well as ATP formation (Varum et al. 2009). Treatment with antimycin A maintained the 
cells pluripotent, even after bFGF withdrawal, most likely due to a shift in the metabolism 
towards glycolysis, as demonstrated by an increase in lactate dehydrogenase (LDH) 
activity and partially by an increase in ROS production at complex III, leading to 
upregulating of Nanog expression (Varum et al. 2009). In vitro, Nanog, a homeobox 
transcription factor, is enriched in pluripotent cell lines but not in adult tissues. From the 
most prominent transcription factors that have been identified to be essential to the ES cell 
pluripotency more than 90% of the promoter region in the genes bound by Oct4 and Sox2 
are also bound by Nanog (Pan et al. 2007). Moreover, increasing Nanog levels in ES cells 
can stimulate pluripotent gene activation from the somatic cell genome (Pan et al. 2007.) 
A negative loop was described to be formed by Nanog, Oct4 and FoxD3, which allow the 
maintenance of Oct4 levels. Another study corroborated these results demonstrating that 
iPS cell lines generated in the presence of rotenone, antimycin A and potassium cyanide 
showed an increased reprogramming efficiency and exhibited full differentiation potential 
in vitro and in vivo (Son et al. 2013). Although these compounds promote efficient iPS 
cells generation, differentiated cells obtained from these pluripotent cells exhibited a 
substantial increase in ROS production and growth retardation, most probably as a result 
of cellular damage after exposure to the mitochondrial inhibitors (Son et al. 2013) 
Inhibition of the insulin/insulin growth factor-1 signaling pathway also was shown to 
enhance reprogramming efficiency (Chen et al. 2011). On the other hand, when glycolysis 
was inhibited by sodium oxamate and by 2-deoxyglucose, (which is taken up by the 
glucose transporters and is phosphorylated in most cells by hexokinase, generating 2-
deoxyglucose-6-phosphate, a competitive inhibitor of glucose-6-phosphate isomerase that 
catalyzes the conversion of glucose-6-phosphate into fructose 6-phosphate in the second 
step of glycolysis), reprogramming efficiency was significantly reduced (Son et al. 2013). 
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Moreover, a metabolomic analysis of genes involved in glycolytic and mitochondrial 
oxidative phosphorylation pathways corroborated these findings and also that bioenergetic 
status of somatic cells appear to correlate with their reprogramming efficiencies 
(Panopoulos et al. 2012).  
Interestingly, gene expression profiles and methylation patterns of iPS cells are influenced 
by prolonged culture in vitro; the higher the passage number, the more closely they 
genetically and functionally resemble the hES cells (Panopoulos et al. 2012). Varum and 
collaborators (2011) found that hES cells express high levels of hexokinase II and have an 
inactive PDH complex, which results in lower levels of acetyl-CoA to enter the TCA cycle 
(Varum et al. 2011). The authors also observed that hES cells have higher total protein 
levels of mitochondrial complexes II, III and V subunits when compared with 
differentiated cells. The upregulation of the TCA cycle could be a reason for these higher 
levels of mitochondrial electron transport complexes; alternatively, the transcription factor 
c-Myc, which is important to maintain cell pluripotency and self-renewal, has been related 
to mitochondrial biogenesis (Li et al. 2005). Nevertheless this overall increase in 
mitochondrial electron transport complexes does not reflect into an increase in 
mitochondrial activity. This finding suggests a rejuvenation of mitochondrial function and 
energetic capacity during the process of reprogramming. Recently, Austin Smith’s group 
at Cambridge was able to reprogram adult keratinocytes, fibroblasts or adipose-derived 
stem cells to “a true ground-state” pluripotency (Takashima et al. 2014). The reset of self-
renewal requirements and transcription factor complement in human PSC could be 
achieved by overexpressing Nanog and Klf2 or could be independent of transgene 
expression by combining two inhibitors of the Erk pathway and of glycogen synthase 
kinase-3 with LIF (Takashima et al. 2014). Interestingly, human stem cells ‘reset’ to the 
earliest developmental pluripotent state resorted more to OXPHOS for ATP production 
than conventional PS cells, indicating that mitochondrial metabolism might be different in 
the pristine state. Basal oxygen consumption rate (OCR) and the activity of electron 
transport chain activity was substantially higher in reset cells, as evidenced by a greater 
OCR in response to the mitochondrial uncoupler FCCP (carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone). Mitochondria of reset cells also hadlower 
mitochondrial membrane potential. Additionally, the cytochrome c oxidase (complex IV) 
gene family was highly expressed in reset cells than conventional PS cells for 14 out of 17 
genes, similarly to ESC. This mitochondrial activation was confirmed by culturing “reset 
cells” in 2-deoxyglucose to inhibit glycolysis or under reduced glucose concentrations to 
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increase the dependency on mitochondrial respiration; under these conditions, the cells 
formed undifferentiated colonies, unlike conventional PS cells. The reset cells where 
further implanted into mouse preimplantation embryos and successfully incorporated into 
the ICM and preimplantation epiblast (Takashima et al. 2014). 
 
1.4.4.  Metabolic profile of pluripotent stem cells 
Metabolomic analysis has demonstrated that iPS cell metabolism is quite different from 
their progeny source and similar, but not identical, to ES cells. Yanes and collaborators 
(2010) resorting to liquid chromatography-electrospray ionization mass spectrometry 
showed that mouse embryonic stem (mES) cells are characterized by the abundant 
presence of unsaturated lipid metabolites, including fatty acids, whose levels decrease 
upon differentiation; importantly, the unsaturated metabolome is highly susceptible to pro-
oxidative events, which may have a critical role in cell fate (Yanes et al. 2010). The most 
up-regulated metabolites identified are signal transduction molecules such as lipid 
messengers and inflammatory mediators, namely arachidonic acid, docosapentaenoic acid, 
eicosapentaenoic acid, linolenic acid, diacylglycerols, glycerophosphocholines, 
glycerophosphoglycerols, and eicosanoids such as prostaglandin E2 (Yanes et al. 2010). 
Eicosanoid specific signaling pathway inhibitors where used such as desaturase inhibitors 
sesamin, a selective inhibitor of 5Δ desaturase; curcumin , an inhibitor of 5Δ and 6Δ 
desaturase, COX inhibitors (SC236, a selective COX-2 inhibitor; SC560, a selective COX-
1 inhibitor, LOX inhibitors AA-861 and BW-A4C, selective 5-LOX inhibitors and a Ca
2+
-
dependent PLA2 inhibitor PTK (palmityl trifluoromethyl ketone) to promote maintenance 
of pluripotent state in mESCs when cultured in neuronal differentiation condit ions (Yanes 
et al. 2010). Inhibition of these pathways successfully stimulated the pluripotent state of 
ES cells, delaying the loss of Nanog and Oct4 expression (Yanes et al. 2010). 
Additionally, the levels of unsaturated fatty acid metabolites were lower in iPS compared 
to ES cells (Panopoulos, Yanes et al. 2012). 
Furthermore, the metabolites involved in the S-adenosyl methionine (SAM) cycle, such as 
SAM, 5′-methylthioadenosine, hypoxanthine and inosine, important for transmethylation 
reactions, such as DNA methylation, were all significantly elevated in iPS, compared to 
ES cells (Panopoulos et al. 2012). Recently, the threonine (Thr) metabolism was also 
shown to regulate intracellular SAM levels and histone methylation, such that depletion of 
Thr from the culture medium or knockdown of threonine dehydrogenase (Tdh) in mES 
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cells decreased SAM accumulation and trimethylation of histone H3 lysine 4 (H3K4me3), 
leading to slowed growth and increased differentiation (Shyh-Chang et al. 2013). Tdh 
expression levels have been shown to be more abundant in mESCs than in MEFs (Wang et 
al. 2009, Shyh-Chang et al. 2013), and Tdh inhibition was shown to abolish mESC 
growth. The importance of Tdh consists in converting Thr into both glycine and acetyl-
CoA (and also NADH), which appears to optimize the synthesis of SAM to maintain a 
high SAM/S-adenosylhomocysteine ratio (Shyh-Chang et al. 2013). Moreover, Thr 
provides glycine for purine biosynthesis to support rapid DNA replication.  
SAM is essential for pluripotency maintenance in human ES and iPS cells and their 
depletion triggers demethylation of H3K4me3, global DNA demethylation, p53 signaling 
activation, and decreased expression of the pluripotent marker Nanog, but not Oct3/4 
(Shiraki et al. 2014). Nonetheless, if methionine depletion is prolonged and cells are not 
submitted to differentiation, human ES/iPS cells undergo apoptosis (Shiraki et al. 2014).  
As previously referred, the metabolic profile of ES and iPS cells is very similar, but not 
exactly the same. This suggests that metabolite levels have a relevant role in regulating the 
epigenetic changes during reprogramming. 
 
1.4.5.  Stem cell differentiation – role of mitochondrial function and ROS 
During differentiation stem cells undergo a metabolic switch from glycolysis to oxidative 
phosphorylation. On differentiation, mitochondria from mouse and human ES cells suffer 
morphological and functional changes increasing the cristae number and generating an 
extensive reticular network of tubular structure (Cho et al. 2006, St John et al. 2006, 
Facucho-Oliveira et al. 2007) Recently, Zhang et al demonstrated that uncoupling proteins 
(UCP) have an essential role during differentiation. UCP2 is overexpressed in pluripotent 
stem cells and is repressed during differentiation, allowing the transition from glycolysis 
to glucose oxidation in mitochondria (Zhang et al. 2011). Ectopic UCP2 expression during 
early differentiation inhibits differentiation-associated genes expression and embryoid 
bodies’ formation, impairs this metabolic transition and retards ROS accumulation. UCP2 
has been postulated to be involved in shunting pyruvate out of mitochondria, blocking 
pyruvate oxidation in mitochondria and increasing the glycolytic flux (Zhang et al. 2011). 
Another mechanism apparently involved in differentiation is ROS formation. Cells in an 
undifferentiated state produce minimum amounts of ROS, specially due to an uncoupled 
mitochondrial respiratory chain, low substrate oxidation and high expression of 
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antioxidant genes UCP2, SOD2 (superoxide dismutase 2) and GPX2 (glutathione 
peroxidase 2), which are downregulated during differentiation (Saretzki et al. 2008, 
Armstrong et al. 2010, Zhang et al. 2011). ROS are known to promote lineage-specific 
differentiation. Increasing evidences point out that an accurate endogenous ROS control is 
important for cardiomyocyte formation through the activity of nicotinamide adenine 
dinucleotide phosphate reduced (NADPH) oxidase system, which triggers for 
differentiation (Crespo et al. 2010). The p38 mitogen-activated protein kinase (MAPK) 
phosphorelay system seems to control this process (Crespo et al. 2010). The authors found 
that p38 activation is temporarily upregulated during differentiation in high glucose 
medium. They also reported that mitochondrial ROS have a major role in p38 activation 
since p38 activation was not observed during differentiation in ES cells incubated with a 
mitochondrial-targeted antioxidant (MitoQ). The supraphysiological glucose levels appear 
to induce the production of mitochondrial ROS, which in turn activates the p38 system via 
Nox4 downstream pathway (Crespo et al. 2010).  
Spitkovsky and collaborators (2004) previously observed that mitochondrial changes are 
essential for cardiogenic differentiation in mES cells. The enhancement of mitochondrial 
biogenesis and complex III activity, which are responsible for spontaneous Ca
2+
 
oscillations, are main triggers of cardiomyocyte differentiation (Spitkovsky et al. 2004). 
Differentiation induction leads to profound remodelling of mitochondrial morphology and 
activity. Some studies have shown that proteins involved in fusion and fission machinery 
are changed in pluripotent cells compared to their differentiated counterparts. Wang and 
collaborators (2014) demonstrated that Dynamin-related protein 1 (Drp1, a member of the 
Dynamin family of large GTPases that controls the final part of mitochondrial fission) is 
not critical for mitochondrial biogenesis in stem cell proliferation, but is required for 
neurogenesis, since it delays the reduction of Nanog and Oct4 during differentiation 
(Wang et al. 2014). The authors proved that knockdown of Drp1 has no effect on 
mitochondrial membrane potential, proliferation nor pluripotency of ES cells (Wang et al. 
2014). Similar results were obtained with Drp1 inhibitors to prevent mitochondrial 
division resulting in an increased differentiation and consequently disruption of the self-
renewal of iPS cells (Vazquez-Martin et al. 2012). Gene knockdown of the mitochondrial 
protein growth factor erv1-like (Gfer) in mESCs lead to decreased levels of pluripotent 
markers (Nanog, Oct4, SSEA), which was associated with an upregulation of Drp1 (Todd 
et al. 2010). Cardiac differentiation of stem cells was also associated with downregulating 
of genes involved in mitochondrial fission or inhibition of fusion, including Drp1 by 
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approximately 40%, mitochondrial protein 18 kDa by approximately 66%, optic atrophy 
type 1 (Opa1) by approximately 34%, while mitofusin2 (Mfn2), linked to mitochondrial 
fusion, was upregulated by approximately 272% (Chung et al. 2007). Although little is 
known about the impact of mitochondria fusion/fission dynamics on the acquisition and 
maintenance of stem cell pluripotency, these studies shed some light in this mechanism, 
highly suggesting that reprogramming and/or differentiation processes are dependent on 
genes that influence mitochondrial morphology.  
A study concerning osteoblasts differentiation from human mesenchymal stem cells found 
that mitochondrial respiratory function was enhanced in several aspects, including an 
increase in mtDNA copy number, protein levels of respiratory complexes subunits and 
oxygen consumption rate (Chen et al. 2008). Mitochondrial biogenesis regulators genes 
such as mitochondrial transcription factor A (TFAM), peroxisome proliferator-activated 
receptor-c coactivator-1α (PGC-1α) and DNA polymerase γ (POLG) were also 
upregulated following differentiation (Chen et al. 2008). Nonetheless, when the 
intracellular ROS levels were examined both superoxide anions and hydrogen peroxide 
were significantly decreased in the beginning of differentiation though increased aerobic 
metabolism. Concomitantly, a notorious upregulation of antioxidant enzymes SOD2 and 
catalase ensured a proper redox environment for cell differentiation by preventing excess 
ROS and thus oxidative stress (Chen et al. 2008). These mechanisms can be extremely 
controversial and depend on the type of stem cells, the spontaneous or specific 
differentiation, as well as the level of differentiation. Prigione and colleagues (2010) found 
that the expression of biogenesis factors, including POLG, TFAM, and PGC-1α, was 
induced in undifferentiated iPS cells compared to somatic fibroblasts, in agreement with 
the array data, and mostly decreased upon differentiation into fibroblast-like cells 
(Prigione et al. 2010). During spontaneous differentiation the protein expression of 
TFAM, PGC-1α, and nuclear respiratory factor-1 (NRF-1) was slightly increased in the 
undifferentiated hES cells, compared to their differentiated counterparts (Cho et al. 2006). 
The factors essential for mitochondrial biogenesis (TFAM, POLG and NRF1) seem to be 
upregulated in undifferentiated cells and this may represent a nuclear response to 
decreased content of mitochondrial DNA, observed before in somatic cells depleted of 
mtDNA (Holmuhamedov et al. 2003, Lloyd et al. 2006{Holmuhamedov, 2003 #637)). 
Concordantly, disruption of mitochondrial function during differentiation by CCCP 
(carbonyl cyanide m-chlorophenylhydrazone) lead to an abnormal transcription in the 
expression of HOX genes both in mouse and hES cells (Mandal et al. 2011).  
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Moreover, Schieke and collaborators (2006) demonstrated that there is a link between 
intrinsic mitochondrial function and stem cell fate. Cells exhibiting low ΔΨm were more 
prone to undergo mesodermal differentiation and more resistant to teratoma formation, 
whereas cells retaining high ΔΨm behaved the opposite way (Schieke et al. 2008). 
Regulation of mitochondrial oxidative capacity and function seems to be under the control 
of the mTOR signaling pathway. Indeed, manipulating mTOR signaling and mitochondrial 
function affected ES cell differentiation and pointed out to a central role of the mTOR-
mitochondria axis in ES cell biology. An interaction between mTOR and PGC-1α was 
previously described, suggesting that differences in mitochondrial biogenesis might be a 
potential explanation (Cunningham et al. 2007). A common target of mTOR and PGC-1α 
is the transcription factor yang 1 (YY1) whose function is controlled by mTOR and is 
recruited to the promoter regions of the genes encoding PGC-1α and cytochrome c 
(Cunningham et al. 2007). The fact that mitochondria are in a less-functional 
hyperpolarized state helps to maintain low levels of ROS in stem cells, fundamental for 
retaining the capacity for self-renewal.  
As described before, ES cells have higher expression levels of antioxidant enzymes than 
differentiated ones, whereas an incremental level of ROS induces differentiation. ES cells 
also maintain high levels of telomerase activity, protecting telomerase shortening, which is 
reduced upon differentiation (Saretzki et al. 2008). A high telomerase activity was 
associated with antioxidant defence and DNA repair in mESC (Saretzki et al. 2008). 
Telomerase shortening are enhanced by ROS production and surprisingly it started rising 
only 2 and 3 weeks after the differentiation process, indicating that the fast telomere 
shortening during the 1st week must be caused by some other mechanism(s), most likely 
adaptation to telomerase loss (Saretzki et al. 2008). 
 
 
 
1.4.6. Mitochondrial modifications and stem cell biology – current knowledge in 
neurological disorders 
The iPS cell technology has an enormous potential and their applications are immense, 
covering pathological studies, drug screening, and cell-replacement therapy development. 
Mitochondria have a pivotal role in stem cells reprogramming and during differentiation, 
as described before in this review. Moreover, mitochondrial dysfunction has been 
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associated with the pathogenesis of several neurological disorders such as Alzheimer’s 
(AD), Parkinson’s (PD) and Huntington’s diseases (HD), amyotrophic lateral sclerosis, 
schizophrenia and bipolar disorder.  
Schizophrenia has been defined as a neurodevelopmental disease that causes impairments 
in several cognitive domains, including memory, executive functions, attention, motor 
abilities and spatial functions, leading to a mental deterioration (Heinrichs et al. 1998). 
Most individuals with schizophrenia have a disruption of fundamental neural circuits 
encircling cortical-cerebellar-thalamic-cortical subsystems (Andreasen et al. 1998). 
Altered cell respiration, elevated levels of oxidative stress and an impaired oxidative stress 
response has been reported in peripheral and central tissues of schizophrenia patients (Yao 
et al. 2004). Recently, several groups reprogrammed skin fibroblasts from schizophrenic 
patients into IPS cells and successfully differentiated them into neuronal lineages. 
Robicsek and collaborators (2013) reprogrammed iPS cells from hair follicle 
keratinocytes, which were then differentiated into β3-tubulin+/tyrosine 
hydroxylase+/DAT+dopaminergic neurons. Schizophrenia-derived dopaminergic cells 
showed impaired ability to differentiate, while glutamatergic cells were unable to 
maturate. Interestingly, abnormalities were found in protein levels of mitochondrial 
respiration (complex I) and mitochondrial network dynamics (Rosenfeld et al. 2011, 
Robicsek et al. 2013). Another group observed that neural precursor cells from 
schizophrenic patients presented increased levels of ROS, which could be a consequence 
not only of an aberrant production of ROS, but also of an impaired regulation of 
antioxidant responses (Paulsen Bda et al. 2012). Moreover, other researchers detected that 
SZ iPS cells NPCs show abnormal gene expression and protein levels related to 
cytoskeletal remodeling and oxidative stress, leading to aberrant migration and increased 
oxidative stress (Brennand et al. 2014). 
Friedreich’s ataxia (FRDA), another frequent neurodegenerative disorder, is an autosomal 
recessive multisystem disorder characterized by neurodegeneration and cardiomyopathy 
(Gomes et al. 2013). The disease is caused by reduced levels of frataxin, an essential 
mitochondrial protein involved in iron-sulfur cluster synthesis (Campuzano et al. 1996). 
Most patients are homozygous for a GAA triplet repeat expansion within the frataxin 
(FXN) gene (Campuzano et al. 1996), which leads to partial silencing frataxin 
transcription. The normal gene has up to 40 GAA repeat, while disease-associated alleles 
enclose 100–1000 GAA repeats (Campuzano et al. 1996). Depletion of frataxin mainly 
leads to mitochondrial dysfunction and increased sensitivity to oxidative stress, as well as 
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impairment of Fe-S cluster-containing proteins and altered cellular iron metabolism, 
(Schmucker and Puccio, 2010). Recently, iPS cell lines were generated from Friedreich 
ataxia patients and differentiated into neuronal and cardiac lineages.(Ku et al. 2010, Liu et 
al. 2011, Eigentler et al. 2013, Hick et al. 2013). These cells retained expanded GAA 
repeats and expressed reduced frataxin levels, epigenetic changes and repeat instability, 
although no evidence of Fe-S cluster biogenesis defects was observed. IPS cells-derived 
cardiomyocytes and neurons presented a delay in maturation and lower mitochondrial 
membrane potential (Ku et al. 2010, Eigentler et al. 2013, Hick et al. 2013). 
Several research groups were able to produce patient-specific dopaminergic (DA) neurons 
from iPS cells derived from patients afflicted by PD, a neurodegenerative disorder 
characterized by selective degeneration of dopaminergic neurons in the substantia nigra 
pars compacta (Byers et al. 2011, Devine et al. 2011, Nguyen et al. 2011, Seibler et al. 
2011, Soldner et al. 2011, Imaizumi et al. 2012, Jiang et al. 2012, Sanchez-Danes et al. 
2012). A study performed in two PARK2 patients carrying parkin mutations has shown 
abnormal mitochondrial morphology and aberrant tubulovesicular organelle structures 
adjacent to the Golgi in PARK2 iPS-derived neurons, but not in normal iPS cells 
(Imaizumi et al. 2012). The authors also found increased oxidative stress and lower levels 
of GSH in PARK2 iPS cell-derived neurospheres (Imaizumi et al. 2012). Nguyen and 
collaborators (2011) generated iPS cells that carry the mutation in the leucine-rich repeat 
kinase-2 (LRRK2) gene and reported increased activation of oxidative stress-response 
genes and enhanced α-synuclein protein expression, as well as increased sensitivity to 
caspase-3 activation and cell death following exposure to stress agents (Nguyen, Byers et 
al. 2011). Cooper and collaborators (2012) generated iPS cells from PD patients carrying 
mutations in PTEN-induced putative kinase 1 (PINK1) and LRRK2 genes and also 
observed an increased vulnerability to cellular oxidative stress (Cooper et al. 2012).  
Folmes et al. (2013) generated iPS cells from a patient with mitochondrial 
encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) that represents 
a prototypical metabolic derangement due to a high heteroplasmy burden at position 
G13513A (Folmes et al. 2013). MELAS fibroblasts demonstrated stable heteroplasmy 
with 53% wild-type sequence and 47% G13513A sequence, compared to control 
fibroblasts (Folmes et al. 2013). Cells derived with 50% heteroplasmy and devoided of 
mutated mtDNA at the disease-causing position in the ND5 subunit of respiratory chain 
complex I maintained their genotypes throughout lineage specification and differentiation 
(Folmes et al. 2013).  
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For HD several iPS cell lines have been specifically generated since the HD iPSC 
Consortium was created 
(HTTp://www.ninds.nih.gov/funding/areas/neurodegeneration/iPSC_Executive_Summary.
htm). HD patient-derived iPS cell lines exhibited mild instability of the expanded CAG 
repeat allele with passage or after differentiation. Neural progenitor cells (NPCs) exhibited 
changes in cytoskeleton, adhesion and energetics that were correlated with the number of 
CAG repeats. In a cluster formation assay HD NPCs showed significantly decreased cell-
cell adhesion properties and reduced intracellular ATP/ADP ratio. Those lines where 
successfully differentiated into forebrain cell types and DARPP-32-positive neurons 
presenting disease-associated changes in electrophysiology, metabolism, cell adhesion and 
cell death for lines with both medium and longer CAG repeat expansions. Higher CAG 
expansion neural cultures were shown to be more susceptible to acute noxious stimulus. 
Upon BDNF removal there was increased cell death, as demonstrated by an increase in 
caspase 3/7 activity; conversely, addition of four times the normal concentration of BDNF 
could partially rescue this deleterious phenotype. Handling of intracellular Ca
2+
 levels was 
also impaired following a glutamate stimulus in the higher CAG expanded line. Other 
toxic stimulus, such as hydrogen peroxide (to induce oxidative stress) and 3-
methyladenine (3-MA) (autophagy inhibition) increased cell death in the HD lines. Thus, 
HD iPS cells are more prone to cell death, as demonstrated after the withdrawal of trophic 
support, or following the addition of glutamate, or other cell stressors.  
Moreover, genetic correction of CAG repeat in iPS cell lines revealed a reversion in 
disease phenotypes, including a decrease in the susceptibility to cell death and altered 
mitochondrial bioenergetics. In the genetically corrected-derived NSCs the authors also 
found normalization in the levels of BDNF. The manipulated HD-iPS cells derived NSCs 
were transplanted into the striatum of HD mouse model brains; the cells underwent 
differentiation in vivo to DARPP-32-expressing neurons and glial cells two weeks after 
grafting (An et al. 2012). These data suggest that genetically corrected cells are able to 
efficiently populate the mouse striatum and place us closer to generate autologous cells for 
cell-replacement therapy (An et al. 2012).  
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1.5.Therapeutic strategies in HD 
1.5.1.Genetic strategies 
1.5.1.1.Gene addition 
To replace the missing function of a gene a site-specific gene addition into a 
predetermined endogenous locus in human cells can be performed. Gene insertion 
methods intent to deliver DNA fragments such as cDNA or shRNA for overexpression. 
This procedure frequently results in random insertion into the host genome generating, as 
a consequence, a partial or complete silencing of the transgene suggesting a promoter 
inactivation or methylation, which has been described for stem cells, or an insertional 
mutagenesis leading to genome instability and toxicity can also occurs (Cavazza et al. 
2013). The first successful gene transfer was in SCID-X1 where ex vivo retroviral gene 
transfer of the γc-chain (cytokine receptors) to autologous HSC (CD34+ bone marrow cells) 
was achieved (Cavazzana-Calvo et al. 2000). Later, gene engraftment of multipotent 
hematopoietic stem cells resulted in ADA transgene expression in lymphocytes and red 
blood cells restoration the immune function (Aiuti et al. 2009).  
In HD, genetic data, in humans and transgenic animal models, suggest that HTT can act 
synergistically by conferring deleterious gain-of-function on the target proteins and also 
by loss-of-function effects secondary to reduction in wtHTT expression. Overexpression 
of the protein may contribute for ameliorate disease phenotype although evidences are not 
so convincing (Luo et al. 2009, Parsons et al. 2014). 
 
 
1.5.1.2.Silencing 
Since the seminal work done by Fire and Mello in 1998 about interfering RNA (RNAi) a 
lot has been done to improve this technique and use it in clinic applications (Fire et al. 
1998). RNAi is a double-strand RNA (dsRNA) that induces degradation of a target protein 
mRNA by activating the RNA-interfering silencing complex (RISC). RNAi can be deliver 
as short dsRNAs that have complete complementarity to a target mRNA or most 
frequently introduced in the form of a vector based short hairpin RNA which consists of a 
sense sequence about 21-23 bases long followed by a six to eight base non-complementary 
loop and another 21 base sequence complementary to the sense sequence (Brummelkamp 
et al. 2002). This double strand RNA is synthesize in the nucleus of cells, processed by 
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Drosha, a ribonuclease (RNase) III, and translocated into the cytoplasm where Dicer, a 
RNase II, chops into short interfering RNA (siRNA). After incorporation into the RISC, 
the guide strand has to be selected by Ago2, which contains endonuclease activity to 
cleave the passenger strand, dissociating it from the complex. The activated RISC is then 
target to the complementary mRNA leading to degradation originating a post-
transcriptional gene silencing mechanism (Lee et al. 2003, Rand et al. 2005, Gonzalez-
Alegre 2007). This approach has shown potential applications in neurodegenerative 
disease, especially in targeting mutant forms of protein that leads to disease phenotype as 
in HD (Boudreau et al. 2009, Drouet et al. 2009), Machado–Joseph disease (Alves et al. 
2010), AD (Nilsson et al. 2010) or PD (Sapru et al. 2006). In a recent study, RNA 
interference of mHTT expression mediated by virus vector delivery of short hairpin RNAs 
(shRNAs) ameliorated early-stage disease phenotypes in transgenic mouse models of HD 
(Harper et al. 2005, Franich et al. 2008). 
However, siRNA are commonly associated with undesirable side effects which include the 
effects caused by the activation of the “interferon response”, the “saturation effects” and 
last the “off targeting effect”. This latter refers to the possibility of the sh/siRNA interfere 
with the expression of different other transcripts. siRNA off-targeting seems to be dose 
dependent, thus a recommendation is to scale down as much as possible the concentration 
of siRNA or to chemical adjust the synthetic siRNA and its sequence (Scaggiante et al. 
2011) 
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Figure 1.17.- Mechanism of RNAi silencing introduced to cells by different methods. 
 
 
Another current method of gene silencing or modulation of RNA metabolism employs 
antisense oligonucleotides (ASOs). ASOs are a 12 to 25-mer chemically modified 
synthetic nucleic acids that bind and alter RNA function through an array of different 
mechanisms. Although in nature these sequences are rapidly target to degradation, 
chemical modifications confers high stability against nuclease degradation and low 
toxicity to these molecules (Stein et al. 1988). RNA manipulation can be either through 
the recruitment of the enzyme RNaseH for degradation or by non-degradative mechanisms 
where ASOs binds sterically hampering translation, 5’ capping, or splicing (Bennett et al. 
2010) (Figure 1.17). RNaseH is an enzyme that recognizes RNA–DNA heteroduplexes, 
cleaves the RNA strand, and releases the DNA. Non-degradative mechanisms don’t 
involve activation of RNaseH enzyme but act by repressing translation, modulating 
splicing, and inhibiting microRNAs. Almost half of the genetic disorders are due to 
mutations that alter pre-mRNA splicing (Mills et al. 2012). ASOs can be design to bind 
pre-mRNA structure and modulate splicing, in vitro and in vivo, masking splicing 
enhancers and repressor sequences, inducing the skipping of one or more additional exons, 
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restore the transcript reading frame and restore the inclusion of alternatively spliced exons 
(Aartsma-Rus et al. 2007, Siva et al. 2014) 
To be effective as therapeutic ASOs must reach and hybridize with target RNA without be 
cleaved by endogenous nucleases. Modifications to the phosphate backbone have been 
made to reduce the degradation and increase the tissue half-life and in the sugar ring to 
increase target binding affinity. The earliest changes were performed in the 
phosphorothioate group, through the substitution of non-bridging oxygen in the phosphate 
backbone with a sulfur atom. Another strategy is replacing sugar phosphate backbone for a 
morpholine ring. To increase binding affinity to target RNA some chemical modification 
of the 2’ position of the sugar have been made, specially the 2’-O-methyl and 2’-O-
methoxyethyl modification which allows reduce nonspecific protein binding and 
consequently ASOs toxicity. Locked nucleic acid is an analog of the 2’-O-methyl RNA 
(Southwell et al. 2012). Despite conferring high affinity to RNA, these modifications 
reduce or even completely obstruct RNaseH enzyme cleavage. To overcome this 
limitation a “gapmer” design was adopt where a 2’-modified residues region flanks a 
longer central unmodified region allowing RNaseH cleavage at the central region of the 
ASO.  
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Since the major limitation to the systemic delivery of therapeutic AONs to the CNS is the 
blood-brain barrier (BBB) the most promising studies focus on intramuscular injection 
with AONs targeting the DMD gene. The method involves exon-skipping treatment that 
abolish the production of dysfunctional dystrophin in Duchenne muscular dystrophy 
(Endesfelder et al. 2005, Aartsma-Rus et al. 2007, Ferlini et al. 2010, Pramono et al. 
2012). To overcome this drawback animal studies employed alternative routes of 
administration (intraparenchimal injections in specific brain areas, intracerebroventricular 
injections, intrathecal injections), sometimes administering the AONs through the use of 
micro-osmotic pumps (Siva et al. 2014). Assuming AONs treatment for neurogenetic 
disorders may require administration for a long time and repeated dosing, it would be 
preferable to have a less invasive administration pathway such as nasal administration that 
could avoid toxicity due to systemic administration (Dhuria et al. 2010) or extracellular 
Figure 1.18.- Antisense oligonucleotide mechanisms of action. ASOs enter cells through plasma 
protein receptors on the cell surface, resulting in ASO compartmentalization into endosome. ASOs are 
released from the vesicles and move into the nucleus. In the nucleus, ASOs can bind directly to mRNA 
structures and prevent the formation of the 5’-mRNA cap, modulate alternative splicing, dictate the 
location of the polyadenylation site and recruit RNaseH1 to induce cleavage. In the cytoplasm binds to 
mRNA and sterically blocks the ribosomal subunits avoiding translation. 
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vesicles in the form of exosomes capable of crossing the BBB (Lee et al. 2012). 
Nevertheless a wide range of neurodegenerative disorders could potentially benefit from a 
knockdown therapeutic strategy. Theoretically all the diseases secondary to single aberrant 
protein can be treated with ASO. ASOs can be used in human neurodegeneration to 
decrease total protein, increase total protein, modulate splicing or inhibit miRNAs to 
modulate genes expression.  
A promising treatment for a CNS-neurodegenerative disorder using ASOs targets the 
human SOD1 transgene in the transgenic rat model of amyotrophic lateral sclerosis (ALS) 
(Smith et al. 2006). A clinical trial is currently ongoing in ALS patients with SOD1 
mutations (ClinicalTrials.gov 2009). 
For HD, nonselective HTT silencing and allele-specific mHTT silencing strategies are 
being pursued with ASOs. Evers et cols (2011) observed a significant reduction on protein 
and RNA levels of HTT in patient-derived fibroblast cell lines with a preferential allele 
specific reduction of mutant HTT and this allele specificity was improved ASOs dose-
dependent (Evers et al. 2011). In a recent study Østergaard et cols (2013) using RNase H 
active ASOs to target an SNP in the HTT gene achieved a high allele-selective 
downregulation of mHTT mRNA and protein in HD patient-derived fibroblasts and in the 
CNS of a fully humanized mouse model of HD (Ostergaard et al. 2013). Also a transient 
infusion of a human-specific HTT ASO into cerebrospinal fluid of symptomatic HD 
mouse models and nonhuman primates resulted in broad distribution throughout the brain. 
A selective 60–75% reduction of the human mHTT transgene up to 12 weeks post-
infusion termination and amelioration of HD like phenotype was observed (Kordasiewicz 
et al. 2012). In BACHD mice, another full length human mHTT transgenic model, a total 
knockdown of HTT mRNA and protein was attained with 14 days of 
intracerebroventricular (ICV) infusion of ASOs. The treatment resulted in a partial 
recovery of motor deficits and a halting of disease progression albeit at 16 weeks post-
treatment both mRNA and protein levels had returned to nearly basal levels. The 
therapeutic benefits extended to an additional 5 months period (Carroll et al. 2011). For 
AD, ASOs directed against the Aβ region of APP were injected intracerebroventricular or 
systemically in the tail vein. A decrease in Aβ APP expression and Aβ production was 
observed proceeded of a phenotype improvement (Chauhan et al. 2007, Fiorini et al. 2013, 
Farr et al. 2014, Farr et al. 2014). Another study showed that suppressing Glycogen 
synthase kinase 3, in 12-month-old SAMP8 mice, an AD model, with ASOs treatment, 
improved learning and memory, reduced oxidative stress and decreased tau 
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phosphorylation. (Farr, Ripley et al. 2014). RNA processing manipulation through ASOs 
is a particularly attractive method with great potential for treating many diseases. 
RNA reprogramming can also be achieved by spliceosome-mediated RNA trans-splicing 
(SMaRT
®
) (Puttaraju et al. 1999, Mansfield et al. 2000).  
The process where introns are removed from the mRNA and exons are join together to 
form mature mRNA is called cis-splicing and is catalyzed by the spliceosome, an 
enzymatic complex of many proteins and four small ribonucleoprotein particles (snRNPs): 
U1 snRNP, U2 snRNP, U5 snRNP and U4/U6 snRNP (Lim et al. 2001). A less common 
splicing process is trans-splicing, which occurs between two independently transcribed 
RNA precursors to form a composite mRNA and was suggested as a mechanism to 
generate new genes by retrotransposition (Bruzik et al. 1992). The SMaRT
®
 approach uses 
constructs called pre-trans-splicing molecules (PTMs) that are engineered to bind to 
specific pre-mRNAs in the nucleus and generate a trans-splicing event mediated by the 
spliceosome. PTMs comprise three domains: (i) A binding domain, complementary to the 
target intron and serves to tether the PTM to a specific location within the target; (ii) a 
splicing domain, which contains splicing elements that are equivalent to those found in 
cis-splicing precursors; and (iii) a coding domain, consisting of an exon or exons that are 
trans-spliced to the target. The splicing domain has the purpose of maximize trans-splicing 
activity and usually contais potent branchpoint sequence (UACUAAC) and a long 
pyrimidine-rich tract. The coding sequence can be one or more, few exons or the entire 
coding sequence. SMaRT
®
 act in three different ways: (i) 3’ exon replacement (Puttaraju 
et al. 1999, Dallinger et al. 2003), (ii) 5’ exon replacement and (Mansfield et al. 2003, 
Wally et al. 2008, Rindt et al. 2012) (iii) internal exon replacement. SMaRT
®
 as an RNA-
repair technology has been proven in a variety of models in vitro, ex vivo and in vivo (Liu 
et al. 2002, Chao et al. 2003, Pergolizzi et al. 2003). Recently Rindt et at (2012) 
demonstrate that 5’ exon replacement of HTT by spliceosome mediated pre-mRNA trans-
splicing can be achieved in cultured cells using a binary transfection system consisting of 
a HTT minigene and a pre-mRNA trans-splicing module (Rindt et al. 2012). Importantly, 
trans-splicing was also detected in endogenous HTT by the PTM lentivirus in fibroblasts 
of HD patients in the absence of minigene. Since an important part of Huntington 
pathology is accumulation of mutant protein, trans-splicing can effectively reduce the load 
by converting the mutant allele to wild-type and increasing the level of the wild-type form. 
The excision of an exon 1 with expanded polyQ tract results in a truncated RNA species 
lacking a polyadenylation signal susceptible to degradation in the nucleus.   
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1.5.2. Repair
1.5.2.1. Homologous recombination 
As DNA is continuously exposed to damage agents, cells created their how endogenous 
mechanism to repair DNA double strand breaks (DSB). When complementary stands of 
the DNA helix breaks at sites close enough from each other that base-pairing and 
chromatin structure are insufficient to keep the two DNA ends juxtaposed and DSB are 
generated. Two main largely distinct and complementary pathways for DNA DSB repair 
coexist in cells —homologous recombination (HR) and non-homologous end-joining 
(NHEJ) (Jackson 2002). During HR, the damaged chromosome enters into synapsis with 
an undamaged DNA molecule with which it shares extensive sequence homology and will 
be used as template. This method can be used to manipulate the human genome, replace or 
modify specific chromosomal regions, or insert reporters and genes in specific promoter 
locations (Capecchi 1989). Spontaneous DSBs often occur, whereas artificial DSBs are 
introduced by irradiation or site-specific endonucleases (Yajima et al. 2013). The 
efficiency of HR is extremely low in mammalian around 10
−6
 to 10
−7
 and this process can 
only allow efficient correction of mutations within a ≈200-bp window surrounding the 
break. To improve efficiency and reproducibility of this technique reporter cell lines can 
be generated with the help of gene-editing technology as engineered nucleases, chimeric 
restriction endonucleases, homing endonucleases and ‘chemical’ nucleases.  
 
1.5.2.2. Zinc finger nucleases 
Restriction endonucleases and modification methylases are simple bacterial enzymes that 
recognize specific sequences in duplex DNA. Zinc-finger nucleases (ZFNs) are hybrid 
restriction enzymes that cut DNA at any preferred site and result of the fusion of zinc 
finger proteins (ZFP) to the cleavage domain of Fok I endonuclease (Kim et al. 1996). 
These chimeric endonucleases are inactive as monomers and interact through their 
cleavage domains (Figure 1.19).  
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Figure 1.19. - DNA cleavage site recognition by zinc-finger nucleases (ZFNs). ZFN dimer is bound to a 
DNA target. Each ZFN is a synthetic protein consisting of an engineered zinc finger DNA-binding domain 
fused to the cleavage domain of the FokI restriction endonuclease.  
 
Cys2His2 zinc fingers (“zinc fingers”) define the most common transcription factor family 
in organisms ranging from yeast to humans (Razin et al. 2012). The DNA-binding domain 
is derived from the C2H2 motif of ZFP, holding 28 amino acids length including an α 
helix that can specifically bind 3 DNA nucleotides. Each ZF motifs recognizes 3–4 base 
pairs and binds via the α-helix into the major groove of the DNA double helix. These 
modules are rearranged in a specific order necessary to recognize a given sequence in a 
target locus. Each individual ZFN contains three-finger modules recognizing up to 18 bp 
binding site specific enough to just bind a single location in the genome (Liu et al. 1997). 
The complete target sequence thus consists of two 9-18 bp binding sites in opposite 
orientation separated by a 6-bp spacer (Liu et al. 1997). More recently a two DNA-binding 
domains, each containing four zinc-finger motifs and thus recognizing a total of 24 bp was 
assembled and proved to be highly specific in DNA cleavage and exhibited decreased 
cytotoxicity (Urnov et al. 2005). The construction of ‘artificial’ DNA-binding proteins that 
can bind the 64 possible DNA triplets would allow the selection of zinc finger that could 
be linked in tandem to target DNA sequences. Theoretically this system can increase the 
efficiency of gene targeting at a specific locus. This approach can be useful for gene 
disruption in model organisms for generate knockout animals or in mammalian somatic 
cell genetics, particularly in human ES cells, in which the ZFN can be transiently 
expressed. Also associated to HR can be a powerful tool for genome editing and further 
correction or for specific and stable ZFN-mediated gene addition (Urnov et al. 2010). A 
major concern about the therapeutic approach with technique is its specificity. In general 
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‘off-target’ cleavage – in which ZFNs might destroy or injure unexpected regions in the 
human genome without detection- can lead to reduced efficiency of on-target modification 
and cytotoxicity (Olsen et al. 2010).  
This method was efficiently used to target three genes in human pluripotent cells 
(Hockemeyer et al. 2009). Two reporter genes were successfully added to hiPSCs and 
hESCs (OCT4, PITX3) and a transgenes was inserted into the AAVS1 locus to generate a 
robust drug-inducible overexpression system (Hockemeyer et al. 2009). Reinhardt et al 
also resorting to this technique reprogrammed iPSCs from PD patients where a correction 
vector was cotransfected with ZFNs designed to introduce a double-strand break adjacent 
to the G2019S mutation of the LRRK2 gene (Reinhardt et al. 2013). 
 
1.5.2.3.TAL effectors 
Transcription activator-like effector nucleases (TALEN) are artificial design nucleases 
targeting specific DNA and like ZFN capable of creating DSBs in the genome. These 
nucleases result from the fusions of the FokI cleavage domain and DNA-binding domains 
derived from TALE proteins. TALEs contain multiple 33–35-aminoacid repeat domains 
that each recognizes a single base pair. Different repeat types recognize different DNA 
base pairs. The repeats can be ordered to yield TALEs with desired DNA specificity. 
Members of this effector family are highly conserved and differ mainly in the amino acid 
sequence and number of repeats. As TALEs are large molecules, Miller et al. designed and 
synthesized truncated forms of the protein. Concluded that the most active combination of 
63-bp C terminus and a 14–18-bp spacing allows higher cleavage efficiency (27%) 
comparable to ZFN (Miller et al. 2011) (Figure 1.20). 
 
 
Figure 1.20. - TALE nuclease with 63 or 28 amino acids in C terminus and FokI endonuclease domain. 
TALE nuclease dimer bound to DNA and upon FokI dimerization DNA cleaveage occurs. 
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As TALENs function as dimers, pairs can recognize 32- to 40-bp DNA sequences. 
Recently, Hockemeyer et al generated hESC and iPSC single-cell-derived clones carrying 
transgenic cassettes solely at the TALEN-specified location with similar efficiency and 
precision as do zinc-finger nucleases (Hockemeyer et al. 2011). Resorting to TALENs, 
modification of livestock embryos genome was achieved, more precisely KO of genes and 
large chromosomal rearrangements (Carlson et al. 2012). 
 
 
1.5.2.4.Crispr/CAS 
The type II prokaryotic CRISPR was first discovered in 1987 in Escherichia coli (Ishino et 
al. 1987). This bacterial adaptive immune systems known as clustered regularly 
interspaced short palindromic repeats (CRISPR) and CRISPR associated (Cas) systems 
uses a combination of proteins and short guide RNAs to recognize and cleave 
complementary DNA sequences and works as a mechanism to defend against viruses and 
foreign DNA. CRISPR are found in most archaeal (~90%) and bacterial (~40%) genomes 
(Horvath et al. 2010). Are clusters of short DNA noncontiguous repeats separated by 
nonhomologous variable sequences called spacers found at regular intervals and are often 
adjacent to Cas genes. CRISPR in combination with Cas proteins, forms the CRISPR/Cas 
systems. In type II systems consist of just four Cas genes, where Cas9 is always present. 
Cas9 is a large protein that includes two nuclease domains and provides the enzymatic 
machinery required for the acquisition of new spacers from invading elements and 
posterior destruction. The integration of those short sequences (usually 23 and 47 bp in 
length) from foreign genetic elements into repetitive genetic elements provides resistance to 
bacteria. This process comprises three stages. The first is adaptation, where foreign DNA 
is recognized, and a fragment of this DNA inserted as a new spacer into a host CRISPR 
array. A short conserved sequence called the protospacer adjacent motif (PAM), flanks the 
spacer sequence in the viral genome and determines the targets of most CRISPR/Cas 
systems. In the second occurs the transcription of a CRISPR cluster into a long precursor-
crRNA (pre-crRNA). This process is dependent on a trans-activating crRNA (tracrRNA), 
a 25 nt long stretch complementary to the crRNA repeat, encoded in the environs of 
CRISPR loci. Cas9 binds to tracrRNA:crRNA complex, which forms a RNA duplex that 
are substrates for endonuclease RNase III. Cleavage of this duplex generates short 
CRISPR RNAs (crRNAs). Transcription is controlled by promoter located within the 
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leader sequence that contains promoter elements and possible binding sites for regulatory 
proteins. In the final stage, the interference reaction, Cas protein complex use these mature 
crRNAs to target the viral foreign RNA by complementarity and degrade (Garneau et al. 
2010, Richter et al. 2012, Richter et al. 2013) (Figure 1.21). 
 
 
 
 
Figure 1.21.- A) The CRISPR/Cas system proteins can target and cleave invading DNA in a sequence-
specific manner. CRISPR–Cas systems function in three steps: adaptation or immunization (involving the 
acquisition of spacers), biogenesis of CRISPR RNA (crRNA; encoded by the repeat–spacer regions) and 
interference (cleavage of invading nucleic acid). B) RNA-guided gene targeting in human cells involves a 
C terminus nuclear localization signal with guide RNAs (gRNAs) expressed from the human 
polymerase III promoter. The protospacer-adjacent motif (PAM) targets the correct genomic sequence. 
 
 
Cas9 is an essential player in the CRISPR system as genome editing tool. To engineer the 
type II bacterial CRISPR system a specific small guide RNA (sgRNA), which is designed 
to resemble crRNA:tracrRNA sequence, is fused to Cas9 as well as an eukaryotic nuclear 
localization signal (NLS) and a promoter. The sgRNA expression plasmid contains the 
PAM sequence. The resulting ribonucleoproteins are termed RNA Cas9 guided 
endonucleases (RGENs) and can target single genes or multiple genes enabling efficiently 
and site-specific editing of the DNA sequence (Jiang et al. 2012, Wiedenheft et al. 2012, 
Mali et al. 2013, Richter et al. 2013). This system generates a DSB in the target DNA 
which can be repaired by HR or NHEJ, being the first process preferential for gene repair.  
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Subsequent studies used this process to generate disease models by introducing precise 
point mutations in two target genes allowing to generate, in one-step process, animals with 
multiple gene mutations (Li et al. 2013, Wang et al. 2013).  
The advantageous of this system is that only by changing the sgRNA and maintain the 
CAS9 protein unchanged several targets can be aimed. A single vector can also 
accommodate multiple sgRNAs that will be processed as individual RNAs targeting 
different sites in the genome (Cong et al. 2013). 
A few studies revealed that gene- editing tools can be useful to creating wild-type versus 
mutant cell lines. Some monogenic disease iPSCs lines were “cured” and hence the 
reverse of phenotype when compared to “non corrected” cells. A HD iPSCs cell line 
mentioned previously with 72 polyglutamine was genetic corrected by HR resulting in a 
21 polyglutamine repeats carrier (An et al. 2012). These cells were successfully 
differentiated into DARPP-32-expressing striatal neurons as well as some of the HD-
iPSCs features described previously (Zhang et al. 2010) were corrected, such as altered 
mitochondrial deficits, lower levels of BDNF, altered cadherin and TGF-β signaling (An 
et al. 2012). 
 
 
 
1.5.3. IGF-1 as a potential therapeutic drug  
The insulin-like growth factors, including IGF-1, IGF-2, and insulin, belong to the insulin-
like peptide hormone superfamily which are single-chain polypeptides that share a similar 
secondary structure, with three α-helixes and three disulphide bonds. IGF-1 exerts its 
action through interaction with the IGF-1 receptor (IGF1-R) although may interact with 
insulin and hybrid receptors. IGF-1-triggered cellular responses are essential for the 
regulation of tissue formation and remodeling, bone growth, prenatal growth, brain 
development, and muscle metabolism (Laviola et al. 2008). 
IGF1-R is highly expressed within the brain and is essential for normal brain development. 
In the rat brain, a widespread localization with distinct distribution patterns was found. 
The higher concentration is in regions related to olfaction, autonomy, and sensory 
processing, as well as in the pituitary gland, where they are involved in the regulation of 
growth hormone release (Werther et al. 1989). IGF-1 appear to be involved in enhancing 
nerve cell metabolism (Bondy et al. 2002) and modulate neuronal excitability (Carro et al. 
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2000) promoting antiapoptotic actions, and protect nerve cells against insults (Carro et al. 
2003).  
Upon IGF-1 binding, tyrosine kinase of the IGF-IR is activated, resulting in 
autophosphorylation of tyrosines on the intracellular portion of the β-subunit including 
tyrosine residues in the juxtamembrane and COOH-terminal domains. The phosphorylated 
tyrosine 950, in the juxtamembrane domain, acts as docking site for several receptor 
substrates, including the insulin receptor substrates and Shc proteins thus initiating 
phosphorylation cascades. Phosphorylated IRS-1 can activate the p85 regulatory subunit 
of PI3K, leading to activation of several downstream substrates, including Akt. 
Subsequently the protein synthesis is enhanced through mTOR and p70 S6 kinase 
activation and triggers the antiapoptotic effects of IGF-IR through phosphorylation and 
inactivation of Bad. Another downstream pathway that can be activated is through the 
recruitment of Grb2/SOS by phosphorylated IRS-1 or Shc. It recruits Ras and activates the 
Raf-1/MEK/ERK pathway and downstream nuclear factors, resulting in the induction of 
cell proliferation (for review, (Laviola et al. 2008) (Figure 1.22). 
 
 
 
 
 
 
 
 
Figure 1.22.- Transduction of signals and biological actions induced by insulin or IGF-1 through 
their receptor. Adapted from (Laviola et al. 2008). 
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The downstream phosphorylation of Akt by IGF-1 appears to be involved in the regulation 
of glucose transport via the facilitative GLUT4 and glycogen synthesis in peripheral 
tissues and nerve process membranes in the normal developing brain (Cheng et al. 2000). 
Another target of insulin/IGF signaling via Akt in the brain is GSK3 since it was a major 
colocalization of its phosphorylated form with abundant glycogen stores specifically in 
IGF-I-expressing neurons suggesting that IGF-I acts in an autocrine manner to promote 
glucose uptake and storage as glycogen in developing projection neuron (Cheng et al. 
2000). 
Modifications in IGF-1/Akt pathways were described in HD. Recent evidences 
demonstrate that Akt is cleaved into an inactive form by caspase-3 leading to a 
downregulation of this survival pathway (Colin et al. 2005). Previously, was shown that 
HTT is phosphorylated on serine-421 by Akt and this exerts a protective effect against the 
toxicity of polyglutamine-expanded huntingtin (Humbert et al. 2002, Pardo et al. 2006). 
Furthermore phosphorylation at S421 was reported to reduce the nuclear accumulation of 
huntingtin. The nuclear fragments of mutant huntingtin depend on cleavage at amino acid 
586 by caspase-6 and thus phosphorylation at S421 reduces its cleavage and consequently 
its nuclear targeting and also the total cellular level of full-length huntingtin (Warby et al. 
2009). Those evidences lead to an increase attention of IGF-1 role in preventing and 
rescuing the damage of striatal neurons. Duarte et al (2011) demonstrated that peritoneal 
infusion of IGF-1 partially restored plasmatic levels of IGF-1 in R6/2 mice and reverse 
metabolic defects (weight loss and impaired glucose tolerance) and improved animal 
behavior, reflected on paw clasping scores (Duarte et al. 2011). Although these data 
suggests a favourable role for IGF-1 in HD, conflicting results were published. Pouladi et 
al (2010) showed that YAC128 mice have increased levels of IGF-1 and correlate directly 
with increased body weight (Pouladi et al. 2010). M o r e o v e r ,  i n  HD patients h igh 
plasma IGF-1 was associated with cognitive decline (Saleh et al. 2010) and additionally, 
in R6/2 mice, higher levels of insulin receptor substrate 2 was related with reduced 
lifespan and increased neuronal oxidative stress and mitochondrial dysfunction 
(Sadagurski et al. 2011). However, activation of IRS2 in mutated exon1-expressing cell lines 
induced the clearance of accumulated mHTT through a mTOR-independent macroautophagy 
pathway (Yamamoto et al. 2006).  
More evidences were reported in other medical conditions. IGF-1 has been suggested to 
exert protective role against stroke in rats when administered intracerebroventricularly 
(Lin et al. 2009, Liu et al. 2009), intranasal administration in spinocerebellar ataxia-1 mice 
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rescues motor phenotype (Vig et al. 2006) and was shown to down regulate glial 
activation and induces expression of endogenous growth factor with anti-depressant 
activity therefore reducing depressive-like behavior (Park et al. 2011) 
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1.6. Hypothesis and specific aims of the present work 
HTT, a large and ubiquitously expressed protein, when mutated, is responsible for the 
appearance of a devastating neurodegenerative disease - HD. Although recent findings 
have enlightened the pathophysiological pathways surrounding its mechanisms and 
clinical features much is still unknown about the trigger event(s). This thesis focuses on 
clarify some pathological mechanisms involved in the disease development but also 
identify possible therapeutic targets and therapeutic approaches aiming to rescue MSN 
from neurodegeneration and death in vivo and in vitro. 
 
We divide this study in three approaches. The first aimed to evaluate the possible 
protective role of IGF-1 pathways against behavior impairment in HD and mechanisms of 
action. For this purpose, we used animal models expressing full length mHTT and tested a 
novel methodology for administration of IGF-1 into the HD brain. Indeed, BBB is one 
major limitations of therapeutic success for peripheral administrated compounds and this 
technique can overcame this.  
 
The second approach aimed to identify the role of HTT mutation on human neural 
progenitors division and reverse the phenotype through an allele specific silencing 
approach. For this purpose, we combined the use of neural stem cells derived from WT 
and adult-onset HD-hESC and SNP-targeting allele specific HTT mRNA interference.  
 
The third approach aimed to elucidate the pathological mechanisms surrounding the 
timeline of mitochondrial and metabolic dysfunction as well as the role of oxidative stress 
as a trigger factor. For this purpose, we used human iPSCs-HD, which most possible 
represent initial stages of the disease, and characterized their proliferative and neuronal 
differentiation potential.  
 
Thus, the overall aim of this study is to validate possible therapeutic strategies focusing 
either in neurotropic factors involving protective intracellular signaling pathways activated 
by IGF-1 or in silencing specifically the allele responsible for mHTT expression, always 
targeting to ameliorate HD phenotype.  
Moreover, a combination of therapeutic approaches seems necessary to offset the multiple 
effects of mHTT. Additionally, cells reprogrammed from patients with a genetic 
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neurodegenerative disease, such as HD, have an enormous therapeutic potential but the 
possibility of genetic damage during reprogramming exists. Thus, molecular regulatory 
mechanisms of pluripotent cells carrying mHTT still need to be assessed as this could 
affect both the safety and function of differentiated cells. 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II - IGF-1 INTRANASAL ADMINISTRATION 
RESCUES HUNTINGTON’S DISEASE PHENOTYPES IN YAC128 
MICE 
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2.1. Introduction 
Huntington’s disease is a rare genetic neurodegenerative disease that mainly affects 
striatal (caudate nucleus and putamen) medium spiny neurons (mostly composed by 
GABAergic neurons) and cortical neurons. HD pathophysiological features have been 
linked to the accumulation of mutant huntingtin (mHTT) forming soluble oligomeric or 
insoluble inclusions (mainly nuclear) (Vonsattel et al. 1998, MacDonald et al. 2003). 
mHTT can sequester several proteins, leading to cellular dysfunction, which involves 
transcription deregulation, synaptic and mitochondrial dysfunction and energy 
deregulation (for review;( L a n d l e s  e t  a l .  2 0 0 4 ,  R a m a s w a m y  e t  a l .  
2 0 0 7 ) . Indeed, mitochondrial dysfunction and altered mitochondrial dynamics due 
to expression of mHTT may occur through dysregulation of mitochondrial-related 
nuclear transcription and calcium dyshomeostasis and/or a direct interaction of N- 
terminal polyglutamine expanded tract with mitochondria (Panov et al. 2004, Orr et al. 
2008, Weydt et al. 2009). This has been closely related with impairment in energy 
metabolism and apoptotic features occurring both in the central nervous system (CNS) 
and in peripheral tissues, such as the human HD muscle (Ciammola et al. 2006) and 
cybrid lines derived from HD patient peripheral blood platelets (Ferreira et al.  2010, 
Ferreira et al.  2011). In a previous study, glucose metabolism was found to be 
significantly decreased in the striatum, and temporal and frontal cortical lobes, in both 
preclinical and affected HD patients (Ma et al. 2007). Furthermore, increased brain 
lactate levels found in HD patients and human HD cybrids, largely suggest altered 
mitochondrial function and bioenergetics accompanying the HD phenotype (Koroshetz 
et al. 1997, Ferreira et al. 2011). Hence, metabolic abnormalities are common features 
of the disease, with controversial descriptions of HD patients featuring a higher risk 
of developing diabetes ( F a r r e r  1 9 8 5 )  and even normoglycemic patients 
showing impaired insulin secretion, with a simultaneous decrease in insulin sensitivity 
and an increase in insulin resistance (Lalic et al. 2008). Some of these features have 
been replicated in the R6/2 mouse line, a model recapitulating early/juvenile onset HD 
(Bjorkqvist et al. 2005). Accordingly, we previously showed that diabetic features in 
R6/2 can be rescued upon treatment with insulin growth factor-1 (IGF-1). Continuous 
peripheral IGF-1 therapy was capable of partially restoring plasma IGF-1 levels in R6/2 
mice and consequently reverse metabolic abnormalities such as weight loss and 
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impaired glucose tolerance, as well as animal behavior, such as paw clasping scores 
(Duarte et al. 2011). 
HD is also associated with altered intracellular signaling pathways essential for the 
control of neuronal survival. Decreased levels of cyclic adenosine monophosphate 
(cAMP) were found in the striatum, which compromise protein kinase A (PKA)/cAMP 
response element-binding (CREB)-binding protein (CBP)/CREB-mediated signaling 
and transcription, with reduced expression of target genes such as brain-derived 
neurotrophic factor (BDNF) (Gines et al. 2003, Zuccato et al. 2003). Indeed, mHTT 
leads to aberrant accumulation in the nucleus of repressor element-1 transcription 
factor/neuron restrictive silencer factor (REST/NRSF), which activates activation the 
repressor element 1/neuron-restrictive silencer element (RE1/NRSE) located within 
the BDNF promoter, resulting in reduced BDNF transcription in HD (Zuccato et al. 
2003).  
Another pro-survival signaling molecule, Akt (or protein kinase B) was downregulated 
during neuronal dysfunction in a rat model of HD and in human peripheral tissues (Colin et 
al. 2005). In this respect IGF-1 has received much attention due to its role in 
preventing and rescuing the damage of striatal neurons (Alexi et al. 1999, Humbert et 
al. 2002). Two main well known signaling pathways can be activated through the IGF-1 
receptor, the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin 
(mTOR) and the Ras/mitogen-activated protein kinase (MAPK) pathway (Vincent et 
al. 2002). Importantly, activated Akt plays a key role in the prevention of program cell 
death through phosphorylation and inactivation of caspase 9 (Kermer et al. 2000). 
Moreover, the IGF-1/Akt pathway was recognized to counteract the toxic properties of 
mHTT. This appears to be mediated by the direct phosphorylation of HTT by Akt at 
serine 421 (S421) (Humbert et al. 2002), which can also restore HTT function in 
microtubule-based anterograde and retrograde transport of trophic factors, namely 
BDNF-containing vesicles (Colin et al. 2008, Zala et al. 2008). 
IGF-1 mRNA was previously shown to be decreased in the striatum and skin fibroblasts 
of HD patients, which appears to correlate with data in striatal cells from HD knock-in 
mice and in the R6/2 mice (Pouladi et al. 2010). In contrast with these animal 
models, increased levels of IGF-1 were observed in YAC128 mice, expressing human 
full-length mHTT, and correlated with increased body weight (Pouladi et al. 2010). 
High plasma IGF-1 was also associated with greater cognitive decline in HD patients 
(Saleh et al. 2010); moreover, increasing levels of insulin receptor substrate 2 (IRS2, 
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which mediates the signaling cascades of insulin and IGF-1) in the brains of R6/2 mice 
reduced lifespan and increased neuronal oxidative stress and mitochondrial dysfunction 
(Sadagurski et al. 2011). Nevertheless, activation of IRS2 in cell lines inducibly expressing 
exon1 of mHTT induced the clearance of accumulated mHTT through a mTOR-
independent macroautophagy pathway (Yamamoto et al. 2006). Additionally, activation 
of the IGF-1/Akt pathway can also inhibit mHTT-induced striatal cell death and 
formation of nuclear inclusions ( H u mbe r t  e t  a l .  2 0 0 2 ) . Such conflicting results 
regarding the role of IGF-1 led us to test the influence of enhancing the brain levels of 
this neurotrophic factor in HD mice. The YAC128 HD mouse model recapitulates 
several disease signs and symptoms, including the expression of full-length mHTT, 
age-dependent motor deficits and selective striatal degeneration (Van Raamsdonk et al. 
2007, Barker et al. 2013), as well as increased susceptibility of striatal neurons to 
excitotoxicity and apoptosis  (Zhang et al. 2008, Barker et al. 2013) . In early stages 
of the disease, mice develop a hyperkinetic phenotype, followed by progressive motor 
deficit on the rotarod at 6 months, with progression to hypokinesia by 12 months of age 
(Van Raamsdonk et al. 2007, Barker et al. 2013). A correlation between rotarod 
performance at 6 and 9 months and neuronal loss at 12 months of age, as well as the 
appearance of nuclear HTT staining, was previously established in this mouse model 
(Slow et al. 2003). Although YAC128 mice are well characterized in terms of neuronal 
loss and disease progression, few studies have focused on peripheral and cerebral 
metabolism, as well as on the possible benefits of IGF-1 administration. Taking into 
account that neuronal dysfunction occurs before striatal atrophy and neurodegeneration, 
and that motor deficits are evident in 6 month-old YAC128 mice, we hypothesized that 
brain IGF-1 supplementation could trigger IGF-1 receptor signaling pathways and 
ameliorate metabolic function, thus rescuing HD phenotype in YAC128 mice prior to 
major symptomatic features. In order to promote IGF-1 delivery in the brain, the 
peptide was administered through intranasal (i.n.) infusion. The i.n. delivery constitutes 
a method to target therapeutics to the CNS; indeed, this represents an alternative to 
invasive methods and exhibits benefits in the treatment of neurologic disorders, since 
compounds easily overcome the blood-brain barrier, reducing systemic exposure and 
side effects (Liu et al. 2002, Thorne et al. 2004, Hanson et al. 2008). Administration of 
IGF-1 through this route was previously demonstrated to deliver the neurotrophic factor 
to multiple areas of the CNS, where it can activate IGF-1 signaling pathways (Thorne et 
al. 2004). The present work presents a novel methodology for therapeutic administration 
 85 
 
of IGF-1 into the HD brain. Indeed, effective amelioration of HD motor phenotype, 
intracellular signaling pathways and energy metabolism are accomplished following 
IGF-1 i.n. administration in YAC128 mice. 
 
2.2. Materials and methods 
2.2.1.Materials 
Haemoglobin A1C kit was purchased to Biosystems S.A. (Barcelona, Spain). PCR 
reagents, such as MasterMix, Taq polymerase, proteinase K, primers, DNA ladder (100 
bp) and DNA loading dye were acquired from Invitrogen® (Carlsbad, CA, USA). D- 
glucose and human insulin recombinant were from Sigma-Aldrich Co (St. Luis, MO, 
USA). Recombinant human IGF-1 (rhIGF-1) was supplied by BioVision
®
 
(Mountain View, CA, USA). Insulin (mouse) Elisa kit was obtained from ALPCO 
(Salem, USA). Quantikine® mouse/rat IGF-1 immunoassay was purchased from R&D 
Systems, Inc. (Minneapolis, USA). Pyruvate and Lactate colorimetric assay kits were 
obtained from Abcam (Cambridge, U.K.). Antibodies against P(Ser473)-Akt, Akt, 
P(Thr202/Thr204)- Erk(42/44), Erk(42/44), P(Ser2448)-mTor and mTor were obtained 
from Cell Signaling (Beverly, MA, USA); anti-HTT (MAB1266) and anti-α-tubulin 
were obtained from Chemicon (Hampshire, U.K.). Anti-P(Ser421)-HTT was produced 
at Institut Curie, Orsay, France. 
 
2.2.2.Experimental animals 
In this study we used male HD transgenic hemizygous YAC128 (line 53), expressing 
full-length human mHTT with ~128 CAG repeats, and non-transgenic wild-type (WT) 
littermate mice with 6 months of age. All animals were generated from our local colony, 
with breeding couples gently provided by Dr. Michael Hayden (University of British 
Columbia, Vancouver, Canada). The YAC128 mice were maintained on FVB/N 
background and compared with WT littermate mice (FVB/N strain). Mice were 
housed in groups with ad libitum access to chow food and water under standard 
conditions (12 h light/dark cycle, 22ºC). All animal studies were performed according 
to the Helsinki Declaration and EU guidelines (86/609/EEC). Painful procedures were 
performed under anesthesia with Avertin® (12 μl/g body weight). 
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2.2.2.1.Genotyping 
Three week-old mice were genotyped by using a tail-tip DNA Polymerase Chain 
Reaction (PCR) standard procedure. Primers used were: LyA1 (CCT GCT CGC TTC 
GCT ACT TGG AGC), LyA2 (GTC TTG CGC CTT AAA CCA ACT TGG), RyA1 
(CTT GAG ATC GGG CGT TCG ACT CGC), RyA2 (CCG CAC CTG TGG CGC 
CGG TGA TGC), Actin Foward (GGA GAC GGG GTC ACC CAC AC) and Actin 
Reverse (AGC CTC AGG GCA TCG GAA CC). PCR protocol consisted in 35 cycles, 
with the following temperatures and times for each step: denaturation – 94ºC for 30 s; 
annealing – 63ºC for 30 s; elongation – 72ºC for 30 s. At the end of the cycles, DNA 
was left at 70ºC for 10 min. PCR products were analyzed on 1.7% agarose gels 
followed by staining with ethidium bromide and visualized under a UV trans-
illuminator, Gel Doc XR system (BioRad
®
, Hercules, USA). A 100-bp ladder 
(Invitrogen
®
) was used as a size marker. 
 
2.2.2.2.Intranasal administration of IGF-1 
All experiments used rhIGF-1 (molecular weight 7.6 kDa), which was reconstituted in 
water to a concentration of 1.0 mg/ml, according to manufacturer's instructions and 
stored at –20º C until used. Prior to intranasal administration, animals were 
anesthetized with Avertin
®
 (12 μl/g body weight). Intranasal administration was 
performed as described previously (Liu et al. 2002), with slight modifications. Mice 
were placed in supine position and a heated pad was inserted under the dorsal neck to 
induce a hyperextension of the head back. A total of 35 µl rhIGF-1 (35 µg) or vehicle 
solution (0.9% NaCl) was given as nose drops (3.5 µl/drop in each nostril corresponding 
to 7 μl/administration), alternating between the left and right nostrils for 5 times, at 
intervals of 4 minutes. Subsequent doses were given each 48 h, for 2 weeks (Figure 
2.1.). Animals were divided into 4 groups: 1) WT+vehicle; 2) YAC128+vehicle; 3) 
WT+IGF-1; 4) YAC128+IGF-1. 
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2.2.2.3.Body weight 
Body weight was measured using a high precision electronic weighing scale, Kern 440-
47 N®, from Kern & Sohn GmbH (Balingen, Germany) and assessed in early afternoon, 
before and after behaviour tests, glucose/insulin tolerance tests, or every two days 
during IGF-1/saline treatment, from the age of 26 weeks (pre-treatment) to 29 week-old 
mice (post-treatment) (Figure 2.1.). Results were expressed as body weight (g). 
 
2.2.2.4.Blood collection and plasma isolation 
Blood was collected either from caudal vein (in living, anesthetized mice), twice/week 
(before, during and after treatment), or directly from the heart by transcardial punction 
(immediately after animal's sacrifice) with a heparinized syringe (100 U/ml heparin). 
Plasma was obtained by centrifugation at 5 000 xg, for 2 min, at 4 °C, in an Eppendorf 
Centrifuge 5415 C, to determine glucose, insulin and IGF-1 levels. 
 
2.2.2.5.Blood glucose levels, glucose tolerance test and insulin tolerance test 
Blood glucose levels were determined twice/week by a digital glucometer (Johnson & 
Johnson Company, Milpitas, CA, USA). Glucose Tolerance Test (GTT) and 
Figure 2.1. - Experimental protocol. One week prior and after treatment animals were subjected to 
several tests. Six-month-old YAC128 or wild-type mice were subjected to intranasal (i.n.) rhIGF-1 (35 μg 
every 2 days) or vehicle (0.9 % NaCl) treatment for 2 weeks. D day, GTT glucose tolerance test, BW 
body weight, ITT insulin tolerance test 
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Insulin tolerance test (ITT) were performed the week prior and three and five 
days after treatment, respectively (Figure 1). 
GTT analyses the rate of glucose clearance from blood (2009). 12h before GTT test, 
mice were kept fasted. Then, 2 mg D-glucose/g body weight were given 
intraperitoneally and glycemia was determined after 0, 15, 30, 60 and 120 min. Results 
were expressed as mg glucose/dl blood and as the area under the curve (AUC). 
ITT analyses the capacity of glucose transporters to uptake glucose, as a response to 
an increase in plasma insulin levels (Bruning et al. 1997). Before the test, mice were 
kept fasted for two hours (from noon to 2 p.m.) in their cages. Basal glycemia was 
measured before insulin injection, corresponding to time 0. Then, an intraperitoneal 
injection of 1 μU human recombinant insulin/g body weight was given to mice and 
glycemia was monitored at 
15, 30, 60 and 90 min. Results were expressed as mg glucose/dl blood and as AUC. 
AUC was calculated using trapezoidal integration. Trapezoidal rule is a numerical 
integration method used to approximate the integral or the area under a curve. Animals 
were allowed to recover for two days before further testing. 
 
2.2.2.6.Measurement of glycated haemoglobin 
After the sacrifice, 100 μl of total blood was isolated to measure glycated haemoglobin 
(HbA1c). We used the Haemoglobin A1C kit (Biosystems S.A.) consisting of an ion 
exchange chromatographic-spectrophotometric method. Briefly, a hemolysate was 
prepared from total blood, where the labile fraction was eliminated and haemoglobins 
were retained by a cationic exchange resin. Haemoglobin A1c was specifically eluted 
after washing away the haemoglobin A1a+b fraction and quantified by direct 
spectrophotometric reading, at 415 nm. The % of HbA1c was obtained by 
calculating: %HbA1c =
AHbA1c×VHbA1c
AHbtotal×VHbtotal
  . Results were expressed as % of total 
haemoglobin.  
 
2.2.2.7.Behaviour analysis 
To measure motor ability, exploratory capacity and anxiety in mice, two 
behavioural test paradigms were performed, the rotarod and the openfield tests (Figure 
1). Mice were allowed to adapt to test room for at least 1 h before behaviour studies. 
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Procedures were consistently performed for all animals, between 12 p.m. and 18 p.m., 
with tests made in lit room, temperature of 25
0
C and at minimum noise levels. The two 
tests were performed the week prior and after treatment and with 24 h interval between 
them. Behaviour equipment was cleaned thoroughly with 30% ethanol before each 
animal trial. 
Rotarod test- performed in a Rotarod apparatus, model LE8200 from Panlab®, 
(Barcelona, Spain). Animals were tested before and six days after treatment, at 26 and 
29 weeks of age, respectively. Mice were gently grabbed by the tail and placed on the 
roller lane of the rotarod. The rotarod unit was composed of Perspex base with 362 
(wide)×240 (diameter)×400 (high) mm with an integrated drum (250 mm diameter) 
containing a rod (30 mm diameter) and 5 lines (50 mm wide). Before the test, mice 
were allowed to train for 40 s, at a constant speed of 4 rpm, to allow familiarization 
with the equipment. After a two hour resting, each mouse was tested for 4 sessions on 
the rod, with a gradual acceleration rate from 4-40 rpm during 5 min, each one 
separated by a 30 min resting period (Carter et al. 2001). When the animal fell off the 
rod, the time latency to fall and rotation speed were automatically recorded. Results 
were expressed as latency to fall off rotarod, in seconds (s). 
Open Field exploration test (shown as supplementary data) - Animals were tested 
before and seven days after treatment in an Open Field apparatus from Panlab®, 
(Barcelona, Spain). The system is composed by 2 square frames with 22 x 22 cm size, a 
frame support and a control unit. Chamber walls and floor are made of transparent 
Plexiglass. Open field arena is divided into a grid of equally-sized areas by infrared 
photocell beams or lines drawn on the chamber floor, for visual scoring of activity 
by the experimenter. A central square (18 cm x 18 cm) is drawn in the middle of the 
open field. The discrimination of central square is relevant because some mouse 
strains have high locomotor activity and cross the lines of the test chamber many times 
during a test session. The number of central square entries and the duration of time 
spent in the central square are measures of exploratory behaviour and anxiety. A high 
frequency/duration of these behaviours indicates high exploratory behaviour and low 
anxiety levels (Carrey et al. 2000). FRAMES (photo beam sensors) are equipped with 
32 infrared photocells, 16 placed in axis X and 16 placed in axis Y. Photocell works at a 
wavelength of 950 nm and its information is multiplexed at a rate of 40Hz. System 
gives data about fast (5 cm/s) and slow (2 cm/s) movements, fast and slow stereotypes, 
number of fast and slow rearing and number of fast and slow nose-pokes in the hole-
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board test. During the test, which lasted for 30 min, lights were on, with the same 
illumination levels as the holding room, and the test recorded with a digital camera. The 
test started with the mouse placed in the center of the chamber and the experimenter left 
the testing room after this procedure, since sudden motion or noise could affect 
exploratory activity. Mice were allowed to freely explore the chamber for 30 min and 
each line crossed or photocell beam break was scored as one unit of activity. Defecation 
and grooming activities were also scored. At the end of the test, the mouse returned to 
home cage and allowed to rest for two days before further testing. Results were 
expressed as the maximal and mean velocity (cm/s), distance travelled, slow and fast 
movements (%), time spending in central square (s), and rearing and resting time (s). 
 
2.2.2.8.Brain tissue preparation and total blood collection 
At the end of the study (one week after the last i.n. administration, in 30 week-old 
mice), the animals were anesthetized with 30 µl/g body weight Avertin® and tissues 
and blood were collected. Blood was collected by transcardial punction, as described 
above. Mice were perfused with 1% PBS (phosphate buffered saline) to eliminate blood 
clots from tissues, and the brain was removed and dissected into striatum and cortex 
(in ice, at 0-4ºC), which were frozen at -80ºC for posterior analysis. Afterwards, the 
brain tissues were thawed and homogenized in PBS or lysis buffer, supplemented with 
protease and phosphatase inhibitors, with a Potter-Elvejhem homogenizer with a 
Teflon pestle, at 300 rpm. The homogenates were then frozen/thawed 3 times in liquid 
nitrogen and stored at -80ºC for later use. Buffered solution contained (in mM): 250 
sucrose, 20 Hepes, 10 KCl, 1.5 MgCl2, 1 EDTA, and 1 EGTA, pH 7.4, supplemented 
with 1 mM DTT, 100 M PMSF and 1:1000 of a broad spectrum protease inhibitor 
cocktail containing chymostatin, pepstatin A, leupeptin, and antipain (1 mg/mL). For 
the analysis of phosphorylated proteins, the supplemented solution also included 1% 
SDS, 50 mM NaF, 1 mM sodium o-vanadate and 0.1 M okadaic acid. Protein 
concentration was determined with Bradford® assay (Bio-Rad Laboratories, Hercules, 
CA, USA). 
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2.2.2.9.Assessment of plasma and brain levels of insulin and IGF-1 
Using the previously described plasma and brain tissue homogenates, insulin and IGF-1 
levels were measured with Insulin (mouse) Elisa kit (ALPCO) and Quantikine 
mouse/rat IGF-1 Immunoassay (R&D systems), respectively, according to 
manufacturer’s instructions. For insulin, the optical density was measured using a 
microplate reader (SpectraMax Plus 384 spectrophotometer, Molecular Devices, 
Winnersh, UK) at 450 nm with a reference wavelength of 620 nm. For IGF-1, the 
optical density of each well was measured at 450 nm, with a correction set to 540 nm 
using the same apparatus. Results were obtained as pictograms per milliliter, 
normalized to the amount of protein per sample, and thus expressed as 
pictograms/milliliter protein or nanogram//milligram protein. 
 
 
2.2.2.10.Analysis of adenine nucleotides 
Levels of adenine nucleotides (ATP, ADP and AMP) were determined from brain 
homogenates in PBS, which were maintained at -20ºC until the analysis. The samples 
were assayed by separation in a reverse-phase high-performance liquid chromatography 
(HPLC), using a Lichrospher 100 RP-18 (5 µm) HPLC column from Merck (Darmstadt, 
Germany), upon an isocratic elution with 100 mM phosphate buffer (KH2PO4, pH 6.5) 
and 1% methanol, with a flow rate of 1 ml/min and detection at 254 nm, as previously 
described (Stocchi et al. 1985). The required time for each analysis was 6 min. The 
chromatographic apparatus used was a Beckman-System Gold, consisting of a 126 
Binary Pump Model and 166 Variable UV detector. Peak identity was determined by 
following the retention time of standards. Cellular energy charge was calculated using 
the formula: ([ATP] + 0.5 [ADP])/([ATP] + [ADP] + [AMP]) (Rego et al. 1997). 
 
2.2.2.11.Assessment of brain levels of pyruvate and lactate 
Pyruvate and lactate levels were measured colorimetrically, by using Pyruvate Assay 
kit and Lactate Assay Kit (from Abcam®), according to manufacturer’s instructions. 
In the pyruvate assay, pyruvate is oxidized by pyruvate oxidase, generating a product 
detected by spectrophotometry at 570 nm. In the lactate assay, lactate is oxidized by 
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lactate dehydrogenase to generate a product detected at 450 nm using a SpectraMax 
Plus 384 spectrophotometer. Results were expressed as nmol/mg protein. 
 
2.2.2.12.Western blotting 
Dissected cortical and striatal tissues were homogenized in a supplemented lysis buffer 
containing phosphatase and protease inhibitors (as described before). The samples were 
denatured with SDS sample buffer (50 mM Tris-HCl, pH 6.8, 2% sodium dodecyl 
sulphate, 5% glycerol, 0.01% bromophenol blue and 100 mM DTT), at 95ºC, for 5 min. 
Samples containing the denatured proteins (100 μg) were subjected to SDS/PAGE and 
transferred onto polyvinylidene difluoride (PVDF) Hybond-P membranes. Then, 
membranes were blocked for 2 h at room temperature in Tris-buffered saline (TBS; pH 
7.4) plus 5% nonfat dry milk and 0.1% Tween 20, and incubated with antibodies against 
phosphorylated proteins such as P(Ser473)-Akt (1:1000), P(Thr202/Tyr204)- 
Erk(42/44) (1:1000), P(Ser2448)-mTor (1:1000) or P(Ser421)-HTT (1:200), overnight, 
at 4ºC, with gentle shaking. The membranes were reprobed for total protein with the 
antibodies for anti- Akt (1:1000), Erk(42/44) (1:1000), mTor (1:1000) or HTT 
(MAB2166) (1:250), and for total protein loading control with anti-α-tubulin (1:20000). 
Membranes were further incubated with anti-rabbit IgG and anti-mouse IgG+IgM 
secondary antibodies (1:20000), for 90 min, at room temperature, and developed using 
ECF fluorescent reagent. Fluorescence signal was analyzed using the QuantityOne 
software and the results were given as fluorescence intensity (INT)/mm2. Data were 
presented as the ratio of phosphorylated protein/total protein or protein levels/α-tubulin. 
Immunoreactive bands were visualized with VersaDoc Imaging System (BioRad®, 
Hercules, USA). 
 
 
2.2.2.13.Data analysis and statistics 
Results are the mean±SEM of the indicated number of independent experiments in 
figure and table legends. The F test was performed to analyze the interaction term, as 
described in the figure and table legends. Statistical significance was analyzed using 
parametric tests, namely two-way ANOVA, followed by Bonferroni post-test. Data that 
do not meet the assumptions of normality were submitted to rank transformation 
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method followed by parametric analysis of ranks (Mitchell et al. 1994). P<0.05 was 
considered significant. 
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2.3. Results 
2.3.1.Intranasal treatment with rhIGF-1 increases cortical but not plasma or 
striatal levels of IGF-1 in WT and YAC128 mice 
Intranasal (i.n.) administration was previously proven to be an effective method to 
deliver IGF-1 into most caudal brain regions and peripheral tissues (Thorne et al. 2004) 
. Plasma and brain (cortex and striatum) tissue levels of IGF-1 were assessed after two 
weeks of i.n. administration, in both WT and hemizygous YAC128 mice. No changes 
were observed in plasma IGF-1 levels between saline-treated YAC128 and WT mice 
(Fig. 2.2.A), which may account for the fact that WT mice were as overweighed as 
YAC128 mice (Table 1). The plasma levels of IGF-1 slightly increased, although non-
significantly, in rhIGF-1-treated YAC128 and WT mice, compared to saline-treated 
animals (Fig. 2.2.A), possibly reflecting some absorption of IGF-1 from the nasal 
passages through the cervical lymph nodes (Rosen et al. 1999). In striatal samples from 
IGF-1-treated YAC128 mice we also observed a slight tendency for an increase in IGF-
1 levels, although this was not significant when compared to saline-treated HD mice 
(Fig. 2.2.B). Importantly, a significant increment in IGF-1 levels was observed in 
cortical tissue of IGF-1-treated wild-type and YAC128 mice (Fig. 2.2.C). These data 
show that this method is efficient in delivering IGF-1 to the brain tissue (particularly 
the cortex) and that enhanced levels can still be detected one week after the 
administration has ended. 
 
 
 
 
 
 
 
 
 95 
 
 
2.3.2.IGF-1 administration influences blood metabolic parameters 
A correlation between plasma IGF-1 levels, body weight and HTT levels was previously 
described in YAC128 mice expressing full-length human HTT. Increased plasma IGF-1 
levels were shown to regulate body weight in YAC128 mice (Pouladi et al. 2010). 
Thus, we also measured body weight before and after IGF-1 i.n. treatment (Table 1). All 
mice were shown to be overweight, since a normal weight for FVB/N mouse strain is 
between 25-30 g (Pouladi et al. 2010) , whereas both WT and YAC128 mice body 
weight largely exceeded those values, ranging from 28 to 45 g. Moreover, i.n. 
Figure 2.2 - Effect of intranasal rhIGF-1 treatment on plasma and brain levels of IGF-1 in WT and 
YAC128 mice. Six month-old WT and YAC128 mice were treated for 2 weeks with intranasal rhIGF-1 
(35 μg every two days) or saline (0.9% NaCl), as described in Materials and Methods. Blood and brain 
samples were collected from animals one week after treatment. (A) shows plasma IGF-1 levels in saline 
and rhIGF-1 treated mice; no interaction between genotype and treatment was found (F(1,29)=0.95, p=ns) 
(n=8-9 mice per treatment and genotype). For the striatal IGF-1 levels (B) no significant interaction was 
found either (F(1,10)=0.84, p=ns) (n=3-6 brain samples per treatment and genotype). Two-way ANOVA 
analyses revealed a significant effect of treatment on IGF-1 levels in the cortex (F(1,9)=6,36, p<0.05), but 
no interaction between genotype and treatment (F(1,9)=1.38, p=ns) (C) (n=3-6 brain samples per 
treatment group and genotype). IGF-1 levels were determined in duplicates by the Quantikine Mouse/Rat 
IGF-1 Immunoassay. Data are the mean ± SEM of the indicated number of animal samples. Multiple 
comparisons using two-way ANOVA followed by Bonferroni correction (*p< 0.05). 
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treatment with IGF-1 did not produce any changes in body weight (Table 1), despite 
the rise in plasma IGF-1 levels (Fig. 2.2.A). YAC128 mice under a FVB/N background 
start to gain weight, compared to WT mice, after 2 months of age, which has been 
related with the background strain in which they were developed (Van Raamsdonk et 
al. 2007). High body weight in both WT and YAC128 mice was not due to the diet; in 
a subgroup of animals the diet was changed during a month to a less caloric diet without 
access restriction, but no significant differences were detected on body weight or plasma 
glucose levels (not shown).  
 
Body weight and plasma glucose levels were measured the week before (pre) treatment and after (post) 
the treatment. Plasma glucose and glycated hemoglobin (HbA1c) levels were measured under fed 
conditions, using a glucometer and a kit for analysis of glycosylated hemoglobin, respectively. Data are 
mean±SEM of the indicated number of animals/group (n). Repeated measures ANOVAwas performed for 
body weight and plasma glucose levels. Two-way ANOVA analyses shows no difference effect of 
genotype or treatment on HbA1c levels [F(1,10)=0.02, p =ns] n.d. not determined 
 
We further examined the changes in glycemia, since there is some controversy 
regarding the prevalence of diabetes in HD. Data in Table 1 show similar, although 
high, glycemia levels in all groups of animals, under fed conditions, which were not 
altered after IGF-1 treatment. A more reliable method to characterize a diabetic 
phenotype is the measurement of glycated haemoglobin (HbA1c), which reflects 
average glycemia over the preceding 6 weeks (Bennett et al. 2007).  All animals 
exhibited values above 9.1% of HbA1c determined by the BioSystem method, which 
correspond to pathological values reported by The International Federation of Clinical 
Chemistry Working Group (NGSP), over 6.4%, and the National Glycohaemoglobin 
Standardization Program (NGSP), over 8.0%. These results suggest that FVB strand 
Table 2 - Effect of rhIGF-1 treatment on body weight, plasma glucose and HbA1c in WT and YAC128 mice 
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mice have basal hyperglycemia, which is likely to progress to diabetes, although 
this is apparently independent of the genotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To better characterize the hyperglycemic background in these animals and exploit 
glucose intolerance or insulin sensitivity/resistance in WT and YAC128 mice, the 
glucose tolerance test (GTT) and the insulin tolerance test (ITT) were performed. 
Figure 2.3 - Effect of intranasal rhIGF-1 treatment on glucose and insulin tolerance tests in 
YAC128 and WT mice. For glucose tolerance test (GTT) (a–c), glucose (2 mg/g body weight) was 
intraperitoneally administered following 12 h fasting and blood collected for measurement of glucose 
levels after 0, 15, 30, 60, and 120 min. For insulin tolerance test (ITT) (d–f), mice were fasted for 2 h 
following intraperitoneal administration of insulin (1 μU/g body weight) and blood glucose levels 
determined at 0, 15, 30, 60, and 90 min. The area under the curve (AUC) for GTT (in c) was calculated 
from data in graphs a and b, and the AUC for ITT (in f) from graphs d and e, using the trapezoidal rule. In 
a, two-way ANOVA for repeated measures showed that there was no interaction of genotype and saline 
treatment [F(12,108)=1.75, p =0.06], but there was a significant effect of time [F(4,108)=124.91, p 
<0.001] onGTT values. In b, a significant interaction between time×genotype×treatment was found 
[F(12,209)=3.38, p <0.0001]. A difference was found (determined by two-way ANOVA for repeated 
measures after Bonferroni correction) on pretreated YAC128 mice at 60min, showing higher levels of 
glucose than WT mice, which was ameliorated following i.n. IGF-1 treatment. IGF-1 treatment 
significantly reduced glucose levels in WT and YAC128 mice (c). In d and e, pretreated YAC128 mice 
exhibited higher glucose levels at 15 min, compared to WT mice. In e, a significant interaction between 
time×genotype×treatment was found [F(12,88)=3.38, p <0.01]. Pretreated YAC128 mice showed 
increased glucose levels at 60 and 90 min, compared to WT mice; i.n. administration of IGF-1 in 
YAC128 mice reduced significantly glucose plasma levels at 90 min. Data are the mean±SEM of n =4–7 
mice per treatment group and per genotype). Statistical significance: *p <0.05, **p <0.01, or ***p <0.001 
by two way ANOVA for repeated mea ures followed by Bonf rroni correction, for comparison b tween 
pretreated YAC128 and WT mice; and +p <0.01 using two-way ANOVA for comparison between pre- 
and posttreated YAC128 mice. 
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The GTT assesses the ability of WT and YAC128 mice to deal with an acute glucose 
load. In the IGF-1 treated group, pre-treated YAC128 mice showed higher levels of 
glucose at 60 min, compared to WT mice (Fig. 2.3.B). WT mice treated with IGF-1 
exhibited a better response in GTT with a significant reduction in glucose levels at 
several time points (Fig. 2.3.B). Moreover, the AUC values for the GTT showed a 
reduction in glucose values after treatment with IGF-1 in both WT and YAC128 mice 
(Fig. 2.3.C). 
The ITT is used to evaluate insulin sensitivity and/or insulin resistance. YAC128 mice 
showed a lower capacity to regulate blood glucose concentrations 15 min after a bolus 
of intraperitoneal injection of insulin since the levels detected were significantly higher 
compared with the WT group before treatment  (Fig. 2.3.D,E). After 2 weeks of i.n. 
treatment with IGF-1, YAC128 mice significantly reduced plasma glucose levels 
after 120 minutes, compared to values prior to IGF-1 administration (Fig. 2 . 3.E). 
Analysis of AUC for the ITT showed a significant reduction in both WT and YAC128 
glucose values after IGF-1 treatment (Fig. 2.3 . F), which may be accounted for by the 
treatment procedure since a decrease in AUC values in the ITT were also observed 
in saline- treated YAC128 mice. Nevertheless, these data suggest that YAC128 mice 
bear some systemic insulin resistance, while IGF-1 can partially restore the uptake of 
glucose. 
 
Insulin levels were determined in plasma and brain homogenates. Insulin was quantified by an ELISA 
Assay. YAC128 mice showed similar brain levels of insulin compared to WT. IGF-1 i.n. treatment 
slightly increased plasma insulin levels in YAC128 mice. Data are the mean±SEM of the indicated 
number of animals/group (n). Two-way ANOVA analyses shows no effect of genotype or treatment on 
levels of plasma [F(1,11)= 0.39,p =ns] and total brain [F(1,12)=0.81, p =ns] insulin levels  
 
 
Table 3 - Effect of rhIGF-1 treatment on plasma and brain insulin levels in WT and YAC128 mice 
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Figure 2.4 - Effect of rhIGF-1 intranasal administration on rotarod test in YAC128 and WT mice. 
YAC128 andWT mice littermates were allowed to adapt to the behavior test room and procedures before 
tested in four trials on an accelerating rotarod (4–40 rpm), for 5 min. A significant interaction between 
genotype and treatment [F(3,68)=3.79, p <0.05] was found. Data are the mean±SEM of 9–12 mice per 
treatment group and genotype. Statistical significance: *p <0.05, **p <0.01, by repeated-measures 
ANOVA 
Because administering IGF-1 in R6/2 mice enhanced plasma insulin levels (Duarte 
et al. 2011), we also measured insulin in plasma and brain in YAC128 and WT 
mice. No significant differences in plasma or brain insulin levels were found 
between the animals before treatment (Table 2). Following IGF-1 administration 
there was a slight, although not significant, increase in plasma insulin levels in 
YAC128 mice (Table 2), suggesting that changes in ITT do not reflect significant 
modifications in plasma insulin levels. No significant differences in insulin levels were 
found in total brain samples after i.n. IGF-1 treatment in WT or YAC128 mice (Table 
2). 
 
2.3.3.IGF-1 treatment ameliorates motor impairment in YAC128 mice 
In accordance with prior motor impairment described in YAC128 mice (Slow et al. 
2003), we observed that 6 month-old YAC128 mice exhibited impairment in motor 
coordination and balance, compared to WT littermates (Fig. 2.4.). Considering all pre-
treated WT and YAC128 mice (in saline and IGF-1 groups) a very significant decrease 
in the latency to fall off the rotarod was observed in WT mice compared to YAC128 
littermates (respectively 50.80 ± 4.34 s; n=18 versus 31.36 ± 2.62 s; n=21, p<0.001). 
IGF-1 i.n. administration significantly improved motor impairment in YAC128 mice, 
with a significant increase on time spent on the rotarod apparatus (Fig. 2.4.). 
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Mice locomotor activity was further measured using an openfield apparatus. YAC128 
mice showed similar locomotion and exploration behavior profiles as their WT 
littermates (Fig. 2.5.). Moreover, IGF-1 treatment did not affect most of the 
parameters analyzed, except for the maximal velocity, which increased in YAC128 
mice, compared to untreated mice (Fig. 2.5.). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 - Influence of IGF-1 intranasal administration on openfield exploration on YAC128 and 
WT mice. YAC128 and WT littermates (n=5-10 mice for treatment group and for genotype) were tested 
in an openfield activity box over a period of 30 min as described in Material and Methods. Locomotor 
horizontal activity was recorded and analyzed for maximal (A) and mean velocity (B) (cm/s), distance 
travelled (cm) (C), slow movements (MS) (D) and fast movements (MF) (E) (% of total movement), time 
spent in central square (s) (F), rearing (G) and resting time (RT) (s) (H). There was no effect of genotype 
or treatment on openfield performance, except maximal velocity which increased in the YAC128 mice 
IGF-1 treated (F(7,50)=9.27, p<0.01). Data are the mean ± SEM of the indicated number of animals. 
Statistical significance: ttp< 0.01 by Student's t-test. 
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2.3.4.IGF-1 administration promotes cortical and striatal intracellular 
signaling pathways 
IGF-1 is one of the most important activators of PI3K/Akt/mTOR signaling pathway, a 
stimulator of cell growth and proliferation (Latres et al. 2005).. In HD, there is clear 
evidence that IGF-1/Akt neuroprotective pathway is altered (Humbert et al. 2002, Colin 
et al. 2005). In order to examine whether IGF-1 i.n. delivery involves activation of Akt, 
Erk or mTOR signaling pathways, we analyzed the activation of these proteins in 
cortical and striatal lysates from IGF-1- versus saline- treated WT and YAC128 mice. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Influence of rhIGF-1 intranasal administration on Akt, Erk, and mTOR 
phosphorylation in the striatum of YAC128 mice. Striatal tissue was isolated 1 week following i.n. 
treatment with rhIGF-1 or saline and lysates were submitted to SDS-PAGE gel electrophoresis. No 
interaction between genotype and treatment occurred for all proteins analyzed. Two way ANOVA 
analyses revealed that there is a significant effect of genotype on levels of anti-P(Ser473)Akt (A.i) 
[F(1,13)=6, p <0.05], and levels tended to be higher in YAC128 IGF-1-treated mice. For the relative 
levels of other downstream IGF-1 effectors Akt (B.i) [F(1,19)= 0.40, p =ns], Erk (B.ii) [F(1,20)=0.0003, 
p =ns] and their activated (phosphorylated) forms, anti-P(Thr202/Thr204)Erk (B.i) [F(1,16)=0.45, p 
=ns] and anti-P(Ser2448)mTOR (C.i) [F(1,10)=0.004, p =ns], there was no significant effect of 
genotype or treatment. When considering mTOR (C.ii), there was a significant effect of the treatment 
[F(1,17)= 7.64, p <0.05]. Data are the mean±SEM of 3–4 mice per genotype and treatment, performed 
in duplicates. The bar graphs represent the quantitative analysis of the blot images shown in A.iii, B.iii, 
and C.iii. In order to use two-way ANOVA test, we performed a rank transformation of the data 
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In striatal tissue a decrease in Akt activation (P-(Ser473)Akt) was observed in saline- 
treated YAC128 mice, which was partially rescued after treatment with IGF-1 
(Fig.2.6A.i). Conversely, no significant changes were observed on Erk or mTOR 
phosphorylation due to expression of full-length mHTT, and IGF-1 failed to further 
activate Erk or mTOR (Fig. 2.6.B-C). Nevertheless, IGF-1 promoted protein expression 
levels of mTOR, as observed in Fig. 2.6.C.ii-iii. 
 
 
 
Figure 2.7. Influence of rhIGF-1 intranasal treatment on Akt, Erk, and mTOR 
phosphorylation in the cortex of YAC128 mice. Cortical tissue was isolated `1 week following i.n. 
treatment with rhIGF-1 or saline and lysates were submitted to SDS-PAGE gel electrophoresis. No 
interaction between genotype and treatment occurred for all proteins analyzed. Two-ANOVA 
analyses revealed that the levels of anti-P(Ser473)Akt (A.i) tend to be higher in YAC128 IGF-1-
treated mice [F(1,22)=3.20, p =0.084]. For the relative levels of other downstream IGF-1 effectors 
Akt (B.i) [F(1,26)=0.2, p =ns], Erk (B.ii) [F(1,19)=0.32, p =ns], and mTOR (C.ii) [F(1,14)=0.46, p 
=ns], and their activated/phosphorylated forms anti-P(Thr202/Thr204)Erk (B.i) [F(1,26)=0.02, p 
=ns] and anti-P(Ser2448)mTOR (C.i) [F(1,23)=0.02, p =ns] no significant effect of 
genotype×treatment interaction was observed. Data are the mean±SEM of 3–4 mice per genotype 
and treatment, performed in duplicates. The bar graphs represent the quantitative analysis of the blot 
images shown in A.iii, B.iii, and C.iii . In order to use two-way ANOVA test, we performed a rank 
transformation of the data 
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HD mice also showed decreased activation of Akt in cortical samples, as compared to 
WT littermates (Fig. 2.7.A.i). After treatment with IGF-1, YAC128 mice exhibited an 
increase in Akt phosphorylation (Fig. 2.7.A.i). However, no differences inactivation 
or expression levels of Erk or mTOR were found between WT and YAC128 cortical 
tissue before or after treatment with IGF-1 (Fig. 2.7.B-C). Data obtained in brain striatal 
and cortical samples from IGF-1-treated YAC128 mice largely suggest that IGF-1 
activates Akt intracellular signaling. 
 
2.3.5.Phosphorylation of mHTT at S421 is increased following IGF-1 i.n. 
treatment  
Activation of IGF-1/Akt pathway was previously shown to be protective in neurons 
expressing mHTT, as a result of increased phosphorylation of HTT on Ser421 by Akt 
(Humbert et al. 2002). The IGF-1/Akt pathway is downregulated in HD (Humbert et al. 
2002, Colin et al. 2005) and phosphorylation of HTT at P(Ser421)-HTT progressively 
declines in the striatum of YAC128 mice (Metzler et al. 2010). Thus, we further 
examined the changes in Ser421 phosphorylation and differential protein levels of wild-
type HTT (wtHTT) and mHTT in saline- and rhIGF-1-treated WT and YAC128 mice. 
In the striatum, the levels of P(Ser421)-mHTT increased approximately 3-fold in 
YAC128 mice after IGF-1 treatment (Fig. 7A.i), whereas wtHTT in WT or YAC128 
mice failed to be activated (Fig. 2.8.A.i). Interestingly, the levels of wtHTT in the 
striatum of YAC128 mice were enhanced after IGF-1 treatment (Fig. 2.8.A.ii), 
suggesting that IGF-1 levels may regulate the expression of wtHTT in the striatum. 
In cortical tissue we observed an increase in P(Ser421)-wtHTT (by 2.4-fold) and in 
P(Ser421)-mHTT (by 2.3 fold) in YAC128 mice treated with IGF-1, although this was 
not significant (Fig. 2.8.B.i). No major differences were seen in the expression levels 
of wtHTT and mHTT in cortex following IGF-1 administration (Fig. 2.8.Bii). These 
data support that IGF-1 treatment increases the phosphorylation of mHTT on Ser421. 
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Figure 2.8. - Phosphorylation of wild-type and mutant HTT at Ser421 following intranasal IGF-1 
treatment in WT and YAC128 mice. Brain tissue was isolated and striatal and cortical lysates were 
electrophoresed on 6 % SDSPAGE and probed with anti-P(S421)HTT (A.i, B.i) selective antibody, 
followed by reprobing with anti-HTT (MAB2166) (A.ii, B.ii). The ratio between the levels of wt pS421-
wtHTT and total wtHTT and pS421-mHTT and total mHTT were analyzed for WT and YAC128 mice in 
striatal (A) or cortical (B) brain samples. wtHTT-IGF-1 wild-type huntingtin in saline-treated mice; 
wtHTT+IGF-1 wild-type huntingtin in rhIGF-1-treated mice; mHTT-IGF-1 mutant huntingtin in saline-
treated mice; mHTT+IGF-1 mutant huntingtin in rhIGF-1-treated mice. IGF-1 i.n. administration 
increased pS421-mHTT/mHTT in striatum of YAC128 mice. Data are the mean±SEM of 3–4 mice per 
genotype and treatment, run in duplicates. In order to use two-way ANOVA test, we performed a rank 
transformation of the data 
 
 
2.3.6.rhIGF-1 improves energy deficits in YAC128 mice brain 
It is widely recognized the relationship between mHTT and energy deficits, which may 
be accounted for by mitochondrial dysfunction, namely by interfering with oxidative 
phosphorylation (Browne et al. 2004, Bossy-Wetzel et al. 2008). Energy deficiencies 
have been described early in the pathogenic process, and precede pathological and 
symptomatic markers of disease onset (Gil et al. 2008). Previously, IGF-1 was 
suggested to have a primordial role on glucose metabolism (Petersson et al. 2009). 
Since bioenergetic abnormalities affect different areas of the brain, we examined the 
effect of IGF-1 administration on total brain energy metabolic parameters. 
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Metabolic abnormalities in HD YAC128 mice were ascribed to a reduction in YAC128 
mice brain energy charge (Fig. 2.9.A). According to Atkinson’s hypothesis the cell 
stabilizes its energy charge and the normal brain value is between 0.85 and 0.95, 
exhibiting little circadian variation (Ataullakhanov et al. 2002). In our study, WT 
mice exhibited a value of energy charge approximate to the normal range. 
Interestingly, treatment with IGF-1 was able to recover the energy levels in YAC128 
mice (Fig. 2.9.A). 
 
 
Figure 2.9. - Effect of rhIGF-1 intranasal administration on brain energy charge and pyruvate and 
lactate levels of YAC128 mice. Brain energy charge (a) was determined in YAC128 and WT littermates 
as ([ATP]+0.5 [ADP])/([ATP]+[ADP]+[AMP]). The tissue lysates were assayed for ATP, ADP, and 
AMP by separation in a reverse-phase HPLC with detection at 254 nm. There was a significant effect of 
genotype on YAC128 mice brain energy charge [F(1,12)=6.12, p <0.05], which was ameliorated after i.n. 
treatment with IGF-1. Pyruvate (b), lactate (c), and lactate/ pyruvate ratio (L/P) (d) were determined in 
total brain samples from 
 
 
To determine whether decreased adenine nucleotides and energy balance was a 
consequence of altered pyruvate and/or lactate levels, as determined previously 
(Koroshetz et al. 1997), brain levels of pyruvate, lactate and lactate/pyruvate (L/P) ratio 
were also assessed. In total brain samples, YAC128 mice showed lower pyruvate levels 
(Fig. 2.9.B). Consequently, YAC128 mice brain also exhibited higher L/P ratio, 
compared to WT mice (p=0.059) (Fig. 2.9.D); importantly, rhIGF-1 i.n. administration 
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was able to significantly reduce this ratio (Fig. 8D), in agreement with the improvement 
in energy parameters. 
In summary, YAC128 mice show impaired total brain energy metabolism, with lower 
brain energy change, lower pyruvate levels and higher L/P ratio. Importantly, i.n. 
administration of rhIGF-1 partially recovered energy metabolism through increased 
pyruvate levels and thus glycolytic metabolism in the brain of HD mice. 
 
2.4. Discussion 
Our results show that exogenous rhIGF-1 given through i.n. administration can alleviate 
motor impairment and brain metabolic dysfunction, two characteristic features of HD. 
Interestingly, this occurred concomitantly with the restoration of Akt activity and 
increased phosphorylation of mHTT.  
A major limitation in developing potential therapeutic agents to treat neurodegenerative 
disorders is the blood-brain barrier, which restricts the delivery of several compounds 
and peptides to the brain. Indeed, very little IGF-1 can cross the blood brain barrier 
following systemic administration (Thorne et al. 2004, Laviola et al. 2008). In our study 
IGF-1 brain cortical levels increased following i.n. treatment, largely suggesting that 
IGF-1 can reach the CNS. Concordantly, this method has been successfully applied in 
the treatment of brain injured conditions and neurodegenerative  diseases, such as 
lipopolysaccharide- induced brain injury, focal cerebral ischemia, and spinocerebellar 
ataxia type 1 (Liu et al. 2002, Vig et al. 2006, Cai et al. 2011). Intranasally administered 
compounds and peptides can reach the CNS via the olfactory and trigeminal neural 
pathways, which enervate the nasal cavity, providing a direct connection with the CNS 
(Thorne et al. 2004). The results of our study are in accordance with another study that 
confirmed that i.n. delivery of IGF-1 to the CNS was accompanied by activation of 
signalling pathways in several areas that express high levels of the IGF-1 receptor, 
demonstrating that IGF-1 can reach deeper areas in the brain (Thorne et al. 2004). 
Intranasal administration also resulted in slightly rising the plasma concentration 
(although non-significantly), possibly reflecting continual absorption of IGF-1 from the 
nasal passages (Thorne et al. 2004). 
A condition often found in HD patients is weight loss and muscle wasting, which is 
recapitulated in the R6/2 transgenic mice (Gaba et al. 2005, Goodman et al. 2008). 
In these mice, we have recently shown restoration of body weight after IGF-1 
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peripheral treatment (Duarte et al. 2011). In contrast, the YAC128 transgenic mice are 
overweight, largely exceeding the typical weight for these mice; nevertheless, IGF-1 
treatment failed to produce any change in YAC mice weight. Transgenic mice 
expressing full-length human mHTT, such as BACHD and FVB- YAC128 mice, start to 
gain weight, compared to WT mice, after 2 months of age, which seems to be due to the 
background strain (Van Raamsdonk et al. 2007). Comparing the backcrossing of 
YAC128 mice from the FVB/N strain onto the C57BL/6 strain and the 129 strain, the 
FVB-YAC128 mice were the only that presented an increase in body weight and 
reduced lifespan (Van Raamsdonk et al. 2007). A positive correlation was previously 
found between plasma levels of IGF-1, modulated by full-length HTT, and body 
weight in YAC128 mice; interestingly, YAC18 mice exhibited higher HTT and plasma 
IGF-1 levels and increased body weight than YAC128 mice (Pouladi et al. 2010). The 
mRNA expression of IGF-1 in striatal tissue of YAC128 mice was higher than that of 
WT control, but in cortical tissues IGF-1 mRNA did not change; conversely, in R6/2 
mice with 11 weeks of age IGF-1 plasma levels were largely reduced, which were 
related with decreased body weight and depletion of endogenous full-length HTT 
(Pouladi et al. 2010) IGF-1 is an essential modulator of GH action, acting as a 
neurotrophic and anabolic factor (Juul 2003). Our study failed to reproduce a large 
increase in plasma and brain IGF-1 levels in non-treated YAC128 compared to WT 
mice. This difference may be accounted for by considerable high body weights of our 
WT mice (which are similar to YAC128 mice), as well as for a lower number of 
animals used compared to Pouladi’s study. 
HD has been associated with endocrine abnormalities, glucose intolerance and insulin 
resistance, even in normoglycemic patients (Podolsky et al. 1977, Farrer 1985, Lalic et 
al. 2008). These metabolic changes have been reproduced in R6/2, R6/1 and N171-82Q 
mice, which may culminate, in the later stages, in a diabetic state (Schilling et al. 1999, 
Bjorkqvist et al. 2005, Josefsen et al. 2008). Nevertheless, a previous study highly 
suggested that adult-onset HD patients do not have an increased risk of developing 
diabetes (Boesgaard et al. 2009). Our data reflect hyperglycemic features in FVB 
background. Both WT and YAC128 transgenic mice exhibited elevated glycemia under 
fed conditions (180-260 mg/dl) and pathological values of glycated haemoglobin (>9% 
of total haemoglobin), compatible with diabetes mellitus. Interestingly, significant 
differences were observed between WT and YAC128 before IGF-1 treatment in the 
ITT, which could be related with altered insulin sensitivity to regulate plasma glucose. 
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Following IGF-1 treatment, both groups showed a significant reduction of the ITT-
AUC. Decreased insulin resistance in IGF-1 treated YAC128 mice may be related with 
slightly higher plasma insulin levels and/or possible higher sensitivity to insulin, as 
plasma glucose uptake tend to increase as evaluated by GTT and ITT. Conversely, 
hyperglycemia in R6/2 mice may be a consequence of pathogenic mechanisms 
occurring due to polyglutamine inclusions in pancreatic β-cells, impairing insulin 
secretion (Bjorkqvist et al. 2005). In the R6/2 mice, IGF-1 appears to have a protective 
role against HD-associated peripheral impairment of glucose tolerance, namely through 
increased blood insulin levels, as shown by us  (Duarte et al. 2011). Another possible 
explanation for this improvement involves the IGF-1-induced Akt phosphorylation 
which appears to be linked to both production and translocation of glucose transporter 4 
(GLUT4) from intracellular pools to the membranes in the normal developing brain and 
in regulation of brain hexokinase activity in astrocytes (Laviola et al. 2008). 
Indeed, we found reduced activation of Akt in YAC128 mice in cortical and 
striatal tissue, corroborating a previous study where the levels of Akt and its 
activated form were diminished before neuronal loss in a rat model of HD (Colin et al. 
2005). In peripheral tissues from HD patients, Akt specific activity was also found to be 
reduced, and in final stages of the disease lower Akt levels were observed in 
postmortem brain samples (Colin et al. 2005). These observations demonstrate a linear 
progressive alteration of Akt activation and disease progression (Colin et al. 2005, 
Warby et al. 2009). In IGF-1-treated YAC128 mice Akt phosphorylation was increased; 
under these conditions we also observed motor improvement and amelioration of brain 
metabolic deficits. Mild recovery of motor impairment in YAC128 mice seems to be 
related with the increase in IGF-1 levels in cortical areas. Indeed, restricted motor 
outcome may be related with non-significant IGF-1 levels in the sub- cortical areas, i.e. 
the striatum. In agreement with our study, in spinocerebellar ataxia type 1 transgenic 
model, i.n. administration of IGF-1 was able to improve motor coordination on the 
rotarod behavior test (Vig et al. 2006). Nevertheless, in HD patients Saleh and co-
authors (Saleh et al. 2010) established a negative correlation between plasma IGF-1 
levels and the degree of cognitive deterioration, contradicting another study where IGF-
1 was described to delay cognitive impairment in healthy elderly (Arwert et al. 2005). 
The present data suggest that i.n. IGF-1 can be properly delivered to the brain, 
positively influencing the phenotype of the disease. 
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One putative mechanism proposed for this phenotype rescue involves phosphorylation 
of HTT at Ser421 by Akt. Indeed, HTT is a substrate of Akt and its phosphorylation is 
crucial to mediate the neuroprotective effects of IGF-1 (Humbert et al. 2002). 
Importantly, our results show a large increase in the phosphorylation of mHTT at 
Ser421 upon IGF-1 treatment in striatal and cortical tissue in YAC128, compared to 
saline-treated mice, concomitantly with increased phosphorylation of Akt. Recent 
studies demonstrated that phosphorylation of HTT at S421 restores HTT function in 
microtubule-based transport (Colin et al. 2008, Zala et al. 2008). We verified that P-
wtHTT and P-mHTT was lower in striatum (approximately 2- fold less) in saline-
treated mice. This regional difference in the endogenous pattern of HTT 
phosphorylation, being lower in the striatum relatively to the cortex of wild-type 
mice, may predispose the striatum to degeneration (Warby et al. 2009). Decreased HTT 
phosphorylation was seen prior to overt neuropathology in the YAC128 mice and may 
contribute to HD-related pathogenesis, since a correlation exists between the decline in 
the level of pS421-HTT in the striatum of YAC128 mice and the aged phenotype 
(Metzler et al. 2010). In the present study we demonstrate that IGF-1 promotes the 
activation of cortical and striatal intracellular signaling pathways in YAC128 mice and 
the phosphorylation of mutant HTT at S421. 
Another hallmark of HD is the impairment in energy metabolism. Glucose metabolism 
was found to be significantly decreased in striatum and temporal and frontal cortical 
lobes, in both preclinical and affected HD patients, with marked striatal hypometabolism 
reflecting neuronal atrophy (Ma et al. 2007). The relationship between mHTT and 
mitochondrial dysfunction is widely recognized, resulting in bioenergetic failure 
(Bossy-Wetzel et al. 2008, Rosenstock et al. 2010). This interaction occurs with 
proteins of the respiratory chain, reducing their activity and compromising energy 
metabolism (Milakovic et al. 2005, Rosenstock et al. 2010). Thus, L/P ratio is typically 
elevated due to increased regional brain lactate production (Martin et al. 2007) as a 
result of mitochondrial dysfunction and/or reduced mitochondrial usage of pyruvate, as 
we showed recently (Ferreira et al. 2011) or due to decreased pyruvate levels 
accompanying glycolysis inhibition. In this perspective, mHTT is known to interact and 
decrease the activity of GAPDH (glyceraldehyde-3-phosphate dehydrogenase), which is 
fundamental for the glycolytic pathway (Wu et al. 2007). In the present study, YAC128 
mice brain exhibited lower levels of pyruvate and increased L/P ratio. Our results are in 
agreement with the results obtained by other studies (Martin et al. 2007, Olah et al. 
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2008) since saline-treated YAC128 mice showed a higher L/P ratio, compared to WT 
littermates in brain tissue. This may result from altered glucose metabolism in neurons 
and/or glial cells. A major finding of this study is that IGF-1 ameliorates energy deficits 
in YAC128 mice brain. Treatment with rhIGF-1 was capable of decreasing L/P ratio 
in YAC128 mice brain by increasing pyruvate levels, suggesting the improvement of 
glycolytic function. IGF-1 in the brain can modulate energy metabolism and its decline 
is associated with loss of energy metabolism (Cheng et al. 2000, Pruszak et al. 2007). A 
possible mechanism for IGF-1- induced glycolysis upregulation may occur through 
IGF-1-induced Akt phosphorylation, which may regulate GLUT4 translocation and thus 
increase glucose uptake. In the rat hippocampus, insulin (applied through 
intracerebroventricular administration)- stimulated phosphorylation of Akt was 
localized to neurons and was linked to the translocation of GLUT4 to the plasma 
membrane (Grillo et al. 2009), similarly as described in peripheral tissues. Thus, IGF-1 
may act in an insulin-like manner to promote glucose uptake and possible storage of 
glycogen in non-neuronal cells. 
In conclusion, we demonstrate that the non-invasive route of administration of IGF-1 
through i.n. can be efficient in increasing the levels of the neurotrophic factor in the 
brain, with an important outcome of rescuing motor deficits and glucose metabolic 
dysfunction in HD, even in the YAC128 mice exhibiting slightly increased levels of 
IGF-1 in the striatum. These data provide an experimental basis for establishing 
intranasal administration as an important therapeutic route for the administration of 
neurotrophic factors, such as IGF-1, in HD and in other neurodegenerative diseases. A 
successful therapy approach for HD patients implies that it has to efficiently cross the 
blood brain barrier (BBB) and reach the specific brain area to which it is directed. 
Indeed, i.n. administration can effectively overcome some of the major limitations 
described for other technical approaches (such as transient BBB opening, drug delivery 
vehicles as viral vectors or nanoparticles), since it reduces systemic toxicity and 
increases tissue- specific concentrations. In humans, insulin administration was shown 
to improve cognitive function in patients with early Alzheimer’s disease (Reger et al. 
2008) without overall changing blood glucose or insulin levels (Born et al. 2002). Given 
the promising results in recent animal studies, the clinical potential of such 
neuropeptide/growth factor delivery method in patients suffering from 
neurodegenerative diseases is very significant. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER III - Dominant-negative effects of adult onset mutant 
Huntingtin leads to an altered division of human embryonic stem 
cells derived neural cells 
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3.1. Introduction 
Huntington’s disease is a dominant neurodegenerative disorder caused by abnormal 
extension of a CAG repeat tract in the first exon of at least one of the two alleles of the 
HTT gene (Group 1993); when mutated the huntingtin protein contains an extended 
stretch of glutamine (poly-Q) near its NH2 terminus that is encoded by this tract 
(Persichetti et al. 1995). While in the general population the average CAG expansion is 
18 repeats, patient with HD carry expansion exceeding 35. In most patient with HD, the 
longest CAG expansion of the two HTT alleles range from 41 to 48 with an average 44 
repeats (Andrew et al. 1993, Snell et al. 1993, Rubinsztein et al. 1996, Killoran et al. 
2013). In these patients characteristic psychiatric, cognitive and motor disturbances 
emerge usually between 35 and 50 year old; HD is then inexorably fatal within 10 to 15 
years. Early onset of symptoms, increased severity and more rapid progression of the 
disease is associated with higher CAGs repeat numbers (Andrew et al. 1993). Fewer 
than 10% of patients develop symptoms before age 20. This juvenile variant of the 
disease is characterized by a more widespread and rapidly progressing pattern of brain 
degeneration that cause very different symptoms than adult-onset HD. Patient with 
juvenile-HD carry expansion with usually more than 60 CAGs (Nance et al. 1999, 
Nance et al. 2001, Seneca et al. 2004) 
Huntingtin is a large scaffold protein involve in diverse cellular functions in multiple 
cellular compartments (Li et al. 2004, Fiorini et al. 2013). Among hundreds of protein 
partners, HTT protein interacts with microtubules (MTs), directly with dynein and 
indirectly with dynactin through huntingtin-associated protein 1 (HAP-1) which binds 
to its p150
Glued
 subunit to form the dynein/dynactin complex. This complex regulates the 
microtubule-dependent transport of organelles in neurons (Gauthier et al. 2004, 
Caviston et al. 2007, Colin et al. 2008, Zala et al. 2008), ciliogenesis (Keryer et al. 
2011) and ensure a proper mitotic spindle orientation thus contributing to the regulation 
by HTT of cell fate (Godin et al. 2010, Elias et al. 2014). Current knowledge on 
pathological processes suggested that neuronal loss in HD is caused both by a loss of 
wild-type (wtHTT) functions and the gain of new toxic functions by mutant HTT 
(mutHTT) likely acting both cell and non-cell autonomously (Landles et al. 2004, 
Biagioli et al. 2015).  
Genetic mice and cellular models most often used to study the impact of HTT mutations 
express fragments or full length mHTT with exacerbated poly-Q stretch encoded by 
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expansion over 100 (or even 140) CAG repeats. The capacity of such acute models to 
accurately replicate the decade long pathological processes, originating from the most 
common form of HD mutations (41-48 CAGs), observed in the brain of patient is 
difficult to ascertain.  
Technologies providing access to human pluripotent stem cells (hPSC) (hESCs: 
(Thomson et al. 1998) & hiPSCs: (Takahashi et al. 2007, Yu et al. 2007) have allowed 
the development of a new disease model based on hPSC derivatives that may help 
bridge the gap between our current understanding of HD, based on the wealth of 
existing HD genetic models, and the actual pathological processes occurring in patient. 
A number of disease-specific (i.e mutant) hPSC lines derived from embryos 
characterized as mutant-gene carriers during a pre-implantation genetic diagnosis 
procedure or derived from patient fibroblasts have been obtained. Several of these lines 
(all in the case of HD-human embryonic stem cells (hESC)) carry triplet repeats with 
common lengths for the adult-onset form of the disease (Mateizel et al. 2006, Park et al. 
2008, Zeuschner et al. 2010, Bradley et al. 2011, Consortium 2012). Such HD-hPSC 
lines has just started to be used to decipher the impact of adult or juvenile-onset HTT 
mutation in human cells (Camnasio et al. 2012, Feyeux et al. 2012, Drouet et al. 2014, 
Farr et al. 2014). 
Recently the consequence of HTT mutation for cell division has been deciphered in 
context of cortical development (Molina-Calavita et al. 2014) and mammary carcinoma 
progression using mouse genetic model carrying HTT mutation with expansion over 100 
CAG repeats (Carroll et al. 2011). In the present study we combined the use of neural 
derivatives of wild type and adult-onset HD-hESC and SNP-targeting allele specific 
HTT mRNA interference to address the consequence of adult-onset HTT mutation on 
human neural progenitors division. 
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3.2. Materials and methods 
3.2.1.Cell culture 
Neural cells were derived from H9 (WT XX, passages 40–60, WiCell Research 
Institute) (Thomson et al. 1998), SIVF018 (XX, 46 CAG, passage 18-30, Sydney IVF 
Stem Cells, Australia) (Bradley et al. 2011) and SA01 (WT XY, passages 12, CellArtis 
AB, Göteborg, Sweden) (Heins et al. 2004) embryonic stem cell lines, as previously 
described in (Nicoleau et al. 2013). Neural Stem Cells obtained were maintained on 
poly-L-ornithine and laminin (Sigma, St. Louis, Missouri, United States) coated plates 
until passage 29 and then discarded. Cells were harvested with 0.05% trypsin 
(Invitrogen, Cergy Pontoise, France) and seeded at 100.10
3
 cells/cm
2
 in culture plates. 
NSCs were cultured in 1:1 ratio of Neurobasal: DMEM/Hams’s F-12 (Invitrogen, Cergy 
Pontoise, France), supplemented with 0.1% penicillin/streptomycin, 0.1% β-
mercaptoethanol (Sigma-Aldrich), 1% B27 (Invitrogen, Cergy Pontoise, France), 0.5% 
N2 (Invitrogen, Cergy Pontoise, France), 10 ng/mL FGF2 (Invitrogen, Cergy Pontoise, 
France) and 10 ng/mL EGF (R&D systems, Minneapolis, USA). The medium was 
changed every 2 days or when needed. Cells were plated in multi-well plates 54 hr 
before synchronization using RO-3306 (18hr, 10µM) (Enzo Life Sciences, France). The 
population was released from the G2 block by three washes with pre-warmed drug-free 
media and incubation with fresh media (30 min). 
 
3.2.2.DNA constructs and siRNA 
Genotypes on exon 50 for SNP rs362331 of H9 and SIVF018 NSC lines were analyzed 
by sequencing the PCR product encompassing this SNP generated using the following 
primers: 5’-CCCCAAACGAAGGTACACGA-3’ and 5‘- 
CCTGTTGGCCATCTCTCACC-3’. SIVF018 NSC line is heterozygous at SNP 
rs362331 (C/T) while H9 is homozygous (T/T). shRNAs targeting these SNP (si50C, 
si50T) were designed as previously described (Drouet et al 2014). The SIN-CWP-GFP-
LTR(N)-TRE-si1.1 (complete knock-down, shHTT), SIN-CWP-GFP-LTR(N)-TRE-
si50T (50T allele specific, sh50T), SIN-CWP-GFP-LTR(N)-TRE-si50C (50C allele 
specific, sh50C) and SIN-CWP-GFP-LTR(N)-TRE-siUNIV (shcontrol) plasmids were 
previously described (Drouet et al. 2014). The plasmids encoding N-terminal fragments 
of wild-type (23Q; mCherry-HTT-N586-23Q) and poly-Q HTT (100Q; mCherry-HTT-
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N586-100Q) constructs, were generated by the cleavage of pARIS-HTT encoding full-
length HTT (Myers et al. 1991). 
. 
 
3.2.3.Transfection 
Prior to nucleofection, cells were harvested with trypsin. 5x10
6
 cells were nucleofected 
using the Amaxa® Rat NSC Nucleofector® Kit (Lonza) according to the manufacturer's 
protocol. NSCs were resuspended in 100 μL of nucleofection solution with 5 μg of 
DNA and 0.5 μg pmaxGFP® Vector and electroporated with an Amaxa Nucleofector 
Program A-033 (Lonza) before plating on poly-ornithine/laminin coated dishes. For 
shRNA nucleofection, Five million NSCs resuspended in 100 μL of nucleofection 
solution of the Amaxa® Rat NSC Nucleofector® Kit (Lonza) with 5µg of shRNA 
(1µM) were electroporated with an Amaxa Nucleofector Program A-033 (Lonza) before 
plating on poly-ornithine/laminin coated dishes. All cells were incubated in humidified 
37°C/5% CO2 incubator and medium was changed after 24 hr. 
 
3.2.4.RNA extraction and quantitative RT-PCR 
Total RNA from NSC cells was extracted using RNeasy® Mini Spin Columns (Qiagen, 
Courtaboeuf, France). The purified RNA was then quantified with NanoDropR ND-
1000A spectrophotometer (A260/A280 ratio 1.9–2.1; 28S:18S rRNA ratio on agarose 
gels 2:1). Reverse transcription was performed on 500 ng of RNA using Cloned AMV 
First-Strand cDNA Synthesis Kit (Invitrogen, Cergy Pontoise, France). cDNA synthesis 
was performed using total RNA primed with oligo(dT) (50 μM) mixed with Random 
Hexamers (50 ng/μL) according to manufacturer’s protoco. Quantitative real time-
polymerase chain reactions (QRT-PCRs) are performed with Power SYBR Green PCR 
Mix (ROCHE) and a LC480 system (Roche). Quantification was performed at a 
threshold detection line (Ct value). The Ct of each target gene was normalized to the 
18S housekeeping gene. For primer sequences see Supporting Information Table 4. 
HTT mRNA allelic ratio analysis was performed using “TaqMan® SNP Genotyping 
Assays” (Hs00918153_m1: Applied Biosystems, Foster City, CA, USA) on cDNA used 
for QRT-PCR. The mean of difference of Ct of each target allele (3 technological 
replicate) was used to calculate the HTT allelic ratio expressed in % of SNP 50C and 
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SNP50T in all HTT mRNA (Genomic DNA was used a control sample with 50%/50% 
HTT allelic ratio). 
For the CAG repeats size analysis, a PCR was performed using TaKaRa LA Taq DNA 
Polymerase with GC Buffers (Takara Bio, Madison, USA), according to manufacturer 
protocol, on cDNAs obtained from allele specific cDNA synthesis using specific 
primers for HTT exon 1 5´-AAGGCCTTCGAGTCCCTCAA-3’ and 5’-
CACACGGTCTTTCTTGGTAGC-3’. The expected amplicon size for a normal allele 
with 23 CAG repeats is 281bp. The PCR products were analyzed by the Bioanalyser 
2100 (Agilent, CA, USA) using microfluidic chips which were prepared according to 
manufacturer’s instructions. Analysis of the data was performed using Data Review 
software version A.01.20 Sl211 and presented in the form of electropherograms or 
alternatively as a list of calculated band sizes. 
 
 
Table 4- Sequences of the oligonucleotides used to generate the shRNA targeting the SNP and the 
control. In bold are the sense and anti-sense strands of the shRNA. In red is the position of the SNP  
(Drouet et al. 2014). 
 
 
 
3.2.5.Immunofluorescence 
To visualize spindles, cells were permeabilized with PHEM/0.5% Triton X-100 for 30 
sec then fixed with 4% PAF/PHEM (20 min at RT) and then with -20ºC methanol (5 
min). Cells were rehydrated with PBS/0.1% Triton X-100 (3 washes), blocked in 10% 
Normal Goat Serum (NGS)/PBS (30 min) and incubated with the following antibodies: 
anti γ- tubulin (1:500, T3320 or 1:100, 6557; Sigma-Aldrich); anti-P150Glued (1:100, 
NAME SEQUENCE 
siHTT 
CTAGTTTCCAAAAAAAGAACTTTCAGCTACCAATCTCTTGAATTGGTAGCT
GAAAGTTCTTGGGGATCTGTGGTCTCATACAGAAC 
siscramble 
CTAGTTTCCAAAAAGTATCGATCACGAGACTAGTGACAGGAAGCTAGTCT
CGTGATCGATACGGGGATCTGTGGTCTCATACAGAAC 
si50C 
CTAGTTTCCAAAAACCCTCATCCACTGTGTGCATGACAGGAAGTGCACACA
GTGGATGAGGGGGGGATCTGTGGTCTCATACAGAAC 
si50T 
CTAGTTTCCAAAAACCCTCATCTACTGTGTGCATGACAGGAAGTGCACACA
GTAGATGAGGGGGGGATCTGTGGTCTCATACAGAAC 
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610474; BD Transduction Laboratories), anti-736-HTT (1:300; polyclonal (Arning et 
al. 2007)), anti-NUMA (1:500; Novus biological) 
For dynein intermediate chain (DIC) staining (1:200; mAB 1618 Chemicon) the fixation 
procedure was as followed: cells were immersed in microtubule stabilizing buffer 
(MTSB: 4M glycerol, 100 mM PIPES, pH6.8, 1 mM EGTA, 5mM MgCl2) for 2 min, 
followed by extraction for 2 min in MTSB/0.5% Triton X-100. Cells were then fixed 3 
min with -20ºC methanol. 
For all immunostainings, the slides were counterstained with DAPI (Roche) and 
mounted in Mowiol. The pictures were captured either with a three-dimensional 
deconvolution imaging system as previously described (Gauthier et al. 2004) or with a 
Leica DM RXA microscope equipped with a 63x oil-immersion objective coupled to a 
piezzo and a Micromax RTE/CDD-1300-Y/HS camera controlled by Methamorph 
software (Molecular Devices). Z-stack steps were of 0.3 μm. Images were treated with 
ImageJ (HTTp://rsb.info.nih.gov/ij/, NIH, USA). 
 
3.2.6. Spindle Orientation Quantification and Image Analyses 
 Spindle orientation in metaphase cells stained for γ-tubulin and DAPI to visualize the 
spindle poles and chromatin was quantified using ImageJ software 
(HTTp://rsb.info.nih.gov/ij/, NIH, USA). A line crossing both spindle poles was drawn 
on the Z projection pictures and repositioned along the Z-axis using the stack of Z-
sections. The angle between the pole-pole and the substratum plane was calculated by 
the ImageJ Plug-in. Spindle lengths and cell lengths were quantified along the line that 
crosses both spindle poles. 
The quantification of P150
Glued
 and DIC at spindle poles was achieved with 3D object 
counter plugin (Bolte et al. 2006),; HTTp://imagej.nih.gov/ij/plugins/track/objects.html. 
A circle (radius equal to half of pole-pole distance) was drawn around the pole position, 
and image was cleared outside the circle. Total volume and intensity of the particles 
were retrieved for further analysis.  
Quantification of NUMA at spindle pole was performed on the resulting z-stacks (one 
for each pole) using JACoP plugin (HTTp://imagej.nih.gov/ij/plugins/track/jacop.html) 
which determines the localization of NUMA at spindle poles given by γ-tubulin. 
Manders' overlap coefficient corresponds to the co-localization between both images. 
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Numb distribution at the membrane was done on the resulting z stack by drawing a 
scanline around the cells outline followed by profile plot and analyses of the distribution 
(symmetric vs. asymmetric).  
 
3.2.7.Immunoblotting 
Cells were lysed 72h after transfection (lysis buffer: 50 mM Tris-HCl pH 7.5, 0.1% 
Triton X-100 2 mM EDTA, 2 mM EGTA, 50 mM NaF, 10 mM β-glycerophosphate, 5 
mM sodium pyrophosphate, 1 mM sodium orthovanadate, 0.1% (v/v) β-
mercaptoethanol, 250 µM PMSF, and 10 mg/ml aprotinin and leupeptin). Twenty five 
-PAGE and electrophoretically 
transferred to Protran nitrocellulose membranes from Whatman. Blots were blocked in 
5% BSA/TBST buffer (20 mM TrisHCl, 0.15 M NaCl, 0.1% Tween 20) and incubated 
with anti-HTT D7F7 (1:1000; Cell Signaling Technology, Danvers, USA), anti-polyQ 
1C2 (1:5000; Euromedex, France) and anti α- tubulin (1:1000; Sigma) antibodies for 
1hr. 
3.2.8.Statistical analyses 
GraphPad Prism 5.0 software (San Diego, CA) was used for statistical analysis. Data 
are expressed as mean ± SEM of the indicated number of independent experiments. 
Statistical significance was analyzed using parametric tests, namely Student’s t-test and 
one way-ANOVA. Complete statistical analyses with number of measures are detailed 
in Supplemental Information.  
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3.3. Results 
3.3.1.Human HTT regulates spindle orientation in dividing neural stem cell 
derived from human embryonic stem cells  
We previously showed that HTT modulates spindle orientation in mouse neural and 
HeLa cells, and in cortical progenitors in vivo (Godin et al. 2010). To address whether 
human HTT has the same function, we used neural stem cells (NSC) differentiated from 
wild-type human embryonic stem cells (hESC) (H9 line) and used plasmids encoding a 
short hairpin RNA (shRNA) directed against HTT (shHTT1.1) or a control shRNA 
(shControl) to study the effect of the knock-down of HTT expression (Figures 3.1A). 
HTT protein level measured by western blot was reduced by 70%+/- 16.18 (n=3) in H9-
derived WT-NSCs 72 hours after transfection with the shHTT1.1 plasmid (Figure 3.1B). 
During mitosis, the polyclonal mAb763 antibody labelled HTT at the spindle poles as 
previously described (Godin et al. 2010) (Figure 3.1D). We also observed HTT 
localizing at the cell cortex. Treatment with shHTT led to a statistically significant 
reduction of signal intensity at the spindle pole and to a dispersion of HTT from its 
cortical localization. 
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Figure 3.1. Silencing of HTT in wild-type neural stem cells. 
(A) Schematic representation of HTT. (B) Immunoblotting with anti-HTT and anti-α-tubulin antibody of 
lysates of H9 cells treated with shcontrol and shHTT. The graph represents the quantitative assessments 
of the ratio of HTT over tubulin in each conditions.(C) Immunostainings of shcontrol and shHTT-treated 
cells with anti-γ-tubulin and anti-HTT (4C8) antibodies and DAPI counterstaining. (D) Immunostainings 
of metaphasic shcontrol and shHTT-treated cells with anti-γ-tubulin and anti-HTT antibodies and DAPI 
counterstaining. Quantification of anti-HTT signal at the spindle poles (p=15-20, n=13 cells). 
Results are shown as mean values ± SEM. *p<0.01. 
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We next immunostained with an anti-γ-tubulin antibody, H9-derived WT-NSCs 
transfected with shControl or shHTT1.1 plasmids to analyse in Z-series stacks (∆Z > 1.8 
μm) the position of the spindle poles with respect to the substratum plane (Figures 3.2A 
and 3.2B). Spindle orientation was quantified in metaphasic cells by determining the 
angle between the pole-pole axis (axis of the metaphase spindle) and the substratum 
plane. Non-transfected and WT-NSCs transfected with shControl plasmid showed a 
significantly lower mean angle (7.6º ± 0.7, n=86; 8.1º± 0.9, n=65) compared to 
shHTT1.1-treated cells (18.9º± 2.1, n=74) (Figure 3.2B). In shHTT1.1-transfected WT-
NSCs there was more metaphasic cells with an angle superior to 10º (79.5%) compared 
to control cells (non-transfected 28%; shcontrol 30%;). In particular, there was a 
significant proportion of cells (30.1%) having spindle angles greater than 20º in 
shHTT1.1 condition. 
We confirmed these results using an alternative RNA interference plasmid targeting the 
SNP rs362331 in exon 50 of the HTT gene in the H9 genome. Genotyping of H9 cells 
(supplementary data) revealed that the H9 WT-hESC line is homozygous for the SNP 
rs362331 in exon 50 (T/T). We therefore transfected H9-derived WT-NSCs with a 
plasmid encoding an allele-specific shRNA targeting SNP rs362331 –T in exon 50 of 
the HTT gene (shHTT50T) i.e targeting both allele of the HTT in H9-hESC derivatives 
(Feyeux et al. 2012). H9-derived WT-NSCs treated with shControl had mean spindle 
angles below 10º (8.9º ± 0.7, n=129; 7.4º± 0.6, n=106), while the mean angle in 
shHTT50T-treated WT-NSCs was above 20° (22.4º± 2.3, n=32) (Figure 3.2C). In 
shHTT50T-treated cells, the spindle angles were randomized with more than 33% of the 
metaphasic cells with an angle superior to 20º. 
Next we introduced in WT-NSCs an 586 amino acid N-terminal fragment of human 
HTT (HTT-N586-23Q) that recapitulates HTT function during microtubule-based 
transport (Colin et al. 2008). The nucleotide sequence encoding this fragment was 
modified in order not to be targeted by the shHTT1.1 which specifically targets 
endogenous human HTT (Pardo et al. 2010). HTT-586-23Q/ HTT-N586-Q23 rescued 
the spindle orientation defect observed when silencing HTT in WT-NSCs (Figure 
3.2D).  
Finally, we also analyzed the distribution of cells across mitotic phases based on 
chromosome configurations. HTT-depleted and control WT-NSCs had similar 
distribution of cells across mitotic phases (Figure 3.2E; (Godin et al. 2010)). These 
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findings support that human HTT regulates spindle orientation with no effect on the 
progression through the cell cycle in human neural stem cells. 
 
 
Figure 3.2.- Silencing of human HTT induces spindle misorientation. 
(A) Schematic illustration of spindle angle measurement. (B-D) H9 neuronal stem cells were either non-
treated or treated with shcontrol, shHTT, sh50T or shHTT + N586-HTT-Q23 as indicated. Distribution 
and average of spindle angles of metaphase cells are shown. (B) Cells were stained with anti-γ-tubulin 
and DAPI and Z-X projections are shown. (E) Distribution of H9 cells transfected with shcontrol and 
shHTT in prophase, metaphase and ana/telophase of cell cycle. Results are shown as mean values ± SEM. 
***p<0.001; **p<0.01. 
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3.3.2.HTT is required for the mitotic localization of dynein, dynactin and 
NUMA in human NSCs 
HTT associates with dynein/dynactin to stimulate axonal transport in neurons (Gauthier 
et al. 2004, Colin et al. 2005). Silencing of mouse HTT in neuronal cells mislocalizes 
the P150
Glued
 subunit of dynactin, dynein and the large Nuclear Mitotic Apparatus 
protein NUMA at the spindle poles suggesting that HTT could scaffold these proteins to 
ensure correct spindle orientation (Godin et al. 2010). We immunostained H9-derived 
NSCs for HTT during mitosis and observed a strong HTT labelling at the spindle poles 
(Figure 3.3A). To a lesser extent, HTT also localized at the spindle and microtubules 
plus ends. Dynein, the P150
Glued
 subunit of dynactin and NUMA were present at the 
spindle poles and spindle, along astral microtubules and at cortical sites (Figures 3.3B-
D). We analyzed whether these localizations depend on HTT by silencing endogenous 
human HTT (Figures 3.3E). Silencing of HTT in WT-NSC using shHTT1.1 plasmid 
resulted in partial mislocalization of dynein and P150
Glue
d from the spindle poles 
(Figures 3.3B-D). In contrast, NUMA accumulated at the spindle poles when HTT 
levels were lowered. In HTT depleted human NSC, the astral microtubules and cortical 
localization of dynein, P150
Glued
 and NUMA was reduced. We thus propose that human 
HTT controls the proper localization of several key mitotic proteins and that this may, 
as a consequence, influence spindle orientation in human WT-NSCs. 
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Figure 3.3. - Loss of HTT alters P150
Glued
, dynein and NUMA localization 
(A, B, C) Immunostaining of metaphasic neural stem cells with anti-DIC and anti-HTT (A), anti-P150Glue 
and anti-HTT (B), anti-NUMA and anti-HTT (C). (D, E, F) Immunostaining of metaphasic neural stem 
cells with anti-DIC (D), anti-P150Glue (E), anti-NUMA (F) and anti-γ-tubulin antibodies and DAPI 
counterstaining. Graphs represent the quantification of n=52 and n=60 for D; n=57 and n=60 for E, n=22 
for F. (E) Immunoblotting of extracts of H9 cells treated with shcontrol and shHTT for the presence of 
the indicated proteins. Results are shown as mean values ± SEM. ***p<0.001; **p<0.01. 
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3.3.3.Human adult-onset mutant HTT exerts a dominant negative effect on 
spindle orientation in HD-hESC derived NSCs  
We next addressed the effect of HD mutations on the role of HTT during spindle 
orientation in dividing NSCs derived from hESCs. We first expressed a mutant 586 
amino acid N-terminal fragment of HTT with an expanded polyglutamine stretch of 100 
residues (HTT-N586-100Q) in WT-NSCs derived from H9-hESCs. In WT-NSCs 
expressing HTT-N586-Q100, we observed a significant increase in the mean angle 
compared to controls (16.9º± 1.3; n=51 versus non-treated cells: 7.6º± 0.7, n= 86 and 
WT-NSC expressing an empty plasmid: 8.3º ±1, n=38) (Figure 3.4A). In particular, 
78.4% of metaphasic cells expressing mutant HTT had a spindle angle with an angle 
superior to 10º. 
We then used NSCs differentiated from a hESC lines characterized as carriers of one 
HTT allele with an adult onset mutant-gene during a pre-implantation genetic diagnosis 
procedure (SIVF018 line). In this cell line, the longest CAG expansion size is 46 CAGs; 
the size of CAG expansions and the link between the mutated allele was and the SNP 
rs362331 at exon 50 (50T) was confirmed (Supplementary Figure 1A). Allelic ratio of 
HTT allele using Taqman probe specific for SNP rs362331-T and -C in HD-NSCs 
nucleofected with siRNA targeting SNP rs362331-T(siHTT4) and SNP rs362331-C 
(siHTT5) showed that SNP-targeting RNA interference could discriminate both alellele 
as previously shown (Drouet et al 2014).  
As expression of a mutant HTT fragment leads to a defect in spindle orientation that is 
similar to the loss of function in WT-NSC (Figures 3.2B and 3.4A), we assessed 
whether the allele specific silencing of mutant HTT was associated to a functional 
recovery. Treatment of SIVF018 HD-NSCs with sh50T had no effect on the progression 
through the cell cycle (Figure 3.4C). We compared spindle angles in non-treated, and 
shcontrol- or sh50T-treated SIVF108 cells. Non-treated and shcontrol-treated SIVF108 
HD-NSCs had spindle angles distribution and mean spindle angles comparable to that 
of loss of function situation (19º± 1.2, n=83; 16.8± 1.5, n=61) (Figure 3.4D and see 
Figure 3.2). In contrast, in SIVF018 cells treated with sh50T, most of the cells divided 
with an angle below 10° and the mean spindle angle was comparable to that of wild-
type situation (9.5º±1, n=68). We also expressed a wild-type HTT fragment (N586-
HTT-Q23) in mutant cells and found no effect on the distribution and mean spindle 
angles observed in mutant situation (Figure 3.4E).  
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Taken together, these results indicate that a limited expansion in HTT similar to that 
found in most patients with HD is sufficient to induce a dominant negative effect on 
spindle orientation. Furthermore, an allele-specific silencing of mutant HTT in HD cells 
is associated with a functional recovery during spindle orientation. 
 
 
Figure 3.4.-Allele specific silencing rescues spindle misorientation in NSC derived from HD patients 
(A) H9 neural stem cells were either non-electroporated or electroporated with empty plasmid and N586-
HTT-Q23 as indicated. Distribution and average of spindle angles of metaphase cells are shown.  
(B) PCR (C) Distribution of shcontrol and sh50T SIVF018 cells in prophase, metaphase and 
ana/telophase of cell cycle. (D,E) SIVF018 cells were either non-electroporated or electroporated with 
shcontrol, sh50T and N586-HTT-Q23 as indicated. Distribution and average of spindle angles of 
metaphase cells are shown.  Results are shown as mean values ± SEM. ***p<0.001. 
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3.3.4.Recovery of dynein, P150
Glued
 and NUMA localization after mutant HTT 
allele-specific silencing 
We then asked whether, the functional rescue on spindle orientation induced by sh50T 
treatment of SIVF018 HD-NSCs would impact on the localization of dynein, P150
Glued
 
and NUMA. Cells were treated with shcontrol and sh50T and immunolabelled for these 
proteins (Figures 3.5). In control mutant conditions, the patterns of staining for dynein, 
P150
Glued
 and NUMA were similar to that observed in wild-type cells silenced for HTT 
(compare Figures 3.3 and 3.5). In sh50T cells, the localization of these proteins was 
restored. Indeed, there was more dynein and P150
Glued
 at spindle poles and along astral 
microtubules in SIVF018 HD-NSCs transfected with sh50T as compared to the 
shControl situation (Figures 3.5B and 3.5C). Upon treatment of SIVF018 HD-NSCs 
with sh50T, the spindle pole signal of NUMA was less dispersed than in shcontrol cells 
(Figures 3.5C). 
Our results show that allele-specific silencing of mHTT selectively rescues the 
displacement of dynein, dynactin and NUMA whose correct localization is required for 
spindle positioning. Together, we thus suggest that allele specific silencing rescues the 
phenotype observed in HD cells by restoring HTT function. 
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Figure 3.5. - Allele specific silencing of mutant HTT rescues dynein, dynactin and NUMA 
mislocalization 
(A, B, C) Immunostaining of metaphasic neural stem cells with anti-DIC and anti-HTT (A), anti-P150Glue 
and anti-HTT (B), anti-NUMA and anti-HTT (C). (D, E, F) Immunostaining of metaphasic neural stem 
cells with anti-DIC (D), anti-P150Glue (E), anti-NUMA (F) and anti-γ-tubulin antibodies and DAPI 
counterstaining. Graphs represent the quantification of n=46 for D; n=54 and n=45 for E, n=16 and n=28 
for F. Results are shown as mean values ± SEM. ***p<0.001; **p<0.01, *p<0.05. 
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3.4. Discussion 
Previous studies have established a role for HTT in formation and maintenance of the 
dynein/dynactin complex in neurons (Waterman-Storer et al. 1997, Caviston et al. 
2007). These microtubules associated proteins are essential for microtubule-dependent 
vesicular transport in axons (Gauthier et al. 2004, Caviston et al. 2007, Colin et al. 
2008, Zala et al. 2008). Recently was proven that this complex is critical for spindle 
assembly and maintenance (Godin et al. 2010) as well as for the cell cortex to exert 
pulling forces on astral microtubules (Fink et al. 2006, Laan et al. 2012, Zheng et al. 
2013). HTT seems to be an important key in the recruitment of dynein and dynactin to 
the complex and on distribution of this complex at the cell cortex.  
In our study we found that depleting HTT induces spindle misorientation as well as the 
localization of proteins involved in spindle assembly. More precisely p150
Glued
 subunit 
of dynactin and dynein were drastically reduced at spindle poles and the opposite effect 
was observed with NuMA, an accumulation at the spindles. In fact NuMA–LGN–Gα 
form a complex known to be involved in regulation of spindle orientation (Zheng et al. 
2010, Zheng et al. 2013) and HTT seems to interfere with this recruitment. The mitotic 
spindle orientation dictates the cleavage plane of the mother cell and subsequent 
inherence of cytoplasmic structures by one or both of the two daughter cells (Siller et al. 
2009, Godin et al. 2010, Bornens 2012). During asymmetric division the two daughter 
cells have different sizes and cellular components are preferentially segregated into only 
one cell. This differential inheritance of cell fate determinants is an important process 
for cell fate determination and morphogenesis during development (Kosodo et al. 2004, 
Noatynska et al. 2012). In vivo planar divisions generates two identical cell fates and 
apical/basal spindle orientation generates two different cell types (Willardsen et al. 
2011). The well characterized canonical Notch signaling pathway is a key regulator of 
NSC maintenance in the developing nervous system maintaining the neural precursors 
in an undifferentiated self-renewing state (Borghese et al. 2010). Numb, an endocytic 
adaptor protein that acts as a Notch pathway inhibitor has been associated with neuronal 
differentiation. In later stages of development the differentiated neuronal daughter cell 
inherits Numb (Shen et al. 2002, Wirtz-Peitz et al. 2008). It was reported recently that 
wild-type HTT seems necessary to direct NS cells towards a neuronal fate, and its 
absence causes cells to undergo glial differentiation (Conforti et al. 2013, Nguyen et al. 
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2013). In our study we found that cells lacking HTT tend to divide asymmetrically as 
was shown by heterogeneous inherence of Numb in dividing cells. 
Theoretically treating HD patients should be easy, it only would be necessary to 
suppress mHTT expression, as shown previously in mice models (Yamamoto et al. 
2000). In clinical practice turn off the expression of an autosomal dominant gene in the 
brain is not yet feasible. An interesting approach, which has been explored in the past 
years, is using RNA interference to specific target brain HTT mRNA. Several studies 
have addressed this question, unfortunately using a non-allele specific silencing of HTT 
that cannot distinguish between normal and CAG-repeat expanded transcripts resulting 
in the reduction of both types. Nonetheless, those studies have shown that total 
knockdown of HTT is well tolerated for up to 9 months in rodents and improved HD-
associated abnormalities (Harper et al. 2005, Wang et al. 2005, Franich et al. 2008, 
Boudreau et al. 2009, Drouet et al. 2009). However the prominent question has not yet 
been answered: which are the deleterious effects in long term reduction of endogenous 
wild-type HTT expression and for how long could be tolerated in adult post mitotic 
neurons. An alternative and more safe strategy would be the allele specific silencing of 
mHTT by targeting heterozygous SNPs. Warby and colleagues demonstrated that a 
large percentage of HD European patients belong to a single haplotype with a specific 
set of SNPs (Warby et al. 2009) and two other recent studies confirmed that HD 
patients share polymorphic sites and that a reduced number of siRNA targeting mHTT 
allele can treat up to 75% of HD patients (Lombardi et al. 2009, Pfister et al. 2009). 
Promising results were obtained so far in vitro with HD patient-derived fibroblasts (van 
Bilsen et al. 2008) and NSCs derived from HD patients (Drouet et al. 2014) and in vivo 
using animal models for Machado-Joseph disease (Alves et al. 2008) and of dominant 
inherited ALS (Xia et al. 2006). In cultured cells siRNA have successfully silence the 
mutant HD allele, whereas preserving expression of its wild-type counterpart and in 
NSCs a functional recovery was observed by restoring the mean velocity of BDNF 
vesicles (Drouet et al. 2014). Recently, Carroll and colleagues developed antisense 
oligonucleotides (ASO) able to target both exonic and intronic SNP sites, and were able 
to specifically and potently reduce mHTT levels at in primary human cells, cultured 
primary neurons and the adult CNS of YAC18 and BACHD mice (Carroll et al. 2011). 
In our study in NSC derived from HD patiens we found spindle abnormalities both in 
the cleavage plane (spindle angle) and in location of key proteins for proper spindle 
assembly that could not be rescued by overexpressing wild type HTT. In agreement 
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with aforementioned studies we demonstrate that allele specific silencing can be an 
efficient therapeutic approach in vitro by reversing the phenotype observed in NSC 
derived from HD patients. These data suggest that is feasible to use this therapeutic 
approach to reduce mHTT levels and support the continued development toward using 
RNA-based therapeutics to treat HD. 
 
 
 
SUPPLEMENTAL INFORMATION 
 
Figure 3.6. Supplementary data. A) H9 neural cells have 2 normal alleles while SIVF018 have a normal 
allele with 23 CAG repeats and an expanded with 50 CAGs and is heterozygous for SNP rs362331 at 
exon 50. CAG repeats size detection was obtained using a microfluidic chip from Agilent®. (B) 
Immunoblotting of extracts from SIVF018 scramble and SIVF018 treated with sh50T_1 for 3 days and 
sh50T_2 for 5 days using anti-htt targeting CAG repeats (D7F7) and α-tubulin antibodies and respective 
quantification. C) Distribution and average of spindle angles of metaphase cells in shcontrol and sh50C 
SIVF018 cells.  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER IV - Induced pluripotent stem cells derived from 
Huntington´s disease patients unravel early mitochondrial 
dysfunction and metabolic disturbances 
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4.1. Introduction 
Huntington's disease is an autosomal dominant disease caused by an expansion of CAG 
repeats in the gene encoding for huntingtin (Group 1993). The known prevalence of the 
mutation is 4–10 cases per 100,000 but presumably in Caucasian populations is highly 
underestimates (Morrison 2010, Morrison 2012). The mutant huntingtin abnormal 
interactions results in cellular alterations, including abnormal vesicle recycling, 
disturbance in Ca
2+
 signaling, loss of BDNF, excitotoxicity, decreases in intracellular 
ATP levels, alterations of gene transcription, inhibition of protein clearance pathways, 
mitochondrial and metabolic disturbances inducing neurodegeneration and cell death 
(Zuccato et al. 2010). Several pathological mechanisms have been proposed for 
neurodegeneration, including mitochondrial dysfunction and oxidative stress (Horton et 
al. 1995, Cantuti-Castelvetri et al. 2005, Ferreira et al. 2011, Ribeiro et al. 2014). An 
increase susceptibility of HD striatal medium spiny neurons to ROS was documented 
but the underlying pathogenesis mechanisms are not fully understood (Vonsattel et al. 
2008, Ribeiro et al. 2014). In genetically complex diseases, revealing the mechanisms 
underlying the pathology has not been easy and usually is based on cell or animal model 
that not always reproduce the disease mechanistic in the target cells. Important tools to 
disease modeling have emerged in the last few years with the reprogramming of somatic 
human cells into human induced pluripotent stem cells (hiPSCs) (Takahashi et al. 2007) 
and the use of human embryonic stem cells (hESCs) (Thomson et al. 1998). The 
differentiation capacity into various neuronal lineages has been explored and a few 
novel iPSCs models have been created. These advances allow generating patient-
specific iPSCs and differentiation into cell types affected in disease providing a 
powerful new tool to recapitulate the neuropathologic phenotype in a developmental 
stage. The new iPSC-based disease models reproduce some of the main features of the 
pathology providing important insights into disease biology but not always exhibit the 
neuronal maturation and network defects that are observed in vivo. The first report on 
patient-specific iPSCs was in 2008 when Park and colleagues successfully 
reprogrammed fibroblasts from one patient with Huntington chorea with 72/19 CAGs 
(Park et al. 2008). Further characterization was done by Zhang (2010) showing that 
these cells can differentiate into HD specific neural stem cells (HD-NSCs) and neurons 
with striatal characteristics. Other study found, in lower repeat lengths lines, altered 
lysosomal content that was maintained during proliferation and in hiPS-derived neurons 
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(Camnasio et al. 2012) More recently the HD iPSC Consortium generated iPSC lines 
from HD patients and controls with early onset and late onset HD-iPSC lines 
(Consortium 2012). Those lines where successfully differentiated into neurons with 
striatal phenotype that presented disease-associated changes in electrophysiology, 
metabolism, cell adhesion and cell death for lines with both medium and longer CAG 
repeat expansions. Indeed, HD-iPSC and their differentiated counterparts can help to 
reveal the role of mitochondrial and metabolic dysfunction in early stages of HD.  
More recently 72 polyglutamine iPSC line was genetic corrected and cells were 
successfully differentiated into DARPP-32-expressing striatal neuron reverting some of 
the classical hallmarks of HD (An et al. 2012). In this study, we show that HD-iPSCs 
have altered mitochondria dynamics presenting more negative membrane potential and 
increased intracellular basal Ca
2+
 levels, but reduced Ca
2+
 mitochondrial storage 
capacity. We report a metabolic deficit and a shift favoring glycolysis for ATP 
production in HD-iPSC. Moreover, increased levels of mitochondrial superoxide anion 
and hydrogen peroxide production were observed in HD-iPSCs versus control iPSC. 
Overall, our study suggests that mitochondrial dysfunction occurs in early HD 
pathogenesis. 
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4.2. Materials and methods 
4.2.1.Materials 
Mitotically inactivated murine embryonic fibroblasts (MEFs) were acquired at 
AMSBIO® (Abingdon, U.K.). Matrigel was purchase from Corning
®
 (Amsterdam, The 
Netherlands). Geltrex, MitoSOX
®
 Red Mitochondrial Superoxide Indicator analyses, 
Neurobasal medium, Hoechst 33342, acetoxy-methyl-ester Fura-2 (Fura-2AM), 
Accutase, N-2 Supplement (100X) and B-27® Supplement (50X) were obtained from 
Life Technologies (Eugene, OR, USA). Lipofectamine 3000, MitoTracker Red 
CMXRos, DMEM/F12 and knockout serum replacement were from Invitrogen 
(Carlsbad, CA, USA). L-glutamine, nonessential amino acids, 2-mercaptoethanol, 
XAV939, Y-27632, 2-deoxy-D-glucose, oligomycin, FCCP, 4Br-A23187, ionomycin, 
antimycin A, 3-nitropropionic acid, Mitochondria peroxy yellow 1, SOD Assay Kit, 
decyl-ubiquinone, acetyl-CoA, cytochrome c, nicotinamide adenine dinucleotide 
(NADH), DL-dithiothreitol (DTT), hydrogen peroxide (H2O2), PMSF 
(phenylmethanesulfonyl fluoride), protease inhibitors (chymostatin, pepstatin, A, 
leupeptin and antipain), pyruvate, Rhodamine 123, etomoxir sodium salt hydrate, 
Sodium palmitate and L carnitina were purchase at Sigma-Aldrich Corporation (St. 
Louis, MO, USA). Human FGF2, human EGF, MITOMYCIN C and Dorsomorphin 
were from Tebu-bio (Yvelines, France). SB431542 was from from Tocris Bioscience 
(Bristol, United Kingdom). Dulbecco’s Modified Eagle’s Medium (DMEM) culture 
medium, Fetal Bovine Serum (FBS), penicillin/streptomycin and geneticin were 
purchased by GIBCO (Paisley, UK). Amplite Colorimetric Pyruvate and Amplite 
Colorimetric L-Lactate kits were from AAT Bioquest's (Sunnyvale, CA, USA). 
Pyruvate dehydrogenase (PDH) Enzyme Activity Microplate Assay Kit was from 
MitoSciences (Oregon, USA). Secondary antibodies conjugated to alkaline phosphatase 
(anti-mouse and anti-rabbit) were purchased from Amersham Biosciences 
(Buckinghamshire, UK). Enhanced ChemiFluorescence reagent (ECF), anti-rabbit IgG 
(from goat), anti-mouse IgG+IgM (from goat) were from GE Healthcare (Little 
Chalfort, UK). Antibodies used were anti-OCT4 (Cell Signaling Technology), anti-
SOX2 (Cell Signaling Technology), D7F7 anti-HTT (Cell Signaling Technology); anti-
nestin (), anti-OPA1 (Santa Cruz), anti-DRP1 (BD bioscience), anti-MFN2 (Sigma), 
anti-Fis1 (Novus Biologicals), anti-polyglutamine stretch (1C2) (Millipore), anti-PDK1 
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(Cell Signalling), anti-acetyl SOD2 (Abcam), anti-SOD2 (Abcam) and anti-α-tubulin  
(Sigma). 
 
4.2.2. Human ES cell culture 
Wild-type iPS cell line used was AMS4-iPS (XY, passages 7-30) and HD-iPS4 (XY, 
passage 4-30) with one normal (<35 repeats) and one expanded allele (72 repeats) 
generated by Park and colleagues (Park et al. 2008). Cells were maintained on a layer of 
mitotically inactivated murine embryonic fibroblasts (MEFs) for a variable number of 
passages or allowed to grown under feeder-free conditions on Matrigel® or Geltrex®. 
MEFs were acquired from AMSBIO® inactivated or to expand and were inactivated 
with mitomycin C after 3 passages. Manual dissection was routinely used to passage the 
cells rather than enzymatic methods.  
The iPS cells were cultured in DMEM/F12 supplemented with 20% knockout serum 
replacement, 2 mM glutamine, 1 mM nonessential amino acids, 1% 
penicillin/streptomycin, 100 µM 2-mercaptoethanol and 10 ng/ml recombinant human 
FGF2. Cultures were fed daily and passaged at least once a week. When cells were 
grown in matrigel, medium was conditioned for 24h in mouse embryonic fibroblasts 
and filtered. Neural differentiation was based on dual SMAD inhibition (Chambers et 
al. 2009, Delli Carri et al. 2013, Nicoleau et al. 2013). Colonies were grown on 6-well 
plate in matrigel until reach 100% confluence. Neural induction medium consisted of 
DMEM/F12, Neurobasal, N2 (100x), 2 mM l-glutamine, 100 μm nonessential amino 
acids, 100 μM 2-mercaptoethanol, 1% penicillin/streptomycin and B-27 (50x). Neural 
induction occurred between day 0 and day 10-12. For day 0 to day 5 cells were 
maintained in KSR medium without FGF and incubated with Dorsomorphin 5 μM 
(BMP inhibitor), SB431542 10 μM (TGF-β inhibitor) and XAV939 1 µM (β-catenin-
transcription inhibitor and axin stabilizing agent). Medium was change every day. From 
day 5 to 10-12 medium was gradually replaced by 75 % KSR + 25 % N2 Medium, 50 % 
KSR + 50 % N2 Medium until reach 100 % N2 Medium plus Dorsomorphin 5 μM, 
SB431542 10 μM and XAV939 1 µM (Mak et al. 2012, Delli Carri et al. 2013, 
Nicoleau et al. 2013). Between days 10 and 12, fields full of rosettes become 
morphologically visible. To allow the cells to differentiate, they were replated in 
matrigel coated 12-well plate. For detaching, cells were incubated with Accutase at 37 
°C in 5 % CO2 for 15–20 min. Accutase was diluted in DEM/F12 medium prewarmed 
 137 
 
at 37 °C. Cells were collected and spin 3 min at 1000 rpm at RT and resuspend in 200 
µl into a well of a 12-well plate. Cells were allowed to adhere for 30 min and then more 
300 μl of N2 medium was added supplemented with Y-27632 10 μM, FGF 10 ng/ml 
and EGF 10 ng/ml. Dishes were carefully transferred in a 37 °C, 5 % CO2 incubator and 
leaved overnight. Cells were maintained in the same medium and passaged every 2-3 
days for no more than 10 passages. 
 
4.2.3.Mitochondrial staining 
MitoTracker Red CMXRos is a red-fluorescent dye (ex-578/em-599) that stains 
mitochondria in live cells and its accumulation is dependent upon membrane potential. 
The MitoTracker probe contains a mildly thiol-reactive chloromethyl moiety that keeps 
the dye associated with the mitochondria after fixation. Into the cell medium was added 
400nM of CMXRos for 20 minutes and incubated at 37°C in a humidified atmosphere 
at 95% O2 and 5% CO2. MitoTracker probe passively diffuses across the plasma 
membrane and accumulates in active mitochondria. After removing the media with 
CMXRos, the cells were fixed with 4% paraformaldehyde (pH 7.4) for 10 minutes and 
immunocytochemistry continued as described ahead. 
Mitochondrial morphology was examined with pDsRed2-Mito which encodes a fusion 
of Discosoma sp. red fluorescent protein (DsRed2) and a mitochondrial targeting 
sequence of human cytochrome c oxidase subunit VIII (Mito). The targeting sequence is 
fused to the 5'-end of DsRed2, which is human codon-optimized for high expression in 
mammalian cells. Cells were plated in a 24-well plate and when 70% confluence was 
achieved transfection was performed according to the instructed procedures of 
Lipofectamine™ 3000.  
 
4.2.4.Immunocytochemistry  
Cells were washed with warmed PBS 1x followed by permeabilization with PHEM (5 
mM HEPES, 60 mM PIPES, 10 mM EGTA, 2 mM MgCl2, pH 7.0 with KOH)/0.1% 
Triton X-100 for 30 sec then fixed with 4% PAF/PHEM (20 min at RT). Cells were 
rehydrated with PBS/0.1% Triton X-100 (3 washes), blocked in 3% BSA/PBS (30 min) 
and incubated with the following primary antibody overnight at 4°C: anti-OCT4 
(1.200), anti-sox2 (1:200), anti-nestin (1:200), anti-OPA1 (1:100), anti-DRP1 (1:100), 
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anti-MFN2 (1:300) and anti-Fis1 (1:100). Secondary antibodies and DAPI counterstain 
were applied for 1 h at room temperature. Confocal analysis was performed on a Leica 
TCS SP2 microscope (Leica Microsystems). 
 
4.2.5.Immunoblotting 
Cells were lysed in lysis buffer (50 mM Tris-HCl pH 7.5, 0.1% Triton X-100, 2 mM 
EDTA, 2 mM EGTA, 50 mM NaF, 10 mM β-glycerophosphate, 5 mM sodium 
pyrophosphate, 1 mM sodium orthovanadate, 0.1% (v/v) β-mercaptoethanol, 250 µM 
PMSF, and 10 mg/ml aprotinin and leupeptin). The samples were denatured with SDS 
sample buffer (50 mM Tris-HCl, pH 6.8, 2% sodium dodecyl sulphate, 5% glycerol, 
0.01% bromophenol blue and 100 mM DTT), at 95ºC, for 5 min. Twenty five µg or 
seventy of protein µg was loaded in 6% and 12% gel, subjected to SDS-PAGE and 
electrophoretically transferred onto polyvinylidene difluoride (PVDF) Hybond-P 
membranes. Blots were blocked in 5% BSA/TBST buffer (20 mM TrisHCl, 0.15 M 
NaCl, 0.1% Tween 20) and incubated with anti-HTT (D7F7) (1:1000) and 
polyglutamine stretch (1C2) (1:5000), anti-OCT4 (1:500), anti-PDK1 (1:1000), anti-
acetyl SOD2 (1:500) and SOD2 (1:5000) and α-tubulin (1:10000). Membranes were 
further incubated with anti-rabbit and anti-mouse secondary antibodies (1:10000), for 
90 min, at room temperature, and developed using ECF fluorescent reagent. 
Fluorescence signal was analyzed using the QuantityOne software and the results were 
given as fluorescence intensity (INT)/mm2. Data were presented as the ratio of 
phosphorylated protein/total protein or protein levels/α-tubulin. Immunoreactive bands 
were visualized with VersaDoc Imaging System (BioRad®, Hercules, USA). 
 
4.2.6.Assessment of intracellular pyruvate and lactate 
Cells were washed with ice-cold PBS and extracted with 0.6 M perchloric acid 
supplemented with 25mM EDTA-Na
+
 for pyruvate and PBS for lactate. Cell extracts 
were centrifuged at 14 000 rpm for 5min at 4 °C in order to remove cell debris. Lactate 
and pyruvate were determined in the supernatant by using kits from Amplite 
Colorimetric Pyruvate and Amplite Colorimetric L-Lactate from AAT Bioquest's 
(Sunnyvale, CA, USA) respectively. Results of lactate and pyruvate content were 
obtained in µg/mg protein and expressed as a ratio of lactate/pyruvate  
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4.2.7.Measurement of ATP  
In experiments targeting to inhibit glycolysis, the culture medium was replaced by 
DMEM with glucose (GLUC) or supplemented with 2-deoxy-D-glucose (2-DOG) a 
competitive inhibitor of glucose metabolism (Wick et al. 1957) for 2 hours (Ferreira et 
al. 2011). To further inhibit mitochondrial ATP synthesis 2 μg/ml of oligomycin was 
added to glucose-containing medium or supplemented with 2-DOG. Additionally to 
analyze the glycolytic metabolism in cell bioenergetics status, medium without glucose 
plus 2-DOG was supplemented with 10 mM pyruvate (2-DOG+Pyr) to directly feed the 
mitochondria (Ferreira et al. 2011).  
For ATP measurement, cells were washed with ice-cold PBS, scraped, and extracted 
with 0.6 M perchloric acid, supplemented with 25 mM EDTA-Na
+
, and centrifuged at 
14 000 rpm for 2 min at 4 °C. Pellet was discarded and supernatant was neutralized with 
10M KOH, samples were then centrifuged at 14 000 rpm for more 2 min at 4 °C. The 
resulting supernatants were assayed for ATP determination by separation in a reverse-
phase high-performance liquid chromatography (HPLC), with detection at 254 nm, as 
described previously (Stocchi et al. 1985). The samples were assayed by separation in a 
reverse-phase high-performance liquid chromatography (HPLC), using a Lichrospher 
100 RP-18 (5 µm) HPLC column from Merck (Darmstadt, Germany), upon an isocratic 
elution with 100 mM phosphate buffer (KH2PO4, pH 6.5) and 1% methanol, with a 
flow rate of 1 ml/min and detection at 254 nm, as previously described (Stocchi et al. 
1985). The required time for each analysis was 6 min. The chromatographic apparatus 
used was a Beckman-System Gold, consisting of a 126 Binary Pump Model and 166 
Variable UV detector. Peak identity was determined by following the retention time of 
standards. Cellular energy charge was calculated using the formula: ([ATP] + 0.5 
[ADP])/([ATP] + [ADP] + [AMP]). 
 
4.2.8.Determination of pyuvate dehydrogenase (PDH) E1α subunit protein 
levels and phosphorylation 
PDH expression and phosphorylation were assessed using Pyruvate dehydrogenase 
(PDH) Enzyme Activity Microplate Assay Kit from MitoSciences (Oregon, USA) 
following the manufacturer instructions and using the solutions provided in the kit. 
Briefly, cells were plated at confluent density, allowed to adhere, and fixed with 3.7% 
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formaldehyde/4% sucrose. Cells were permeabilized, blocked and incubated with total 
PDH E1α combined with another antibody against the phosphorylated forms of PDH 
E1α at pSer 232, pSer293 or pSer 300, and developed by dual colorimetric detection. 
Cell density was normalized after Janus Green staining. Absorbance was monitored 
using a microplate reader Spectra Max Plus 384 (Molecular Devices, USA). 
 
4.2.9.Mitochondrial membrane potential (ΔΨm) determination and 
intracellular Ca
2+
 (Ca
2+i
) by fluorimeter 
The ΔΨm was determined using the cationic fluorescent probe Rhodamine 123 
(Rhod123). This positively charged molecule will accumulate within mitochondria in 
inverse proportion to ΔΨm according to the Nernst equation. More polarized 
mitochondria (interior is more negative) will accumulate more cationic dye, and 
depolarized mitochondria (interior is less negative) accumulate less dye. Fluorescent 
dye accumulation in mitochondria is then optically detected by fluorescent plate reader 
(Scaduto et al. 1999). Briefly, iPS cells were cultured in a 6-well plate and NSC in 96-
well plate until reach confluence. For iPS cells, detachment was required previously to 
incubation with the probes. Therefore cells were incubated with Accutase at 37 °C in 5 
% CO2 for 15–20 min. Accutase was diluted in KSR medium prewarmed at 37 °C and 
left for 30 min to minimize the enzyme stress on cells. Then, iPS cells were washed 
twice in Krebs medium and incubated at 37ºC for 30 min with 8 µM Rhod123 and 1.5 
µM acetoxy-methyl-ester Fura-2 (Fura-2AM).  
NSC were incubated in the 96-wells plates directly following the same protocol. After 
incubation, cells were washed once and the basal fluorescence was taken during 5 min 
using a Microplate Spectrofluorometer Gemini EM (Molecular Devices, USA). 
Fluorescence spectra for Rhod123 are 510 nm excitation and 590 nm emission. For 
Fura-2AM, the excitation spectra are at 380 nm (calcium free) and 340 nm (calcium 
complex) with fixed emission at 540 nm. Oligomycin (2 μg/ml) and p-trifluoromethoxy 
carbonyl cyanide phenyl hydrazone (FCCP) (2 μM), (separately or together), which 
produces maximal mitochondrial depolarization, were added to cells and the 
fluorescence was taken during another 5 min. Cells were also challenged with 5 µM of a 
Ca
2+
 ionophore - 4Br-A23187- which is highly selective for Ca
2+
 and increases its 
levels. Furthermore to directly evaluate the role of mitochondria, glycolysis was 
inhibited by adding 2-deoxy-D-glucose (2 mM) and by replacing glucose with pyruvate 
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(10 mM) for 2 hours (pyruvate-based medium) (Rego et al. 2001, Oliveira et al. 2006). 
Results were expressed as the difference between the increase in Rhod123 or FURA-2 
AM fluorescence and upon addition of oligomycin and FCCP or oligomycin/FCCP and 
basal fluorescence values. 
 
4.2.10.Monitoring dynamic changes intracellular Ca2+ and mitochondrial 
membrane potential by single cell microscope 
IPS cells were plated on glass coverslips coated with matrigel and allowed to form 
colonies. When colonies were visible iPS cells were washed with Krebs medium 
containing (in millimolar) 132 NaCl, 4 KCl, 1 CaCl2, 1.2 mM KH2PO4 1.4 MgCl2, 6 
glucose, 10 HEPES, and pH 7.4. Subsequently, glass coverslips were transferred to 
Krebs medium containing 0.2% (w/v) pluoronic acid, 0.1% (w/v) BSA, 1.5 µM Rh123, 
and 8 µM Fura-2AM for 30 minutes in a 37 °C, 5 % CO2 incubator. Cells were rinsed 
with fresh buffer and coverslips assembled in a nonperfused chamber filled with 500µl 
of Krebs medium containing 1.5 µM Rh123. Simultaneous Ca
2+
 levels and Rh123 
fluorescence were acquired by using an inverted fluorescence microscope Axiovert200 
(Zeiss, Jena, Germany) equipped with a dual-band path emission filter (510/40 and 
600/60 nm) and a Lambda DG4 apparatus (Sutter Instruments Company, Novato, CA, 
USA). Oligomycin (2 µg/ml) was added and fluorescence was registered for 3 min 
followed by FCCP addiction, to induce maximal mitochondrial depolarization. 
Calibration of Ca
2+
i responses was performed at the end of the experiment by adding 2 
μM ionomycin (∆m collapse). 
The determinations of fluorescence time courses were calculated on the basis of 1 
microscopic field per coverslip, containing 50 cells. Moreover, individual whole cells 
were identified as regions of interest (ROI). Each experimental condition was assayed at 
least in three different coverslips from three independent culture preparations. 
 
4.2.11.Measurement of ROS (superoxide and hydrogen peroxide)  
For MitoSOX
®
 Red Mitochondrial Superoxide Indicator analyses iPS cells were 
detached by Accutase, collected and allowed to rest for 30 min in KSR medium. 
Subsequently were centrifuged 3 min, 1000 rpm at RT and washed with Krebs medium. 
Cells were incubated at 37ºC with 5 µM MitoSOX® for 30 min, washed with Krebs and 
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the resultant fluorescence analyzed on a Microplate Spectrofluorometer Gemini EM for 
5 min after which were treated with the stressor compounds H2O2 (1 mM), antimycin A 
(1 µM) and 3-nitropropionic acid (3-NP) (300 nM) and fluorescence was measured for 
more 5 min. at  
NSCs were cultured for 24 hr at 37°C in 96-well assay plates coated with matrigel. 
Cells were washed with HBSS (in millimolar: 1.3 CaCl2, 0.5 MgCl2-6H2O 0.4 MgSO4-
7H2O, 5.3 KCl, 0.4 KH2PO4, 4.2 NaHCO3, 137.9 NaCl, 0.3 Na2HPO4, 5.6 D-Glucose 
at pH 7.4) and incubated for 30 min with 5 µM MitoSOX
®
 Red Mitochondrial 
Superoxide Indicator in HBSS and proceed as above described.  
To test the antioxidant response capacity, iPSC were challenged for 2 hr with 300 nM 3-
NP, 100 µM H2O2, 1 µM antimycin A or medium replaced for DMEM without glucose 
and supplemented with 2-DOG. Fluorescence was measure for 5 min, as described, after 
which cells were treated with the stressor compounds cited. Results were obtained with 
excitation at 510 nm and collection at 580 nm. 
Mitochondria peroxy yellow 1 (MitoPY1) is a fluorescent probe that selectively tracks 
to the mitochondria and detects fluxes of H2O2 (Dickinson et al. 2013). Briefly, iPS 
cells were detached by Accutase, collected and allowed to rest for 30 min in KSR 
medium. Subsequently were centrifuged 3 min, 1000 rpm at RT and washed with PBS. 
Cells were incubated at 37ºC with10 µM of MitoPY1 for 30 min.  
After, the cells were washed by removing the MitoPY1 solution and replacing it with 
warm DPBS. As a positive control, stimulation with 100 µM H2O2 was carried out for 
30 min. Fluorescence was measure for 15 min, as described, after which cells were 
treated with the stressor compounds mentioned above. Resultant fluorescence was 
analyzed on a Microplate Spectrofluorometer Gemini EM with excitation at 500 nm and 
collection at 538 nm. 
Differences in the fluorescence was quantified and presented as mean +/-SEM. The 
results were calculated as RFU per mg protein for NSC or per 300.00 cells for iPSC.  
 
4.2.12.Measurement of SOD activity 
Determination of SOD activity was performed accordingly to the SOD Assay Kit 
(Sigma). In order to measure SOD2 activity, 2 mM potassium cyanide (KCN) (which 
inhibits SOD1) was added. SOD2 activity can be measured in the presence of potassium 
cyanide (KCN), since it inhibits SOD1 activity. 
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4.2.13.Preparation of mitochondrial-enriched fractions from iPSC 
In brief, the medium was removed and cells washed once with ice-cold PBS. 
Afterwards were scraped, collected in homogenization buffer (250 mM sucrose, 20 mM 
HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA at pH 7.4) and 
homogenize with a 2-ml glass/Teflon tissue grinder with a tight clearance kept on ice 
with 100 slow up-down strokes. Subsequently the homogenized was submitted to 
centrifugation at 2300 rpm for 12 min at 4 °C. The mitochondria-enriched supernatant 
was collected immediately and kept at −80 °C until analysis. 
 
4.2.14.Measurement of mitochondrial respiratory chain complexes activities 
The mitochondria-enriched fraction was assayed for the activity of mitochondrial 
complexes (Cx) I–III by spectrophotometry. 
 
Complex I: NADH–ubiquinone oxidoreductase assay 
Briefly, in a 1 ml cuvette was added 800 μl of K2HPO4 buffer (0.25 M, pH 7.2), 50 μl of 
fatty acid–free BSA (50 mg/ml), 10 μl of KCN (100 mM) and 30 μl of NADH (5 mM). 
After sample quantification 100 µg of protein was added and the final volume adjusted 
to 990 μl with distilled water. In parallel, a separate cuvette was prepared, containing 
the same quantity of reagents and sample but with the addition of 10 μl of 1 mM 
rotenone solution (blank). To start the reaction 10 μl of ubiquinone-1 (5 mM) was added 
and read for 5 min until the reaction was stopped with 10 μl rotenone (1 mM). Cx-I 
activity, measured at 30°C, was determined at 340 nm by following the decrease in 
NADH absorbance due to ubiquinone (50 μM) reduction to ubiquinol (Ragan 1987). 
Cx-I activity expressed in nanomoles per minute per milligram of protein was 
normalized for citrate synthase activity and corresponds to the rotenone (1 μM) 
sensitive rate. 
 
Complex II: Succinate–ubiquinone oxidoreductase assay 
Briefly, in a 1 ml cuvette was added 500 μl of K2HPO4 buffer (0.1 M, pH 7.4), 10 μl of 
KCN (100 mM), 40 μl of succinate (500 mM), 40 μl of DCPIP (1.5 mM), 40 µM of 
EDTA-K2 (5 mg/5ml) and 10 μl rotenone (1 mM). After sample quantification 150 µg 
of protein was added and the final volume adjusted to 990 μl with distilled water. In 
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parallel, a separate cuvette was prepared, containing the same quantity of reagents and 
sample but with the addition of 10 μl of 50 mM TTFA before solution (blank). To start 
the reaction 10 μl of decylubiquinone (50 mM) was added and read for 3 min until the 
reaction was stopped with 10 µl of TTFA (100 mM). Cx-II activity, measured at 37°C, 
was monitored at 600 nm by following the reduction of 6,6-dichlorophenolindophenol 
(DCPIP) (600 μM) by ubiquinol resulting from this reaction (Hatefi et al. 1978) . Cx-II 
activity expressed in nanomoles per minute per milligram of protein was normalized for 
citrate synthase activity and corresponds to complex II inhibitor, 
thenoyltrifluoroacetone (TTFA), sensitive rate. 
 
Complex III: Ubiquinol–cytochrome c reductase assay 
Briefly, in a 1 ml cuvette was added 620 μl of K2HPO4 buffer (0.056 M, pH 7.2), 150 μl 
of reduced cytochrome c (100 µM), 10 μl of KCN (100 mM), 50 μl of EDTA-K2 (20 
mM, pH 7.2), 50 µl MgCl2-6H2O (100 mM) and 10 μl rotenone (0.5 mM). After sample 
quantification 50 µg of protein was added and the final volume adjusted to 998 μl with 
distilled water. In parallel, a separate cuvette was prepared, containing the same 
quantity of reagents and sample (blank). To start the reaction 2 μl of 10 mM ubiquinol 
was added and read for 5 min until. Cx-III activity was monitored at 550 nm by 
following the ubiquinol reduction of cytochrome c at 30 °C. Cx-III activity expressed in 
nanomoles per minute per milligram of protein was normalized for citrate synthase 
activity. 
 
Complex I+III: NADH cytochrome c oxidoreductase 
Briefly, in a 1 ml cuvette was added 200 μl of Tris-HCl (0.05 M, pH 8.0) medium 
supplemented with 50 µl BSA (5 mg/ml), 150 μl oxidized cytochrome c (0.267 mM) 
and 10 μl KCN (0.024 M) left to incubate for 4 min. After sample quantification 50 µg 
of protein was added and the final volume adjusted to 990 μl with distilled water. In 
parallel, a separate cuvette was prepared, containing the same quantity of reagents and 
sample but with the addition of 10 μl of rotenona solution (blank). To start the reaction 
0.8 mM NADH (26.7 mM) was added and read for 3 min until the reaction was stopped 
with 10 μl rotenone (0.4 mM). The activity of complex I+III was measured at 30°C by 
the change in absorbance at 550 nm (ε = 19.1 mM−1cm−1) due to the reduction of 
oxidized ferricytochrome c (Hagopian et al. 2010). The activity of complex I+III 
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expressed in nanomoles per minute per milligram of protein was normalized for citrate 
synthase activity 
 
Citrate synthase (CS) assay 
Briefly, in a 1 ml cuvette was added 500 μl of Tris (200 mM, pH 8.0) with Triton X-100 
(0.1% (vol/vol)), 20 μl of DTNB (10 mM), 20 μl of AcetylCoA (10 mM) and 50 µg of 
sample. The volume was adjusted to 90 μl with distilled water. The reaction started by 
adding 10 μl of oxaloacetic acid (10 mM). CS activity was performed at 412 nm 
following the reduction of 5,5′-dithio-bis(2-nitrobenzoic acid) (DTNB) (200 μM) in the 
presence of acetyl-CoA (200 μM) and oxaloacetate (100 μM) (Coore et al. 1971). CS 
activity was expressed in nanomoles per minute per milligram of protein. 
 
4.2.15.XF24 extracellular flux analyser 
iPSCs were seeded onto an XF24 Cell Culture Microplate coated with matrigel 
(Seahorse Bioscience) (Zhang et al. 2012) and incubated at 37ºC until confluent. One 
ml of XF Calibrant Solution was placed into each well of the sensor hydration 
microplate and the sensor cartridge placed onto the microplate. The plate was incubated 
with immersed sensors in a non-CO2 incubator at 37 °C for ~16 h (overnight). Fifty ml 
of XF assay medium was supplemented with 17.5 mM glucose, 1 mM pyruvate and 2 
mM glutamine and pH Adjusted to 7.4 at 37 °C. The cell medium was aspirated from 
each iPSC- or NSC–containing XF24 V7 cell culture microplate without disturbing the 
cell monolayers attached on the well bottoms. Gently each well was washed with 0.5 ml 
of XF assay medium at 37 °C. Then, 450 µl of XF assay medium at 37 °C was added to 
each well and the plate putted into a non-CO2 incubator at 37 °C for 1 hour. The final 
additive concentrations of the inhibitors added into injection ports A, B or C was 1 μM 
oligomycin, 0.3 μM FCCP, 1 μM rotenone and 1 μM antimycin. This method allows to 
measure mitochondrial oxygen consumption rate (OCR) and acess the mitochondrial 
function in their native intracellular environment. Glycolysis converts glucose to lactate 
resulting in production of protons released into the extracellular medium following 
acidification of the medium surrounding the cells. This can be measured directly by the 
XF Analyzer and outputted as the Extracellular Acidification Rate (ECAR). Firstly, 
cells were incubated in the glycolysis stress test medium (DMEM D (5030 Sigma), 
NaCl 143mM, Phenol Red 3mg) without glucose for 1 hour a 37°C incubator without 
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CO2. The port A injects a saturating concentration of glucose (10mM) leading to ATP 
and protons production through the glycolytic pathway pyruvate to lactate. The second 
injection is oligomycin, which inhibits mitochondrial ATP production and thus shifts 
the energy production to glycolysis, with the subsequent increase in ECAR. The last 
injection is 2-DOG, which inhibits glycolysis through competitive binding to glucose 
hexokinase. The resulting decrease in ECAR further confirms that the ECAR produced 
in the experiment is due to glycolysis. 
For fatty acid oxidation measurements for hPSCs and NSC KHB assay medium (111 
mM NaCl, 4.7 mM KCl, 2 mM MgSO4 Na2, 1.2 mM HPO4, 2.5 mM Glucose) 
supplemented with 500 mM L-carnitine was used. The exogenous free fatty acid 
palmitate (200 µM), which can be internalized by intact cells, was added into injection 
ports A, B followed by the addition of etomoxir at port C. The component of OCR due 
to palmitate oxidation is determined by the addition of etomoxir, which freely diffuses 
into cells and is an inhibitor of carnitine palmitoyltransferase 1 (CPT1), an enzyme that 
transports long-chain fatty acids across the mitochondrial inner membrane, thereby 
effectively inhibiting fatty acid oxidation. The design a study protocol in the XF24 
Extracellular Flux Analyzer software for analyzing iPSCs and NSC was to set the time 
to mix for 2 min, wait for 2 min and measure for 4 min. OCR and ECAR were 
normalized to protein concentration using the Protein Assay reagent (Bio-Rad) in all 
experiments. 
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4.3. Results 
4.3.1.HD- iPSCs and differentiated Neural Stem Cells express mutant HTT 
and display specific protein expression patterns 
To confirm that mHTT was still expressed by HD cells immunoblots of protein extracts 
were performed. An antibody that recognizes normal and mutant HTT (D7F7) and other 
that only detects the polyglutamine expansion (1C2) revealed that HD-iPSC and HD- 
NSCs express both proteins (Figure 4.1A). The AMS4-iPSC cell line expresses only 
wild type HTT and the HD –iPSC, as described by Park (2008), has one normal (<35 
repeats) and one expanded allele (72 repeats) (Park et al. 2008). 
 
 
Figure 4.1.- Characterization of iPS and NS cell lines. (A) Western blots of HTT expression in iPSC 
and iPSC-derived NSC with the HTT antibody D7F7 and 1C2 demonstrate normal and mutant HTT 
expression. Also the pluripotency marker OCT4 was present in iPSC. (B-D) Expression of pluripotency 
markers OCT4 and SOX2 by induced pluripotent stem cells (iPSC) and Nestin and SOX2 by neural stem 
cells (NSC).  
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The pluripotency of HD-iPSC was confirmed by the detection of specific markers. The 
HD- iPS affected cell lines expressed the markers OCT4 and SOX2 as well as AMS4-
iPSC line (Figure 4.1A, 4.1B). The neural stem cells were generated from the HD and 
wild type iPS cell lines by neural induction protocol. The blockade of SMAD signalling 
was achieved by SB431542 (inhibits the Lefty/Activin/TGFβ), dorsomorphin (BMP 
inhibitor) and XAV-939 (β-catenin-mediated transcription inhibitor) factors. The 
successfully differentiation was confirmed by the expression of Nestin and SOX2 
(Figure 4.1C, 4.1D). HD-NSC grew in defined medium with epidermal growth factor 
(EGF) and fibroblast growth factor-2 (FGF-2) and were expandable for 10 passages and 
could be frozen and thaw very efficiently. 
 
 
4.3.2.Mitochondrial dysfunction and calcium dyshomeostasis in HD-iPSC  
Mitochondrial is an important key player in Ca
2+
 regulation acting as a Ca
2+
 buffer thus 
controlling the impact on cytosolic Ca
2+
 signals and on the activity of Ca
2+
-dependent 
proteins. Ca
2+
 also controls numerous functions on mitochondria and its uptake is 
dependent on mitochondrial membrane potential (∆) (for review,(Demaurex et al. 
2009). The ∆ was explored with the fluorescent lipophilic cationic dye Rhodamine 
123 which selectively accumulates within mitochondria (Perry et al. 2011). When HD-
iPSC where exposed to ATP synthase inhibitor (2 µg/ml oligomycin) and a 
mitochondria uncoupler FCCP (2 µM) ensemble, released more probe than controls 
(Figure 2Ai). To further confirm this data we incubated the drugs at different time 
points. Results found are consistent with a more negative ∆ in HD-iPSC since when 
challenged with oligomycin more probe is release to cytoplasm (AMS4 vs HD - 0.43 ± 
0.28 vs 3.00 ± 0.71, p<0.05) (Figure 4.2Aii-iii). Finally, ∆ was quantified on a single 
cell based on incorporation of specific fluorescent dyes and similar results were 
obtained (Figure 4.2Ci-ii). Although in somatic cells the ∆ is maintained by the proton 
gradient through the electron transport chain, in iPSC ∆ appears to be maintained by 
glycolysis. Hydrolysis of glycolytic ATP due to the conversion of ATP synthase to 
hydrolase activity seems to be essential for maintaining the ∆, proliferation, and 
viability of iPSCs (Cho et al. 2006). Our results are consistent with data from other 
studies since oligomycin induced a completely depolarization and loss of ∆.  
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An association between Ca
2+
 homeostasis dysfunction and ∆ abnormalities was 
described in several studies with mitochondria showing an interaction with mHTT and 
mitochondria (Lim et al. 2008, Sommer et al. 2012). The Ca
2+
 basal levels measured by 
Fura- 2AM probe fluorescence intensity were significantly increased in HD-iPSC (1.57 
± 0.01 vs 1.83 ± 0.003, p<0.0001) (Figure 4.2Bi). After, we tested for functional 
differences in Ca
2+
 handling due to dynamics of mitochondrial Ca
2+
 pool by challenging 
cells with ATP synthase inhibition (2 µg/ml oligomycin) and ∆ collapse with FCCP (2 
µM). Figure 4.2Bi-iii shows that after the uncoupler addition the mitochondria in HD-
iPSC released less Ca
2+
 indicating a lower uptake by mutant cells than in controls. 
Single-cell calcium imaging for quantification of changes in Ca
2+
 were also analyzed. 
When cells are analyzed individually Ca
2+
 levels measured show an increased release 
when mitochondria are totally depolarized with FCCP in AMS4-iPSC (0.08 ± 0.007 vs 
0.04 ± 0.01, p=ns) (Figure 4.2Di-ii).  
Furthermore to elucidate the mitochondrial role in Ca
2+
 handling, we reduced glucose 
levels to 2mM and replaced with pyruvate (10 mM). Removal of glucose leads to 
suppression of glycolysis but increasing pyruvate levels, a mitochondrial energy 
substrate, stimulates mitochondrial energy production and forces the electron transport 
chain to work (Oliveira et al. 2006, Ferreira et al. 2011). Mitochondria from iPSC 
cultures exposed to those conditions became more hyperpolarized as shown in Figure 
4.3Ai. Both HD and AMS4-iPSC released more quenched Rhod123 when stimulated 
with oligomycin, although the dye uptake was significantly higher in HD cells (p<0.01). 
 
Figure 4.2. - Mitochondrial membrane potential measured with the fluorescent lipophilic cationic 
dye Rhodamine 123 and representative Fura-2 analysis of intracellular Ca2+. (A) (i) After 30 minutes 
incubation with Rhod123, fluorescence was measure in the fluorimeter. iPSC were exposed to 2 µg/ml 
oligomycin FCCP ensemble or (ii) separately at the times indicated by the arrows, which respectively 
caused the characteristic quenching (hyperpolarization of ψm) and unquenching (depolarization of ψm) 
(B)(i) iPSC were incubated for 30 minutes with Fura-2AM and basal fluorescence was measured in the 
fluorimeter (ii) followed by the response to oligomycin and FCCP at the times indicated by the arrows.  
(C-D) (i-ii) Time course of iPSC mitochondrial membrane potential and of cytosolic Ca2+ change 
following oligo and FCCP addition measured in the single cell microscope. The results are expressed as 
the mean±S.E.M. from 3 independent experiments. Statistical analysis was performed by one way 
ANOVA, followed by Bonferroni post test. **p<0.01  
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Mitochondria from iPSC cultures exposed to low levels of glucose have increased basal 
Ca
2+
 levels. For AMS4-iPSC the Ca
2+
 levels increased by 0.42 RFU (p<0.001) and for 
HD-iPSC the increased in Ca
2+
 levels was of 0.79 RFU (p<0.001) suggesting an 
increased accumulation of Ca
2+ 
(Figure 4.3Bi). When the low glucose medium iPSC 
cultures are completely depolarized by FCCP a significant magnification of Ca
2+
 release 
was observed (Figure 4.3Bii). 
 
 
 
 
 
 
 
 
4.3.3.Abnormal mitochondrial dynamics in HD-iPSC 
Next, in order to evaluate mitochondria dynamics we incubated cells with MitoTracker 
Red or transfected with pDsRed2-Mito for mitochondrial staining. We observed that 
HD-iPSC stained for MitoTracker Red and pDsRed2-Mito contain mitochondria with 
more elongated and less globular shape than AMS4-IPSC cells and the localization is 
not strictly perinuclear but more disperse in cell cytosol (Figure 4.4). AMS4-iPSC 
Figure 4.3. iPSC were loaded with Rhod123 and Fura-2AM and assayed in low glucose medium 
containing 10 mM pyruvate. The results are expressed as the mean±S.E.M. from 3 independent 
experiments. Statistical analysis was performed by one way ANOVA, followed by Bonferroni post test. 
***p<0.001, **p<0.01, *p<0.05. 
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mitochondria assume a bipolar clustering at the two sides of the nuclei not seem in HD-
iPSC. MitoTracker Red is sensitive to mitochondrial membrane potential and in HD-
iPSC culture it accumulates more in some cells (Figure 4.4i). 
Mitochondrial dynamics is maintained by 2 divergent forces: mitochondrial fusion and 
mitochondrial fission - that balances equally to constantly shape the mitochondrial 
network. More fission results in over-fragmented networks while more fusion leads to 
over-connected networks. Fission is regulated by the dynamin-related protein (Drp1) 
and mitochondrial fission 1 (Fis1). Fis1 is localized to the outer-membrane of 
mitochondria and Drp1 protein is localized in the cytoplasm. Mitochondrial fusion is 
controlled by 3 GTPase proteins: two outer-membrane localized proteins Mfn1 and 
Mfn2, and one innermembrane localized protein Opa1. The GTPases to become active 
have to be recruited to the mitochondria. Immunostainings for those proteins reveal 
reduced overlap with mitochondria particularly for OPA1 and Mfn2 and slight more for 
DRP1 (Figure 4.4Ai-v, 4.4B). Fis1 highly colocalize with the mitochondria (Figure 
4.4B). The levels of fusion/fission markers associated with mitochondria were similar 
for AMS4 and HD-iPSC.  
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Figure 4.4. – Mitochondrial dynamics. (A) ( i)Immunofluorescence analysis of mitochondrial 
proteins TOM20 and MitoTracker red and (ii-v) Opa1, Fis1, Mfn2 and Drp1 fusion and fission 
molecules and pDsRed2-Mito. Fusion molecules Mfn is a mitochondrial outer membrane protein with a 
cytosolic GTPase domain and OPA1 is a GTPase in the intermembrane space. Fission molecules Fis1 is 
localized uniformly to the mitochondrial outer membrane, whereas Drp1 is localized to the cytosol and 
punctate spots on mitochondria. (B) Western blot analysis of mitochondrial fission and fusion proteins in 
HD-iPSC and controls. Images were photographed at ×63. The results are expressed as the mean±S.E.M. 
from 3 independent experiments. Statistical analysis was performed by one way ANOVA, followed by 
Bonferroni post test. ***p<0.001, **p<0.01, *p<0.05  
 
 
4.3.4.Energetic metabolism is impaired in HD-iPSC and HD-NSC 
The metabolic profile of iPSC is quite different upon differentiation (Schieke et al. 
2008, Prigione et al. 2010, Folmes et al. 2011). The bioenergetics processes for ATP 
production, OXPHOS and glycolysis, were examined in iPSC and NSC. Thus the 
oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR), which 
can approximate glycolysis from lactate production, were determined using a XF24 
Extracellular (Figure 4.5). The ratio of OCR to ECAR indicates cellular preference for 
OXPHOS versus glycolysis when mitochondria are coupled for oxygen consumption 
and energy generation. The OCR response to oligomycin A, FCCP and rotenone + 
antimycin A indicate (1) basal mitochondrial and (5) nonmitochondrial components of 
cellular oxygen consumption, (2) oxygen consumed for ATP generation through the 
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complex V versus (3) oxygen consumed with passive proton leakage across the 
mitochondrial inner membrane, which reduces the mitochondrial membrane potential, 
and (4) maximal respiratory capacity in coupled and completely uncoupled conditions. 
OCR studies showed that HD-iPSC consume less oxygen than control, at room air OCR 
was 282.9 ± 15.78 pmol/min/mg protein for control and 234.7 ± 7.63 pmol/min/mg 
protein for HD –iPSC (p<0.05) (Figure 4.5A1). The component of OCR used to 
generate ATP (94.87 ± 28.36 vs 67.69 ± 7.04, p=ns) was slightly although not 
significantly lower as the maximal respiratory capacity (174.3 ± 53.72 vs 137.2 ± 19.72, 
p=ns) (Figure 4.5A2, A4). Proton leakage can have several functions (1) production of 
heat to maintain body temperature, (2) endowment of increased sensitivity of metabolic 
reactions to effectors (3) reduction of harmful free radical production and (4) regulation 
of carbon flux (Buttgereit et al. 2000, Serviddio et al. 2010). HD-iPSC have increased 
OCR proton leaks (34.0 ± 9.24 vs 49.3 ± 3.34; p=ns). OXPHOS was inhibited with 
oligomycin and HD-iPSC showed lower reduction in oxygen consumption suggesting 
that are less dependent on OXPHOS than control.  
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Figure 4.5 - Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) was 
determined by Seahorse XF24 analyzer in iPSC. (A) The mitochondrial inhibitors were sequentially 
injected into different ports and the final concentrations of each were: 1 μM oligomycin, 0.3 μM FCCP, 1 
μM rotenone and 1 μM antimycin A. 1) basal OCR (represents the mean of the first four measurements); 
2) oxygen consumed for ATP generation through the complex V (mean of basal values minus mean of 
measurements after oligomycin A); 3) component of OCR representing passive proton leakage across the 
mitochondrial inner membrane (mean of measurements after oligomycin A minus mean of measurements 
after rotenone + antimycin A) 4) the maximal respiration capacity (mean of measurements after fccp 
minus mean of measurements after rotenona antimycin A; 5) non mitochondrial respiration (mean of 
measurements after rotenona antimycin A minus zero). The results are expressed as the mean±S.E.M.. 
Statistical analysis was performed by t-student test *p<0.05 
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Upon differentiation a marked decrease in mitochondrial oxygen consumption was 
documented in HD-NSC (Figure 4.6A). HD-NSC showed a reduced basal OCR 
compared to control (104.1 ± 2.56 pmol/min/mg protein vs 68.70 ± 0.49 pmol/min/mg 
protein) (p<0.0001) (Figure 4.6A1). All the components evaluated for OXPHOS such as 
the component of OCR used to generate ATP (28.93 ± 2.09 vs 15.25 ± 1.35, p<0.0001), 
the maximal respiratory capacity (148.2 ± 12.47 vs 59.99 ± 5.16, p<0.0001), component 
of OCR passive proton leakage (11.34 ± 0.76 vs 5.99 ± 1.78, p=<0.01) were diminished 
in HD-NSC compared to AMS4-NSC (Figure 4.6A2-5). 
 
 
 
 
 
Figure 4.6. - Oxygen consumption rate (OCR) was determined by Seahorse XF24 analyzer in 
neural stem cells derived from iPSC. (A) The mitochondrial inhibitors were sequentially injected into 
different ports and the final concentrations of each were: 1 μM oligomycin, 0.3 μM FCCP, 1 μM rotenone 
and 1 μM antimycin A. 1) basal OCR (represents the mean of the first four measurements); 2) oxygen 
consumed for ATP generation through the complex V (mean of basal values minus mean of 
measurements after oligomycin A); 3) component of OCR representing passive proton leakage across the 
mitochondrial inner membrane (mean of measurements after oligomycin A minus mean of measurements 
after rotenone + antimycin A) 4) the maximal respiration capacity (mean of measurements after fccp 
minus mean of measurements after rotenona antimycin A; 5) non mitochondrial respiration (mean of 
measurements after rotenona antimycin A minus zero). The results are expressed as the mean±S.E.M.. 
Statistical analysis was performed by t-student test *p<0.05; **p<0.01; ***p<0.001. 
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To further understand mitochondrial respiratory chain alterations we analyzed the 
enzymatic activities of respiratory complexes I, II, III and I+III by spectrophotometry. 
Results were normalized to the protein content and the activity of citrate synthase (CS), 
a mitochondrial matrix enzyme. According to our data, Cx-I and Cx-II present no 
significant differences while the activity was significantly reduced in Cx I+III (211.7 ± 
52.78 vs 40.57 ± 21.44, p<0.05) (Figure 4.7A).  
Taking into account the alterations detected in mitochondrial Cx activities, we further 
determined the complex subunits mitochondrial expression.  
 
 
 
The lower dependence on OXPHOS demonstrated by HD-iPSC is consistent with the 
decrease in mitochondrial enzymatic activity found.  
Another major energy production pathway is glycolysis. Cells with a more glycolytic 
phenotype exhibit significantly higher rates of proton production due to the conversion 
of glucose to lactate, independent of oxygen (extracellular acidification rate) (Ferrick et 
al. 2008). To analyze ECAR, cells were incubated with a high dose of glucose to 
evaluate the glycolysis rate followed by addition of 2-deoxy-glucose that inhibits 
glycolysis, lowering ECAR. The maximum glycolytic capacity of the cells is achieved 
when oligomycin is added, inhibiting mitochondrial ATP production, and therefore 
shifts the energy production to glycolysis increasing in ECAR (Ferrick et al. 2008).. 
Figure 4.7 Activity of mitochondrial respiratory chain complexes I–III and citrate synthase. 
Mitochondrial respiratory chain complexes (Cxs) and citrate synthase (CS) activities were determined in 
mitochondrial fractions isolated from iPSC. Data are the mean ± S.E.M. of 5 independent samples, 
normalized for protein content and citrate synthase activity. Statistical analysis: The results are expressed 
as the mean±S.E.M.. Statistical analysis was performed by t-student test *p<0.05; **p<0.01; ***p<0.001. 
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Additional glucose (from 2.5 mM to 25 mM) maximized ECAR, with 80% increase in 
HD-iPSC whereas AMS4-iPSC ECAR increased by a more modest 52% indicating that 
controls are closer to their maximal glycolytic capacity compared with HD-iPSC. 
Subsequent addition of 2-DOG, which competes for uptake with glucose, HD-iPSC 
glycolysis was repressed 47% from the ECAR maximum whereas AMS4-iPSC 
glycolysis change only 32% from the ECAR maximum (Figure 4.8A), indicating that 
the HD-iPSC glycolysis level is greater than in AMS4-iPSC. Combined, the data 
indicate that HD-iPSC are less sensitive to OXPHOS inhibition but more sensitive to 
glycolysis disruption and AMS4-iPSC functions closer to their maximum glycolytic 
capacity.  
Alternative carbon fuels can be used by cells for ATP production such as fatty acids 
oxidation (Zaugg et al. 2011). Palmitate, a fatty acid, can be internalized at cells by 
carnitine palmitoyltransferase 1 (CPT1), an enzyme that transports long-chain fatty 
acids across the mitochondrial inner membrane, and the component of OCR attributed 
to palmitate oxidation is determined by the addition of etomoxir an inhibitor of the 
transporter. When 200 µM palmitate is added to iPSC no variation in OCR level was 
observed (supplementary data) suggesting that iPSC do not use exogenous fatty acids as 
a carbon source for OXPHOS (Figure 4.8B). 
Figure 4.8. Extracellular acidification rate (ECAR) and fatty acid oxidation was determined by 
Seahorse XF24 analyzer in iPSC. (A) Cells were cultured in assay medium with 2.5mM glucose. ECAR 
changes with glucose (25mM final), oligomycin A (1µM) and 2-DG (100mM final) additions is shown. 
(B) oxygen consumption rate (OCR) following exposure to palmitate, as a direct indicator of fatty acid 
oxidation. The results are expressed as the mean±S.E.M.. Statistical analysis was performed by t-student 
test *p<0.05 
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Pyruvate dehydrogenase (PDH) complex catalyzes the oxidative decarboxylation of 
pyruvate linking glycolysis to the tricarboxylic acid cycle. Three components that 
catalyze the conversion of pyruvate to acetyl-CoA (pyruvate dehydrogenase (E1), 
dihydrolipoamide acetyltransferase (E2), and dihydrolipoamide dehydrogenase (E3)) 
are regulated by the enzymes pyruvate dehydrogenase kinases (PDK) and pyruvate 
dehydrogenase phosphate phosphatase (PDP). PDK and PDP catalyze a 
phosphorylation-dephosphorylation cycle involving specific serine residues on the 
subunitof E1. In our data PDH E1α subunit was significantly increased in HD-iPSC 
(Figure 4.9Ai). We also observed that PDK1 protein levels are up regulated in HD-iPSC 
when compared to control and its expression increases dramatically in AMS4-NSC 
(Figure 4.9Bi). Consistent with upregulated PDK1 expression displayed by HD-iPSC 
higher phospho PDH (PDH E1α serines 232, 293 and 300) levels were found when 
compared to AMS4-iPSC indicative of devoid activity (Figure 4.9Aii).  
Cellular energy can be obtained either by aerobic respiration resulting in greater amount 
of ATP or by anaerobic respiration followed by lactic acid formation. To test energy 
generation in undifferentiated and differentiated iPS cells, ATP content and pyruvate/ 
lactate generation were measured. HD-iPSC exhibited similar production of pyruvate/ 
lactate in comparison to AMS4-iPSC (Figure 4.9C). Differentiated HD cells displayed 
higher amounts of pyruvate as well as lactate than AMS4-NSC. Upon differentiation 
pyruvate levels decrease in both cells lines and lactate production increases for HD-
NSC as long as the ratios lactate/pyruvate. A significantly lower content of cellular ATP 
and ATP/ADP was detected in HD-iPSC (Figure 4.10). Taken together, the results 
suggest that HD-iPSC seems to rely less on mitochondrial respiration and mainly 
produce energy by anaerobic glycolysis followed by lactate production. 
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Figure 4. 9.- (A) (i) Determination of the total PDH levels in iPSC and (ii) activity levels of phospho-
PDH (Ser 232, 293, 300 of the E1-α subunit). (B) (i) Western blotting analysis of PDK1 protein 
levels. (C) Pyruvate and lactate levels on iPSC and their differentiated counterparts. Tubulin was 
used as a loading control. Two way ANOVA analyses revealed that there is a significant effect of 
genotype on levels of phospho-PDH [F(1,44)=98.96, p <0.001]. The results are expressed as the 
mean±S.E.M. Statistical analysis was performed by t-student test and two way ANOVA followed 
Bonferroni analysis *p<0.05; **p<0.01; ***p<0.001. Abbreviations: PDK1, pyruvate dehydrogenase 
kinase one; pPDH: phospho pyruvate dehydrogenase subunit E1a; PDH: pyruvate dehydrogenase. 
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4.3.5.HD-iPSC exhibit mitochondrial dysfunction associated with increased 
oxidative stress 
Mitochondria abnormalities and oxidative stress have been suggested to play a critical 
role in HD neurodegeneration. Previously data of our lab as reported increase 
susceptibility of HD striatal cells to ROS (Ribeiro et al. 2014) . Moreover proteomic 
analysis of HD-iPSC showed that oxidative stress- related proteins such as SOD1 and 
peroxiredoxin (Prx) are affected (Chae et al. 2012). ROS are mitochondrial respiration 
by-products that cause oxidative damage to proteins, lipids, and DNA. Varun and 
colleagues revealed that ROS production increase with iPSC differentiation and it seems 
that a ROS-dependent pathway influences pluripotency (Mandal et al. 2011).  
To better understand if the changes we found in Ca
2+
 handling were related with ROS 
production we further analyze superoxide and hydrogen peroxide production, sub-
products of OXPHOS. To determine the mitochondrial superoxide anion and hydrogen 
peroxide production in iPSC, we used MitoSox Red and MitoPY1 and exposed cells to 
1 µM Antimycin A (AA). AA acts by inhibiting the flow of electrons from cytochrome 
b to cytochrome c1 in complex III. It displaces coenzyme Q, the primary electron 
carrier, thus disrupting the proton gradient across the inner membrane of mitochondria 
and preventing O2 consumption at complex IV as well as ATP formation. Our results 
indicate that HD-iPSCs and HD-NSC are highly susceptible to oxidative stress showing 
Figure 4.10 - (A) – Intracellular iPSC levels of adenine nucleotides ATP, ADP and AMP. The cell 
lysates were assayed for ATP, ADP, and AMP by separation in a reverse-phase HPLC with detection at 
254 nm Statistical analysis was performed by one way ANOVA followed Bonferroni analysis *p<0.05; 
**p<0.01; ***p<0.001.  
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increased basal levels of superoxide anion and hydrogen peroxide (p<0.005) (Figure 
4.11i, Figure 4.12i-ii, Figure 13Ai). When exposed to acute AA, H2O2, 3NP or 
oligo/FCCP stimulus a higher amount of ROS were produced in iPSC and NSC 
compared to control demonstrating a lower capacity to neutralize the produced ROS 
(Figure 4.11Aii, 4.12Bi,ii,4.12Ci, Figure 4.13Bi-ii, 4.13Ci-ii).  
 
 
Figure 4.11.- Characterization of intracellular basal superoxide levels and induction after acute 
incubation with noxious stimulus (A) (i) Intracellular basal superoxide levels measure with Mitosox 
probe. (ii-iii) Generation of superoxide after acute exposure to 1 µM antimycin A. (B) (C) (i-iii) iPSC 
were treated for 2 hours with 100 µM H2O2 or 300 nM 3NP after which basal superoxide was measure for 
5 minutes and exposed to acute stimulus with 1µM antimycin A, 300nM 3NP or 1 mM H2O2 for more 5 
minutes. (D) iPSC were maintained for 30 minutes in low glucose medium containing 10 mM pyruvate 
followed by superoxide measure for 5 minutes and exposition to acute stimulus with 1µM antimycin A,  
300nM 3NP or 1 mM H2O2 and fluorescence acquisition for more 5 minutes. The results are expressed as 
the mean±S.E.M. Statistical analysis was performed by t-student test *p<0.05; ***p<0.001. 
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To evaluate if anti-oxidative stress long term response was also impaired in HD-iPSC 
we incubated cells for 2h with H2O2 100 μM or 3NP 300 nM followed an acute stimulus 
with AA, 3NP and/or H2O2. Basal levels of ROS significantly increased in cells 
incubated for 2 h with the noxious agents (Figure 4.11Bi, Ci). As expected both AMS4 
and HD-iPSC treated with H2O2 for 2h produced more ROS when challenged acutely 
with AA and 3 NP (Figure 4.11Bii-iii, 4.11Cii-iii). In AMS4-iPSC, AA induced an 
enormous production of ROS but 3 NP only resulted in a small change. Incubation of 3 
NP for 2h resulted in higher predisposition of AMS4-iPSC for ROS production when 
exposed to AA but no changes were found for H2O2. For HD-iPSC H2O2 also led to an 
increased production of ROS subsequently to 3 NP exposure. Consistently, as 
previously described iPSC medium was changed to deplete glucose-medium 
supplemented with 10 mM pyruvate to inhibited glycolysis and promote OXPHOS, this 
way stimulating ATP production by mitochondria. No increase in superoxide anion 
production was found except for AMS4-iPSC stimulated with 3 NP (Figure 4.11Dii). 
The lack of augmentation on ROS was most likely due to the short period maintained in 
the depleted medium.  
SOD1 is located in the cytosol and mitochondrion and is extremely important to reduce 
cellular ROS and promote oxidative stress resistance. The total SOD activity and 
particularly the SOD1 activity was found to be extremely reduced in HD-iPSC (SOD2 
12.47±4.31 vs 9.79±3.65; SOD1 9.69±4.42 vs 3.48±0.69) (Figure 4.12Di). In the 
western blotting analysis we observed that SOD is more acetylated in HD-iPSC lines, 
thus more inactive and the expression increases strongly in differentiated cells (Figure 
4.12Dii). The increase amount of ROS found in HD cells is most likely related to 
increased inactivation of SOD2 by acetylation and upon differentiation in total SOD 
expression. 
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Figure 4.12- Characterization of intracellular H2O2 levels in iPSC. (A) (i) MitoPY1 was used to 
measure basal mitochondrial H2O2 levels (ii) iPSC were incubated for 30 minutes with 100 µM H2O2 for 
probe positive control. (B)(i-ii) (C)(i) Generation of H2O2 after acute exposure to 300nM 3NP, 1µM 
antimycin A, 1 mM H2O2 or 2g/ml oligomycin/ 2µM FCCP for 15 minutes. (D) (i) Superoxide dismutase 
(SOD) activity in iPSC. Parallel experiments were conducted in the presence of KCN (2 mM) to inhibit 
SOD1. (ii) Acetylated and total Superoxide dismutase 2 protein levels in iPSC and NSC cell lysates. The 
results are expressed as the mean±S.E.M. Statistical analysis was performed by t-student test and two way 
ANOVA followed Bonferroni analysis *p<0.05; **p<0.01; ***p<0.001. ***p<0.001. 
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Figure 4.13- Characterization of intracellular basal superoxide levels and induction after acute 
incubation with noxious stimulus in NSC (A) (i) Intracellular basal superoxide levels measure with 
Mitosox probe. (ii-iii) Generation of superoxide in AMS4-NSC after acute exposure to 1 µM antimycin 
A, 300 nM 3NP and 1 mM H2O2 (B) (i-ii) and in HD4-NSC. The results are expressed as the 
mean±S.E.M. Statistical analysis was performed by t-student test *p<0.05; ***p<0.001. 
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4.4. Discussion 
This study characterizes a 74 CAG-repeat-expansion iPSC and neural cells derived from 
HD-iPSC line. The correlation between the length of CAG expansion and HD 
phenotype is well known (Andrew et al. 1993, Henley et al. 2009). Recently,iPSC lines 
derived from HD patient fibroblasts (Takahashi et al. 2007, Yu et al. 2007) and human 
embryonic stem cell lines donated mutant embryos were generated (Thomson et al. 
1998) showed great promise in the study of HD mechanisms of disease. In our study we 
directly differentiate iPSC into NSC successfully resorting the combined and specific 
application of a few morphogens, as was previously described (Chambers et al. 2009, 
Delli Carri et al. 2013, Nicoleau et al. 2013).  
In recent years mitochondrial dysfunction has assume a great importance in clarifying 
the link between disease phenotype and upstream mitochondrial pathways that can be 
involved in the initiation phase. Numerous studies suggest that alterations in 
mitochondrial respiration are responsible for the bioenergetics defects found in HD. 
Biochemical studies from HD patients tissue and HD cells and animal models revealed 
decreased activity of several enzymes involved in oxidative phosphorylation such as 
complex I, II, III, and IV (Powers et al. 2007, Browne 2008, Lim et al. 2008, Kim et al. 
2010, Silva et al. 2013). Despite, data from early HD patients do not support major 
deficits in the activity of striatal mitochondrial respiratory complexes sustaining the 
evidence that respiratory chain impairment could be a late secondary event and not the 
pathology trigger (Guidetti et al. 2001, Powers et al. 2007, Powers et al. 2011). 
The work described here has shown that HD-iPSC and NSC demonstrate early signs of 
mitochondrial dysfunction and calcium dyshomeostasis. HD-iPSC seems to be more 
hyperpolarized than wild type since it releases more Rhod123 when exposed to 
oligo/FCCP. Also the basal levels of Ca
2+
 were increased but when mitochondria were 
challenged with oligo/FCCP HD-iPSC released less Ca
2+
 indicating a lower uptake. The 
single cell imaging allow to measure in the same cell ∆ and Ca2+ handling providing 
complementary information to the previous results. The data obtained confirmed a more 
negative ∆ for HD-iPSC, consistent with a higher release of probe after oligomycin 
addition and a lower uptake of Ca
2+ 
since when mitochondria depolarizes less Ca
2+
 was 
release. Although in the majority of cells oligomycin administration induces 
hyperpolarization our data reveals an immediate depolarization. The ATP synthase in 
iPSC seems to have hydrolase activity of glycolytic ATP for maintaining the ∆ more 
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negative. Previous studies have shown that ATP synthase (complex V) is reversed in 
iPSC hydrolyzing glycolytic ATP to maintain the ∆ (Cho et al. 2006, Zhang et al. 
2011). The authors blocked ATP production by glycolysis resulting in a strong decrease 
in ATP levels, whereas inhibition of OXPHOS only caused a slight reduction in ATP 
levels in both hES and iPS cells (Varum et al. 2011, Zhang et al. 2011). Disturbances in 
calcium homeostasis, due to excitotoxicity and/or mitochondrial dysfunction are well 
known features of HD. Is known that intracellular Ca
2+
 concentration is elevated in 
striatal neurons from symptomatic HD in basal condition and after exposure to NMDA. 
In our study iPSC revealed a higher Ca
2+
 concentration but a low mitochondrial Ca
2+
 
storage capacity.  
Glutamate receptors stimulation activates the IP3 signaling pathway increasing Ca
2+
 
release from InsP3R1 in cells expressing mutant huntingtin. Similar results were 
observed by HD Consortium in HD-iPSC where there was a clear CAG-repeat-
expansion-associated phenotype with Ca
2+
 dyshomeostatis after acute pulses and 
chronic exposure to glutamate (Consortium 2012).  
Moreover, in this study replacing pyruvate by glucose in the medium we accentuated 
the cellular bioenergetic consequences of mitochondrial dysfunction as previously 
described in cultured striatal neurons (Oliveira et al. 2006, Ferreira et al. 2011). Recent 
studies showed that mitochondrial fission and fusion may be altered in HD (Wang et al. 
2009, Kim et al. 2010, Shirendeb et al. 2011, Shirendeb et al. 2012). Accordingly, we 
found abnormal mitochondrial structure and functional dynamics in HD-iPSC. Unlike 
previous reports, were mitochondria assume a globular or spherical morphology with a 
dominant perinuclear localization (Facucho-Oliveira et al. 2007, Prigione et al. 2010, 
Zhang et al. 2011, Kelly et al. 2013), HD-iPSC revealed a more elongated and less 
globular shape and the localization is not exactingly perinuclear but more disperse in 
cell cytosol contrasting to control cells data. As well-known mitochondrial fission and 
fusion proteins regulate the morphology, function, integrity and topographic distribution 
of mitochondria. A tight balance between mitochondrial fission and fusion is required to 
maintain ESC pluripotency and regulate the localization of mitochondria (Todd et al. 
2010, Todd et al. 2010, Harvey et al. 2011). Recently Todd et al (2010) demonstrated 
that growth factor erv1-like (Gfer), an inner mitochondrial membrane protein, is 
involved in preserving mouse ESC mitochondrial morphology and function and the KD 
led to a decrease of pluripotency marker expression, impair embryoid body (EB) 
formation and reduce cell survival associated with loss of mitochondrial function. 
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Levels of Drp1 were increased in Gfer-KD ESCs and treating ESC with a specific 
inhibitor of Drp1 rescued mitochondrial function and apoptosis. Moreover, 
overexpression of Gfer resulted in elongation of mitochondria, upregulation of Oct4 and 
Nanog and downregulation of the fission protein Drp1 (Todd et al. 2010, Todd et al. 
2010). Herein immunofluorescent staining of iPSC demonstrates lower mitochondrial 
localization of fusion proteins Mfn2 and OPA1 and higher for fission proteins Fis1 and 
Drp1. Since iPSC are rapidly dividing cells our results suggest that iPSC have impaired 
fusion and enhanced fission to promote proliferation. A recent report described that 
human cancer cell lines exhibit an imbalance of Drp-1/Mfn-2 expression, which 
promotes a state of impaired fusion and enhanced fission contributing fundamentally to 
the proliferation/apoptosis imbalance in cancer pointing to potential commonalities in 
mitochondrial dynamics (Rehman et al. 2012). Kim et al (2010) similarly demonstrated 
elevated levels of Drp1 and reduced levels of Mfn1 in HD caudate nucleus lysates 
consisting with alterations in the expression pattern of mitochondrial fission/fusion 
proteins  (Kim et al. 2010).  
Mitochondrial dynamics has been shown to regulate mitochondrial metabolism (Bach et 
al. 2003, Pich et al. 2005). Previous studies using allelic series of heterozygous CAG 
knock-in mouse ES cell lines show energy metabolism dependency on CAG length 
(Jacobsen et al. 2011). Additionally the HD consortium revealed that human-derived 
HD-NPCs have significantly decrease intracellular ATP and decreased ATP/ADP ratios 
suggesting that energy metabolism is compromised in higher CAG length cell lines 
(Consortium 2012) Our study similarly describes an impaired energetic metabolism in 
HD-iPSC and HD-NSC. We show that HD-iPSC have functional respiratory complexes 
however consume less oxygen than controls while are able to consume O2 at maximal 
capacity. Moreover, upon differentiation a marked decrease in mitochondrial oxygen 
consumption was observed. Those findings are in agreement with a reduced 
mitochondrial electron transport chain complexes activity. Furthermore, HD-iPSC 
seems to rely more on glycolysis for supplying ATP demands since they function closer 
to their maximum glycolytic capacity and fatty acids it is not a carbon source for 
OXPHOS. Overall HD-iPSC seems to have lower OXPHOS activity. Surprisingly the 
decrease in OXPHOS dependence was not expected although a recent study showed that 
hESCs have a high mitochondrial activity that declines disproportionately, alongside 
several related parameters of mitochondrial biogenesis, with differentiation into NSC 
and that this is coupled to a decrease in overall ATP turnover (Birket et al. 2011). The 
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authors reported that hESCs maintain a high rate of mitochondrial oxidative 
phosphorylation compared with hESC-derived NSC, but without increased glycolysis. 
Concomitantly high levels of expression of the mRNA encoding coactivators PGC-1α 
and PGC-1β was observed in hESCs, and upon hESC and iPSC differentiation many 
genes involved in mitochondrial biogenesis, including those encoding the mtDNA 
transcription factor TFAM and the mitochondrial RNA polymerase POLRMT are 
downregulated (Armstrong et al. 2010, Prigione et al. 2010). ATP in hESCs and NSCs 
is mainly directed to protein and nucleic acid synthesis.  
A key metabolic regulator favoring glycolysis versus OXPHOS involves the PDH 
complex (Varum et al. 2011). Varum et al (2011) found that hESC express high levels 
of hexokinase II and have an inactive PDH complex. Tellingly PDH E1α subunit was 
significantly increased in HD-iPSC but serines 232, 293 and 300 residues were more 
phosphorylated. Since phosphorylation of PDH complex can be carried out by four 
PDKs we analyzed PDK1 expression levels. PDK1 levels were up regulated in HD-
iPSC consistent with the inactivation of PDH found. These data confirm that HD-iPSC 
have a greater reliance on glycolysis than controls. Unexpectedly no changes in 
pyruvate/ lactate production were observed in iPSC although afterward differentiation 
HD-NSC cells displayed higher amounts of pyruvate as well as lactate. Moreover, HD-
iPSC disclosed reduced ATP levels. Thus, the results suggest that glycolysis is the main 
energetic pathway in HD-iPSC. During reprogramming to pluripotency metabolic 
changes succeed favoring glycolysis as the referential ATP production mechanism over 
OXPHOS (Varum et al. 2009, Chen et al. 2010, Liu et al. 2013, Son et al. 2013). 
Importantly the hyperpolarized-associated mitochondrial state of HD-iPSC found can be 
related to the reduced ATP consumption and the preferential glycolysis-based energy 
metabolism, as reported formerly (Prigione et al. 2011). 
Insights on the pathogenesis and neurodegeneration of HD exposes mutant huntingtin as 
crucial agent in mitochondrial energy impaired production and cellular respiration, thus 
promoting apoptosis, oxidative stress, and susceptibility to excitotoxicity. Mitochondria 
are both a target and an important source of ROS since superoxide anion is generated in 
a constant manner by the mitochondria. The semiquinone (coenzyme Q) is an important 
electron leakage in the inner mitochondrial membrane. Our results indicate that HD-
iPSCs are highly susceptible to mitochondrial dysfunction associated with increased 
oxidative stress. The increased basal levels of superoxide anion and hydrogen peroxide 
are consistent with the decreased activity of antioxidant enzyme Cu/Zn SOD1 and 
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acetylation of SOD2 and the expression increases strongly in differentiated cells. 
Effectively, HD-iPSC and HD-NSC showed increased vulnerability to the addition of 
exogenous stressors. Preceding studies described an increased amount of cell death in 
the HD lines in response to toxic stressors showing that HD-iPSC are associated with 
increased reactive oxygen species (Consortium 2012). Chae et al (2012) shed some light 
in protein expression profiles that are key regulators in oxidative stress, DNA damage 
and expression of cytoskeleton associated proteins (Chae et al. 2012). Lower levels of 
SOD1, GST and Gpx1 were found in HD-iPSC lines compared to hESC in contrast with 
the upregulation of Prx family members, including Prx1, Prx2 and Prx6 which have 
been implicated as important indicators for cellular ROS signals (Chae et al. 2012). 
In summary, we have carried out a comparative study of HD-PSC line and their 
differentiated counterparts to better identify the abnormalities and pathways that triggers 
neurodegeneration and to distinguish them from the ones that are secondary responses. 
This study takes the advantage of using a model system to elucidate the role of mHTT 
in in vitro differentiation of HD-affected iPSC and it is remarkable that significant 
changes are detected in very early in vitro stage. Considering the significance of iPSC 
research, in particular from disease-specific iPSC lines, brings some important insights 
on the pathogenesis and extended studies should be made with lower CAG carrying 
HD-iPSC lines to draw generalized conclusions. Moreover a valuable approach would 
be genetic correction of the mutated cells to better understand the role of mHTT in the 
early onset of HD phenotypes 
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5. LIST OF ABBREVIATIONS 
3-NP, 3-nitropropionic acid 
Aa, amino acids 
ADP, adenosine diphosphate 
Akt, protein kinase B 
AMP, adenosine monophosphate 
AMPA, 3-hydroxy-5-methyl-4-propionate 
Ask1, apoptosis signal-regulating kinase 1 
ATP, adenosine triphosphate 
AUC, area under the curve 
BDNF, brain-derived neurotrophic factor 
CAG, cytosine-adenine-guanine 
cAMP, cyclic-adenosine monophosphate 
CGG, cytosine-adenine-guanine 
CNS, central nervous system 
CREB - cyclic-adenosine monophosphate response element binding protein 
CTG, cytosine- thymine-guanine 
D1, subtype 1 dopamine receptor 
D2, subtype 2 dopamine receptor 
DA, dopamine 
EGF, Epidermal growth factor 
ELISA- Enzyme Linked Immuno Sorbent Assay 
EMG, electromyography 
ER, endoplasmic reticulum 
GAA, guanine–adenine-adenine 
GABA, γ–aminobutyric acid 
GAD, glutamic acid decarboxylase 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase 
GCC, guanine-cytosine-cytosine 
GLUT, glucose transporter 
GPe, external segment of the globus pallidus 
GPi, internal segment of the globus pallidus 
GTT, Glucose Tolerance Test 
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HAP1, Huntingtin associated protein 1 
HD, Huntington‘s disease 
HIP1, huntingtin-interacting protein 1 
HIP2, huntingtin-interacting protein 2 
HIPPI, HIP1-protein interactor 
HSPs, Heat shock proteins 
HTT, huntingtin 
HTTNT, N-terminal fragments 
IGF-1, insulin growth factor 1 
InsP3R1, inositol 1,4,5-trisphosphate receptors 
iPSC -Induced Pluripotent Stem Cell 
IP31, inositol (1,4,5)-trisphosphate type 1 
IT15, Interesting Transcript 15 gene 
ITT, Insulin Tolerance Test 
KA, Kainic acid 
L/P ratio, lactate/pyruvate ratio 
MA, malonic acid 
mGluR, metabotropic glutamate receptors 
mHTT, mutant huntingtin 
mPTP, mitochondrial permeability transition pore 
MSN, medium spiny neurons 
NAD+, nicotinamide-adenine dinucleotide 
NSC, neural stem cells 
NMDAR, N-methyl-D-aspartate receptor 
NR2, NMDA receptor subunit 
NTL, nucleus tuberalis lateralis 
PBS, phosphate buffered saline 
PCR, polymerase chain reaction 
PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
polyQ, polyglutamine(s) 
QA, Quinolinic acid 
REST, repressor element-1 transcription factor 
ROS, reactive oxygen species 
SBMA, Spinal and Bulbar Muscular Atrophy 
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SDH, succinate dehydrogenase 
SNARE, ethylmaleimide-sensitive fusion protein attachment protein receptor 
SNpc, substantia nigra pars compacta 
SNr, substantia nigra pars reticulata 
SP1, specific protein-1 
STN, subthalamic nucleus 
TAFII, TATA-associated factors 
TBP, TATA-binding protein 
UK, United Kingdom 
UPS, ubiquitin–proteasome system 
UPS, ubiquitin–proteasome system 
VA/VL complex, ventral anterior and ventral lateral thalamic nuclei 
WHO, World Health Organization 
YAC, yeast artificial chromosome 
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